<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article article-type="research-article" dtd-version="1.2" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">60183</article-id><article-id pub-id-type="doi">10.7554/eLife.60183</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Stem Cells and Regenerative Medicine</subject></subj-group></article-categories><title-group><article-title>Induction of osteogenesis by bone-targeted Notch activation</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-194058"><name><surname>Xu</surname><given-names>Cong</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-267064"><name><surname>Dinh</surname><given-names>Van Vuong</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-267065"><name><surname>Kruse</surname><given-names>Kai</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-152113"><name><surname>Jeong</surname><given-names>Hyun-Woo</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-194059"><name><surname>Watson</surname><given-names>Emma C</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-0986-5524</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-152116"><name><surname>Adams</surname><given-names>Susanne</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-160340"><name><surname>Berkenfeld</surname><given-names>Frank</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-194060"><name><surname>Stehling</surname><given-names>Martin</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-267066"><name><surname>Rasouli</surname><given-names>Seyed Javad</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-267068"><name><surname>Fan</surname><given-names>Rui</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-267069"><name><surname>Chen</surname><given-names>Rui</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-267067"><name><surname>Bedzhov</surname><given-names>Ivan</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-194061"><name><surname>Chen</surname><given-names>Qi</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8485-6540</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-152115"><name><surname>Kato</surname><given-names>Katsuhiro</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-132031"><name><surname>Pitulescu</surname><given-names>Mara E</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5322-8146</contrib-id><email>mara.pitulescu@mpi-muenster.mpg.de</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-15679"><name><surname>Adams</surname><given-names>Ralf H</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3031-7677</contrib-id><email>ralf.adams@mpi-muenster.mpg.de</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00pd74e08</institution-id><institution>Max Planck Institute for Molecular Biomedicine, Department of Tissue Morphogenesis, and University of Münster, Faculty of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Münster</named-content></addr-line><country>Germany</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/040djv263</institution-id><institution>Flow Cytometry Unit, Max Planck Institute for Molecular Biomedicine</institution></institution-wrap><addr-line><named-content content-type="city">Münster</named-content></addr-line><country>Germany</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/040djv263</institution-id><institution>Embryonic Self-Organization Research Group, Max Planck Institute for Molecular Biomedicine</institution></institution-wrap><addr-line><named-content content-type="city">Münster</named-content></addr-line><country>Germany</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Ackert-Bicknell</surname><given-names>Cheryl</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03wmf1y16</institution-id><institution>University of Colorado</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Rosen</surname><given-names>Clifford J</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03d1wq758</institution-id><institution>Maine Medical Center Research Institute</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>04</day><month>02</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>11</volume><elocation-id>e60183</elocation-id><history><date date-type="received" iso-8601-date="2020-06-18"><day>18</day><month>06</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2022-02-03"><day>03</day><month>02</month><year>2022</year></date></history><permissions><copyright-statement>© 2022, Xu et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Xu et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-60183-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-60183-figures-v2.pdf"/><abstract><p>Declining bone mass is associated with aging and osteoporosis, a disease characterized by progressive weakening of the skeleton and increased fracture incidence. Growth and lifelong homeostasis of bone rely on interactions between different cell types including vascular cells and mesenchymal stromal cells (MSCs). As these interactions involve Notch signaling, we have explored whether treatment with secreted Notch ligand proteins can enhance osteogenesis in adult mice. We show that a bone-targeting, high affinity version of the ligand Delta-like 4, termed Dll4<sub>(E12)</sub>, induces bone formation in male mice without causing adverse effects in other organs, which are known to rely on intact Notch signaling. Due to lower bone surface and thereby reduced retention of Dll4<sub>(E12)</sub>, the same approach failed to promote osteogenesis in female and ovariectomized mice but strongly enhanced trabecular bone formation in combination with parathyroid hormone. Single cell analysis of stromal cells indicates that Dll4<sub>(E12)</sub> primarily acts on MSCs and has comparably minor effects on osteoblasts, endothelial cells, or chondrocytes. We propose that activation of Notch signaling by bone-targeted fusion proteins might be therapeutically useful and can avoid detrimental effects in Notch-dependent processes in other organs.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>bone</kwd><kwd>osteogenesis</kwd><kwd>Notch signaling</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution>Max Planck Society</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Adams</surname><given-names>Ralf H</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000781</institution-id><institution>European Research Council</institution></institution-wrap></funding-source><award-id>AdG 339409 AngioBone</award-id><principal-award-recipient><name><surname>Adams</surname><given-names>Ralf H</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000781</institution-id><institution>European Research Council</institution></institution-wrap></funding-source><award-id>AdG 786672 PROVEC</award-id><principal-award-recipient><name><surname>Adams</surname><given-names>Ralf H</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution>Leducq Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Adams</surname><given-names>Ralf H</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Bone formation in adult mice can be induced by a bone-binding, recombinant version of the Notch ligand Delta-like 4 without triggering adverse effects in other organs.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Osteoporosis is the most common disease affecting the skeletal system in humans and characterized by low bone mass, reduced mineral density, and disarranged bone microarchitecture. This reduces bone strength and increases the risk of fractures, which leads to secondary health problems and increased mortality (<xref ref-type="bibr" rid="bib39">NIH Consensus Development, 2001</xref>; <xref ref-type="bibr" rid="bib10">Cosman et al., 2014</xref>). The skeletal system is undergoing lifelong remodeling mediated by bone-forming osteoblasts and bone-resorptive osteoclasts (<xref ref-type="bibr" rid="bib61">Walsh et al., 2006</xref>). Disbalance between bone formation and resorption can lead to osteopenia, the loss of bone density, and frequently progresses into osteoporosis (<xref ref-type="bibr" rid="bib14">Feng and McDonald, 2011</xref>). Anti-osteoporosis therapies are either anabolic, by enhancing osteoblast activity, or anti-resorptive, involving the inhibition of osteoclast activity. FDA-approved osteoclast inhibitors include bisphosphonates, such as alendronate, risedronate, ibandronate, and zoledronic acid (<xref ref-type="bibr" rid="bib54">Saag et al., 1998</xref>; <xref ref-type="bibr" rid="bib12">Eastell et al., 2000</xref>; <xref ref-type="bibr" rid="bib8">Chesnut et al., 2004</xref>; <xref ref-type="bibr" rid="bib35">Lyles et al., 2007</xref>) but also the peptide hormone calcitonin (<xref ref-type="bibr" rid="bib7">Chesnut et al., 2000</xref>) and the female sex hormone estrogen (<xref ref-type="bibr" rid="bib53">Rossouw et al., 2002</xref>), whereas a peptide fragment of parathyroid hormone (PTH1–34) and monoclonal antibodies inhibiting sclerostin are used in the clinic to increase bone formation (<xref ref-type="bibr" rid="bib38">Neer et al., 2001</xref>; <xref ref-type="bibr" rid="bib9">Clarke, 2014</xref>; <xref ref-type="bibr" rid="bib29">Li et al., 2009</xref>; <xref ref-type="bibr" rid="bib52">Ross et al., 2014</xref>). Apart from specific drawbacks of individual drugs, systemic administration generally facilitates the emergence of adverse side effects, which could be potentially avoided by directing therapeutic agents to bone. Examples include L-Asp-hexapeptide conjugated-estradiol (E2) (<xref ref-type="bibr" rid="bib56">Sekido et al., 2001</xref>; <xref ref-type="bibr" rid="bib66">Yokogawa et al., 2001</xref>) and conjugates of prostaglandin E2 and bisphosphonate (<xref ref-type="bibr" rid="bib16">Gil et al., 1999</xref>). These drugs contain targeting moieties made of either synthetic bisphosphonates or repeats of negatively charged glutamate (Glu) or aspartate (Asp) amino acid residues, which show high affinity binding to hydroxyapatite, a main component of mineralized bone (<xref ref-type="bibr" rid="bib58">Stapleton et al., 2017</xref>). Apart from enrichment in the skeletal system, the modified drugs show reduced plasma retention, which limits adverse effects after administration (<xref ref-type="bibr" rid="bib56">Sekido et al., 2001</xref>; <xref ref-type="bibr" rid="bib66">Yokogawa et al., 2001</xref>; <xref ref-type="bibr" rid="bib24">Katsumi et al., 2015</xref>). However, the efficacy of these drugs still requires clinical validation and there is still high demand for novel and effective anti-osteoporosis drugs.</p><p>Notch signaling is an evolutionary conserved pathway with numerous functional roles including the regulation of osteogenesis. In mammals, there are four Notch receptors, namely Notch 1–4, and five ligands belonging either to the Jagged/Serrate (Jag1, Jag2) or the Delta-like subfamily (Dll1, Dll3, and Dll4) (<xref ref-type="bibr" rid="bib69">Zanotti and Canalis, 2016</xref>). As both receptors and ligands are transmembrane proteins, their interaction requires cell-cell contact and triggers ligand internalization, which is necessary for Notch receptor activation (<xref ref-type="bibr" rid="bib18">Hicks et al., 2002</xref>; <xref ref-type="bibr" rid="bib40">Noguera-Troise et al., 2006</xref>; <xref ref-type="bibr" rid="bib50">Ramasamy et al., 2014</xref>). Soluble fragments containing the ligand ECD can bind Notch but fail to induce receptor activation and thereby effectively act as antagonists (<xref ref-type="bibr" rid="bib18">Hicks et al., 2002</xref>; <xref ref-type="bibr" rid="bib40">Noguera-Troise et al., 2006</xref>). In skeletal development, Notch signaling in limb mesenchyme controls the maintenance and proliferation of mesenchymal progenitor cells and prevents premature osteoblastic differentiation (<xref ref-type="bibr" rid="bib20">Hilton et al., 2008</xref>; <xref ref-type="bibr" rid="bib13">Engin et al., 2008</xref>). Context-specific Notch signaling also plays important roles in osteoclast differentiation and function (<xref ref-type="bibr" rid="bib68">Yu and Canalis, 2020</xref>). Notch activity in bone marrow (BM) macrophages inhibits commitment to osteoclast differentiation, but it enhances the maturation and function of committed osteoclast precursors (<xref ref-type="bibr" rid="bib21">Jiménez-Alcázar et al., 2017</xref>; <xref ref-type="bibr" rid="bib63">Wu et al., 2010</xref>). Notch is generally a negative regulator of endothelial cell (EC) proliferation and vascular growth, but exerts the opposite function in bone and promotes the formation of type H vessels. This capillary subtype is associated with osteoblast lineage cells and enhances osteogenesis by providing growth factors and other signals (<xref ref-type="bibr" rid="bib50">Ramasamy et al., 2014</xref>; <xref ref-type="bibr" rid="bib26">Kusumbe et al., 2014</xref>; <xref ref-type="bibr" rid="bib47">Polacheck et al., 2017</xref>; <xref ref-type="bibr" rid="bib28">Langen et al., 2017</xref>).</p><p>The reports above suggest that Notch activation, for example, through the administration of exogenous ligand molecules, might have the capacity to enhance bone formation. Given the many functional roles of Notch signaling in different organs and processes, it would be desirable to preferentially direct soluble Notch ligands to bone and thereby limit potentially harmful side effects elsewhere in the body. Here, we report the generation of a soluble, bone-targeted fusion protein, termed Dll4<sub>(E12)</sub>, combining the extracellular domain (ECD) of Delta-like 4 (Dll4), several point mutations to increase affinity for Notch receptors (<xref ref-type="bibr" rid="bib33">Luca et al., 2015</xref>), and a negatively charged poly-aspartate peptide motif (Asp<sub>8x</sub>) mediating binding to hydroxyapatite. We show that Dll4<sub>(E12)</sub> increases bone formation in male adult mice without inducing adverse effects in other organs that have been previously linked to compromised Notch function. The same approach fails to enhance osteogenesis in female and ovariectomized mice, which we attribute to the lower bone surface and reduced retention of bone-targeted ligand in these animals. In contrast, bone formation in response to parathyroid hormone (PTH) is strongly enhanced by Dll4<sub>(E12)</sub> in female mice. Based on the histological analysis of Dll4<sub>(E12)</sub>-treated tissue samples as well as immunohistological and single cell RNA sequencing (scRNA-seq) analysis of bone stromal cell populations, we conclude that Dll4<sub>(E12)</sub> is safe and can be used to activate Notch signaling in bone mesenchymal stromal cells (MSCs) leading to enhanced osteogenesis.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Generation and characterization of soluble, bone-binding Dll4</title><p>Notch signaling plays important roles in the maintenance of mesenchymal progenitor cells and the coupling of angiogenesis and osteogenesis in the developing skeletal system (<xref ref-type="bibr" rid="bib50">Ramasamy et al., 2014</xref>; <xref ref-type="bibr" rid="bib20">Hilton et al., 2008</xref>; <xref ref-type="bibr" rid="bib13">Engin et al., 2008</xref>; <xref ref-type="bibr" rid="bib26">Kusumbe et al., 2014</xref>). To explore whether Notch activation might be therapeutically useful to enhance bone formation in the adult organism, we generated a fusion construct comprising the ECD of Dll4, a critical Notch ligand in ECs, a poly-histidine epitope tag (His<sub>6x</sub>) enabling protein purification and detection, and a carboxyterminal stretch of eight aspartic acid residues (Asp<sub>8x</sub>) mediating binding to hydroxyapatite (Dll4-Asp<sub>8x</sub>) (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Expression and molecular weight of the secreted protein was validated by expression in HEK293 cells followed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) of the culture supernatant (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). Previous work has established that soluble Notch ligands lack the capacity to activate their corresponding receptors and act as inhibitors blocking the interaction between endogenous, membrane-anchored Delta/Jagged ligands and Notch receptors (<xref ref-type="bibr" rid="bib18">Hicks et al., 2002</xref>; <xref ref-type="bibr" rid="bib40">Noguera-Troise et al., 2006</xref>). As expected, Dll4-Asp<sub>8x</sub> inhibits the expression of established Notch target genes in confluent human umbilical vascular endothelial cells (HUVECs) in vitro (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>). When culture dishes were pre-coated with poly-L-lysine enabling the binding of negatively charged molecules, Dll4-Asp<sub>8x</sub> acts as an activator and induces the transcription of Notch target genes in sub-confluent HUVECs (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>). These data indicate that Dll4-Asp<sub>8x</sub> can interact with Notch receptors and that immobilization via the Asp<sub>8x</sub> motif enables Notch activation in cultured cells.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Recombinant Dll4<sub>(E12)</sub> increases bone formation in vivo.</title><p>(<bold>A</bold>) Schematic diagram showing the domain organization of murine Dll4 full-length protein and recombinant Dll4-Asp<sub>8x</sub> and Dll4<sub>(E12)</sub> fusion proteins. The latter contain 6x His epitope tags (green boxes) and negatively charged peptides consisting of eight Asp residues (8x Asp; blue boxes) instead of the transmembrane (TM) domain and cytoplasmic region (CR) of Dll4. Missense mutations were introduced in the MNNL (modulus at the N-terminus of Notch ligands) and DSL (Delta-Serrate-Lin) domains to generate Dll4<sub>(E12)</sub> with increased Notch-binding affinity. The resulting amino acid replacements are highlighted in red. SP, signal peptide. (<bold>B</bold>) Representative overview and high-magnification confocal images of Dll4 staining (green) on the femurs of <italic>pLIVE-Dll4<sub>(E12)</sub></italic> and control-injected mice at the age of 11 weeks. Nuclei, DAPI (blue). Images on the right show higher magnifications of insets in metaphysis (1), bone marrow (2), and cortical bone (3). (<bold>C</bold>) Tile scan confocal images showing Collagen I alpha one chain (Col1a1) staining (green) in sections from <italic>pLIVE-Dll4<sub>(E12)</sub></italic> and control femur. Nuclei, DAPI (blue). (<bold>D</bold>) Representative 3D reconstruction of micro-computed tomography (µ-CT) measurements for tibial metaphysis of 11-week-old <italic>pLIVE-Dll4<sub>(E12)</sub></italic>- and control-injected mice. (<bold>E</bold>) Bone parameters measured by µ-CT analyses: bone volume/total volume (BV/TV) in percentage, trabecular thickness in millimeters, connectivity density in one per cubic millimeter, trabeculae number in one per millimeter, trabecular separation in millimeters, and trabecular number in one per millimeter. Data represent mean ± s.e.m. (n = 5 mice, except for trabecular number with n = 4 mice) (p-values determined by unpaired t-test with Welch’s correction). Graphs at the bottom represent quantitation of eroded surface over bone surface (ES/BS) in percentage and osteoblast surface overs total bone surface (Ob.S/BS) in percentage, calculated from histological HE-stained bone sections. Data represent mean ± s.e.m. (n = 5 mice) (p-values determined by Mann-Whitney U test). (<bold>F</bold>) Representative images of calcein double labeling (7-day time interval) in mineralized sections of the distal femur confirm increased bone formation after <italic>pLIVE-Dll4<sub>(E12)</sub></italic> injection. Quantification of mineral apposition rate (MAR) and bone formation rate (BFR) (right panels). Data represent mean ± s.e.m. (n = 5 mice) (p-values determined by unpaired t-test with Welch’s correction).</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig1">Figure 1E and F</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-60183-fig1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60183-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Generation of Dll4-Asp<sub>8x</sub> recombinant proteins.</title><p>(<bold>A</bold>) Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) analysis of purified Dll4-Asp<sub>8x</sub> recombinant proteins. From left to right, protein molecular mass marker (Marker), extract of untransfected HEK293 cells (Cells (-)) OR <italic>pcDNA3.1-Dll4-Asp<sub>8x</sub></italic>-transfected cells (Cells (+)), supernatant after culture of untransfected (Supernatant (-)) OR <italic>pcDNA3.1-Dll4-Asp<sub>8</sub></italic>-transfected cells (Supernatant (+)), flow-through after loading of Supernatant (+) on His-tag protein purification column (Flow-through), wash buffer (Wash), elute (Elute), elute after dialysis (Elute (AD)), and Opti-MEM culture medium (Medium) were loaded. (<bold>B, C</bold>) RT-qPCR analysis of <italic>DLL4</italic>, <italic>HEY1</italic>, <italic>HEY2</italic>, <italic>HES1</italic>, <italic>EFNB2</italic>, and <italic>NRARP</italic> transcripts in confluent human umbilical vascular endothelial cells (HUVECs) stimulated with soluble (<bold>B</bold>) or in sub-confluent HUVECs stimulated with immobilized Dll4-Asp<sub>8x</sub> or BSA with poly-L-lysine coating (<bold>C</bold>). Data represent mean ± s.e.m. (n = 4 for (<bold>B</bold>) and n = 6 for (<bold>C</bold>)) (p-values determined by multiple unpaired t-test with Welch’s correction).</p><p><supplementary-material id="fig1s1sdata1"><label>Figure 1—figure supplement 1—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B,C</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-60183-fig1-figsupp1-data1-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="fig1s1sdata2"><label>Figure 1—figure supplement 1—source data 2.</label><caption><title>Images of uncropped blots and gels with the relevant bands labeled for <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>, <xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4</xref>, and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>.</title></caption><media mime-subtype="pdf" mimetype="application" xlink:href="elife-60183-fig1-figsupp1-data2-v2.pdf"/></supplementary-material></p><p><supplementary-material id="fig1s1sdata3"><label>Figure 1—figure supplement 1—source data 3.</label><caption><title>ZIP file containing the full raw unedited blots and gels for <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>, <xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4</xref>, and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-60183-fig1-figsupp1-data3-v2.zip"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60183-fig1-figsupp1-v2.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Dll4-Asp<sub>8x</sub> detection in bone.</title><p>(<bold>A, B</bold>) Confocal images showing Dll4 (cyan) and Emcn (red) staining in femoral metaphysis (<bold>A</bold>) and endosteum and cortical bone (<bold>B</bold>) of <italic>pLIVE-Dll4-Asp<sub>8x</sub></italic> and control-injected 11-week-old mice. Nuclei, DAPI (blue). (<bold>C</bold>) Higher magnification images showing pronounced Dll4 signal (cyan, arrows) in proximity of Emcn<sup>+</sup> (red) distal vessels in the <italic>pLIVE-Dll4-Asp<sub>8x</sub></italic> metaphysis. Nuclei, DAPI (blue).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60183-fig1-figsupp2-v2.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 3.</label><caption><title>Bone formation is not increased by Dll4-Asp<sub>8x</sub>.</title><p>(<bold>A</bold>) Tile scan images of Dll4 (cyan) staining in sections of <italic>pLIVE-Dll4-Asp<sub>8x</sub></italic> and control femur. Nuclei, DAPI (blue). Images on the right show higher magnifications of insets in metaphysis (1), bone marrow (2), and cortical bone (3). (<bold>B</bold>) Osterix (OSX), Osteopontin, and Collagen I alpha one chain (Col1a1) (green) immunostaining, as indicated, in <italic>pLIVE-Dll4-Asp<sub>8x</sub></italic> and control femur. Nuclei, DAPI (blue).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60183-fig1-figsupp3-v2.tif"/></fig><fig id="fig1s4" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 4.</label><caption><title>Generation of Dll4<sub>(E12).</sub></title><p>(<bold>A</bold>) Diagram showing the amino acid sequence of mouse and rat Dll4 extracellular domain (ECD). Amino acid replacements shown in red were introduced into the murine sequence for the generation of Dll4<sub>(E12)</sub> with increased Notch-binding affinity. (<bold>B</bold>) Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) analysis of purified Dll4<sub>(E12)</sub> recombinant protein. From left to right, protein molecular mass marker (Marker), supernatant after culture of untransfected (Supernatant (-)) OR <italic>pcDNA3.1-Dll4<sub>(E12)</sub></italic>-transfected HEK293 cells (Supernatant (+)), flow-through after loading of Supernatant (+) on His-tag protein purification column (Flow-through), wash buffer (Wash), elute (Elute), elute after dialysis (Elute (AD)), and Opti-MEM culture medium (Medium) were loaded. (<bold>C, D</bold>) RT-qPCR analysis of <italic>DLL4</italic>, <italic>HEY1</italic>, <italic>HEY2</italic>, <italic>HES1</italic>, <italic>EFNB2</italic>, and <italic>NRARP</italic> transcripts in confluent human umbilical vascular endothelial cells (HUVECs) stimulated with soluble (<bold>C</bold>) or in sub-confluent HUVECs stimulated with immobilized Dll4<sub>(E12)</sub>, Dll4-Asp<sub>8x</sub>, and BSA by poly-L-lysine coating (<bold>D</bold>). Data represent mean ± s.e.m. (n = 3 for (<bold>C</bold>) and n = 4 for (<bold>D</bold>)) (p-values determined by ordinary one-way ANOVA with Tukey’s multiple comparison test). (<bold>E</bold>) Western blot analysis of Dll4<sub>(E12)</sub> protein expression in liver lysate of <italic>pLIVE-Dll4<sub>(E12)</sub></italic> and control-injected mice. GAPDH is used as loading control.</p><p><supplementary-material id="fig1s4sdata1"><label>Figure 1—figure supplement 4—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C,D</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-60183-fig1-figsupp4-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60183-fig1-figsupp4-v2.tif"/></fig><fig id="fig1s5" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 5.</label><caption><title>Dll4<sub>(E12)</sub> immunoreactivity in vivo.</title><p>(<bold>A–C</bold>) Representative confocal images showing Dll4<sub>(E12)</sub> immunoreactivity after <italic>pLIVE-Dll4<sub>(E12)</sub></italic> or control injection in liver (<bold>A</bold>), spleen, (<bold>B</bold>) and lung (<bold>C</bold>). Dll4<sub>(E12)</sub> signal (green) is prominent in liver hepatocytes but undetectable in spleen and lung. Note absence of overt changes in the vasculature (red) of all three organs. Nuclei (DAPI, blue).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60183-fig1-figsupp5-v2.tif"/></fig></fig-group><p>For in vivo experiments in mice, a cDNA encoding Dll4-Asp<sub>8x</sub> was cloned into the vector <italic>pLIVE</italic>, which mediates constitutive protein expression in liver after hydrodynamic tail vein injection (<xref ref-type="bibr" rid="bib21">Jiménez-Alcázar et al., 2017</xref>). Immunohistological characterization of sectioned <italic>pLIVE-Dll4-Asp<sub>8x</sub></italic>-treated femurs isolated from male mice at 2 days post-injection (dpi) and 3 weeks post-injection (wpi) shows strong Dll4 signals at trabecular bone, the endosteum lining the inner surface of compact bone, and around distal vessel buds in proximity of the growth plate. In contrast, no comparable signals are seen in samples from male control animals (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A-C</xref> and <xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3A</xref>). These data confirm the successful expression of recombinant Dll4-Asp<sub>8x</sub> in vivo and binding of the fusion protein to bone. However, Dll4-Asp<sub>8x</sub>-treated bone samples at 3 wpi do not show overt alterations in Osterix<sup>+</sup> osteoblast lineage cells and deposition of the matrix proteins Osteopontin (Opn) and Collagen I alpha one chain (Col1a1) (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3B</xref>).</p></sec><sec id="s2-2"><title>Generation of a high affinity Dll4 fusion protein</title><p>To address the possibility that Dll4-Asp<sub>8x</sub> does not achieve sufficient levels of Notch activation in bone, we also generated a high affinity variant of this protein by introducing multiple point mutations into the Dll4 ECD, which were previously reported to enhance Notch binding and signaling (<xref ref-type="bibr" rid="bib33">Luca et al., 2015</xref>; <xref ref-type="fig" rid="fig1">Figure 1A</xref> and <xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4A</xref>). Following expression in HEK293 cells, SDS-PAGE confirmed the correct molecular weight of the resulting Dll4<sub>(E12)</sub> version of Dll4-Asp<sub>8x</sub> in culture supernatants (<xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4B</xref>). Purified and soluble Dll4<sub>(E12)</sub> inhibits endogenous Notch signaling in cultured HUVECs similar to Dll4-Asp<sub>8x</sub>, whereas Dll4<sub>(E12)</sub> in combination with poly-L-lysine pre-coating induces the upregulation of Notch target genes (<xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4C and D</xref>). To overexpress Dll4<sub>(E12)</sub> in vivo, a cDNA encoding Dll4<sub>(E12)</sub> was cloned into the <italic>pLIVE</italic> vector and the resulting <italic>pLIVE-Dll4<sub>(E12)</sub></italic> construct was administered to male mice via hydrodynamic tail vein injection. Western blot analysis of liver lysates confirmed the expression of Dll4<sub>(E12)</sub> at 3 wpi (<xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4E</xref>). Consistent with the hydroxyapatite-binding properties of Dll4-Asp<sub>8x</sub>, immunohistological analysis of femurs confirms the accumulation of Dll4<sub>(E12)</sub> at the surface of trabecular and cortical bone (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). Notably, histological analysis also reveals a strong increase in the Col1a1-positive area in <italic>pLIVE-Dll4<sub>(E12)</sub></italic>-injected mice (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). Micro-computed tomography (μ-CT) and histomorphometric analysis show significant increases in bone mass and density (bone volume over total volume [BV/TV]), connectivity density and thickness of trabeculae and osteoblast surface in <italic>pLIVE-Dll4<sub>(E12)</sub></italic>-injected tibiae (<xref ref-type="fig" rid="fig1">Figure 1D and E</xref>). However, no significant changes are observed in trabecular separation, trabecular number, and erosion surface (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). In vivo double calcein labeling further argues for enhanced bone formation in mice treated with Dll4<sub>(E12)</sub> (<xref ref-type="fig" rid="fig1">Figure 1F</xref>). Together, these results show that key parameters of bone quality can be enhanced by expression of a soluble, hydroxyapatite-binding version of Dll4 with high affinity for Notch receptors.</p></sec><sec id="s2-3"><title>Lack of adverse biological effects of Dll4<sub>(E12)</sub> treatment</title><p>The Notch pathway is involved in a wide range of biological processes and, accordingly, Notch inhibition in vivo can have serious pathological effects. Considering that circulating Dll4<sub>(E12)</sub> released by liver cells might act as an antagonist of endogenous Notch signaling interactions, we examined several different organs for Dll4 immunoreactivity and the appearance of pathological alterations. While liver hepatocytes show the expected expression of Dll4<sub>(E12)</sub> (<xref ref-type="fig" rid="fig1s5">Figure 1—figure supplement 5A</xref>), no increase in Dll4 immunoreactivity indicating binding of Dll4<sub>(E12)</sub> was seen in spleen or lung (<xref ref-type="fig" rid="fig1s5">Figure 1—figure supplement 5B and C</xref>). In small intestine, Notch inhibition has been linked to toxicity by impairing the formation and distribution of goblet cells (<xref ref-type="bibr" rid="bib63">Wu et al., 2010</xref>). However, intestinal crypts from <italic>pLIVE-Dll4<sub>(E12)</sub></italic>-injected mice show no goblet cell metaplasia (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). While chronic Dll4 blockade was shown to cause sinusoidal vessel dilation in liver (<xref ref-type="bibr" rid="bib65">Yan et al., 2010</xref>), histological analysis reveals no differences between <italic>pLIVE-Dll4<sub>(E12)</sub></italic> and control livers (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). This result is particularly remarkable, as liver is the source of Dll4<sub>(E12)</sub> protein expression after hydrodynamic tail vein injection. Dll4-mediated Notch1 activation is essential for thymic T cell development (<xref ref-type="bibr" rid="bib63">Wu et al., 2010</xref>), but flow cytometry shows comparable numbers of CD4<sup>+</sup> and CD8<sup>+</sup> double positive T cells in thymi from control and <italic>pLIVE-Dll4<sub>(E12)</sub></italic>-injected mice (<xref ref-type="fig" rid="fig2">Figure 2C and D</xref>). While it has been proposed that Dll4-triggered Notch signaling modulates inflammatory responses (<xref ref-type="bibr" rid="bib15">Fung et al., 2007</xref>), inflammatory cytokines are also not significantly increased in plasma from <italic>pLIVE-Dll4<sub>(E12)</sub></italic>-injected mice (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). Notch inhibition was also shown to compromise the barrier function of vascular endothelium (<xref ref-type="bibr" rid="bib47">Polacheck et al., 2017</xref>). However, the extravasation of fluorescent Texas-Red-labeled Dextran is not increased in femurs from <italic>pLIVE-Dll4<sub>(E12)</sub></italic>-injected mice (<xref ref-type="fig" rid="fig2">Figure 2E and F</xref>). Furthermore, there is no significant difference in Texas Red Dextran extravasation in other organs investigated, namely liver, spleen, and lung (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A-C</xref>). The sum of these results indicates that Dll4<sub>(E12)</sub> causes no adverse systemic effects that are known to result from Notch inhibition.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Notch-dependent processes are not blocked by Dll4<sub>(E12)</sub>in vivo.</title><p>(<bold>A</bold>) Alcian blue and nuclear fast red double staining of small intestine. Secretory goblet cells are labeled by Alcian blue. (<bold>B</bold>) Hematoxylin and eosin staining of liver sections of 11-week-old <italic>pLIVE-Dll4<sub>(E12)</sub></italic> and control-injected mice. (<bold>C, D</bold>) Analysis of CD4<sup>+</sup>/CD8<sup>+</sup> cells from <italic>pLIVE-Dll4<sub>(E12)</sub></italic> and control thymi by flow cytometry (<bold>C</bold>) and corresponding quantification (<bold>D</bold>). Data represent mean ± s.e.m. (n = 3 mice) (p-values determined by unpaired t-test with Welch’s correction). (<bold>E</bold>) Confocal images showing comparable extravasation of fluorescent Dextran (70 kD) in femur of <italic>pLIVE-Dll4<sub>(E12)</sub></italic> and control-injected mice. (<bold>F</bold>) Quantitation of Texas Red-labeled Dextran extravasation in femoral metaphysis and diaphysis of <italic>pLIVE-Dll4<sub>(E12)</sub></italic> and control-injected mice. Data represent mean ± s.e.m. (n = 5 mice) (adjusted p-values determined by two-way ANOVA with Tukey’s multiple comparison test).</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig2">Figure 2D and F</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-60183-fig2-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60183-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Inflammatory cytokines are not induced by Dll4<sub>(E12)</sub>.</title><p>Quantification of inflammatory cytokines in the plasma of <italic>pLIVE-Dll4<sub>(E12)</sub></italic>- and control-injected mice. Data represent mean ± s.e.m. (n = 3 mice) (p-values determined by multiple unpaired t-test with Welch’s correction).</p><p><supplementary-material id="fig2s1sdata1"><label>Figure 2—figure supplement 1—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-60183-fig2-figsupp1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60183-fig2-figsupp1-v2.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Dll4<sub>(E12)</sub> does not induce vascular leakage.</title><p>(<bold>A–C</bold>) Representative confocal images and corresponding quantitation showing comparable extravasation of Texas Red-coupled fluorescent Dextran (purple) in liver (<bold>A</bold>), spleen, (<bold>B</bold>) and lung (<bold>C</bold>) of <italic>pLIVE-Dll4<sub>(E12)</sub></italic> and control-injected mice. Vasculature in liver and spleen (<bold>A, B</bold>) has been immunostained for Emcn (green) and in lung (<bold>C</bold>) for CD31 (green). Data represent mean ± s.e.m. (n = 5 mice) (p-values determined by unpaired t-test with Welch’s correction).</p><p><supplementary-material id="fig2s2sdata1"><label>Figure 2—figure supplement 2—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A-C</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-60183-fig2-figsupp2-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60183-fig2-figsupp2-v2.tif"/></fig></fig-group></sec><sec id="s2-4"><title>Effects of recombinant Dll4<sub>(E12)</sub> on bone and vasculature</title><p>Next, we performed a more detailed analysis of the alterations in <italic>pLIVE-Dll4<sub>(E12)</sub></italic> femur at 3 wpi. While Osterix<sup>+</sup> (OSX<sup>+</sup>) osteoblasts are strikingly increased relative to control samples, there is a significant reduction in the number of Runx2<sup>+</sup> osteoprogenitors (<xref ref-type="fig" rid="fig3">Figure 3A and B</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). Dll4<sub>(E12)</sub> treatment was also performed on <italic>Tg(Hey1-EGFP)<sup>ID40Gsat</sup></italic> mice, which express enhanced green fluorescent protein (GFP) under the control of <italic>Hey1</italic>, a Notch target gene. Dll4<sub>(E12)</sub> strongly increases the number of perivascular GFP<sup>+</sup> cells in the metaphysis relative to control animals (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). Notably, these cells are located in close proximity to OSX<sup>+</sup> osteoblasts but lack strong nuclear OSX immunostaining. Vessel-associated Hey1-expressing cells in Dll4<sub>(E12)</sub>-treated mice are also found in the transition zone interconnecting the metaphyseal and diaphyseal vasculature, whereas no GFP<sup>+</sup> cells are found in BM (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). In addition to the increase in OSX<sup>+</sup> cells, Dll4<sub>(E12)</sub> treatment enhances the expression of major non-collagenous proteins involved in bone matrix organization and deposition, namely Opn and Osteocalcin (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). Similarly, immunostaining of the receptor tyrosine kinase PDGFRβ and the proteoglycan NG2, both markers of MSCs, are significantly increased in the <italic>pLIVE-Dll4<sub>(E12)</sub></italic> metaphysis (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2A, B</xref>). Arguing against increased bone turnover involving higher bone resorption, Dll4<sub>(E12)</sub> treatment does not lead to significant alterations in the number of V-ATPase<sup>+</sup> osteoclasts (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). Furthermore, immunohistological analysis reveals that adipocyte number and the expression of critical chondrocyte markers, such as Aggrecan (Acan) and the transcription factor Sox9, are not significantly altered by recombinant Dll4<sub>(E12)</sub> (<xref ref-type="fig" rid="fig3">Figure 3E</xref> and <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2C, D</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Recombinant Dll4<sub>(E12)</sub> increases osteogenesis.</title><p>(<bold>A</bold>) Tile scan confocal images of Osterix (OSX) staining (green) in femurs from <italic>pLIVE-Dll4<sub>(E12)</sub></italic> and control-injected mice. Nuclei, DAPI (blue). Graph shows quantitation of OSX<sup>+</sup> cells. Data represent mean ± s.e.m. (n = 4 mice) (p-values determined by two-tailed unpaired t-test). (<bold>B</bold>) Runx2 staining (green) of <italic>pLIVE-Dll4<sub>(E12)</sub></italic> and control femurs. Nuclei, DAPI (blue). Graph shows quantitation of Runx2<sup>+</sup> cells. Data represent mean ± s.e.m. (n = 4 mice) (p-values determined by two-tailed unpaired t-test). (<bold>C</bold>) Representative images showing Osteopontin (Opn) and Osteocalcin staining (green) in <italic>pLIVE-Dll4<sub>(E12)</sub></italic> and control femur. Nuclei, DAPI (blue). Data represent mean ± s.e.m. (n = 3 mice) (p-values determined by unpaired t-test with Welch’s correction). (<bold>D</bold>) Tile scan images of ATP6V1B1+ ATP6V1B2 (V-ATPase) staining (green) in <italic>pLIVE-Dll4<sub>(E12)</sub></italic> and control femur. Nuclei, DAPI (blue). Graphs show quantification of osteoclast surface/bone surface (Os. S/B S) and osteoclast number/bone perimeter (No. Oc./B. Pm). Data represent mean ± s.e.m. (n = 4 mice) (p-values determined by unpaired t-test with Welch’s correction). (<bold>E</bold>) Tile scan images of Perilipin staining (green) in <italic>pLIVE-Dll4<sub>(E12)</sub></italic> and control femurs. Nuclei, DAPI (blue). Graph shows quantitation of Perilipin<sup>+</sup> adipocytes. Data represent mean ± s.e.m. (n = 3 mice) (p-values determined by unpaired t-test with Welch’s correction).</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig3">Figure 3A–E</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-60183-fig3-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60183-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Activation of the <italic>Hey1-EGFP</italic> reporter by Dll4<sub>(E12).</sub></title><p>Expression of the <italic>Tg(Hey1-EGFP)<sup>ID40Gsat</sup></italic> reporter (green fluorescent protein [GFP], green) in 11-week-old <italic>pLIVE-Dll4<sub>(E12)</sub></italic> and control femur. Note that Dll4<sub>(E12)</sub> increases the number of Osterix<sup>+</sup> (OSX<sup>+</sup>) cells (cyan) and leads to induction of GFP expression in the metaphysis but also in the adjacent transition zone. GFP<sup>+</sup> cells show no or weak nuclear OSX signals (arrows). Vessels, Emcn (red). Nuclei, DAPI (blue).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60183-fig3-figsupp1-v2.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Effect of Dll4<sub>(E12)</sub> on metaphyseal mesenchymal stromal cells (MSCs) and chondrocytes.</title><p>(<bold>A, B</bold>) Tile scan confocal images showing that PDGFRβ (<bold>A</bold>) and NG2 (<bold>B</bold>) immunostaining in the adult metaphysis is increased by recombinant Dll4<sub>(E12)</sub>. Nuclei, DAPI (blue). Graph shows quantitation of PDGFRβ area/DAPI area (<bold>A</bold>) and NG2 area/DAPI area in percentage. Data represent mean ± s.e.m. (n = 3 mice) (p-values determined by unpaired t-test with Welch’s correction). (<bold>C, D</bold>) Representative confocal images of chondrocyte staining in adult metaphysis showing that Acan<sup>+</sup> (<bold>C</bold>) and Sox9<sup>+</sup> (<bold>D</bold>) chondrocytes are not affected by <italic>pLIVE-Dll4<sub>(E12)</sub></italic> injection. Nuclei, DAPI (blue). Graphs show quantitation of Acan<sup>+</sup> cells number (<bold>C</bold>) and Sox9<sup>+</sup> cells number (<bold>D</bold>). Data represent mean ± s.e.m. (n = 3 mice) (p-values determined by unpaired t-test with Welch’s correction).</p><p><supplementary-material id="fig3s2sdata1"><label>Figure 3—figure supplement 2—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2A-D</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-60183-fig3-figsupp2-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60183-fig3-figsupp2-v2.tif"/></fig></fig-group><p>To assess whether blood vessels in long bone are altered by treatment with Dll4<sub>(E12)</sub>, we examined the expression of some known vascular makers such as Endomucin (Emcn) and VEGFR3 in femoral sections. Low VEGFR3 immunostaining was previously shown to mark type H vessels columns that are associated with OSX<sup>+</sup> osteoprogenitors in the metaphysis, whereas vessel buds in direct proximity of growth plate chondrocytes and the sinusoidal (type L) vasculature of the BM show high anti-VEGFR3 signal (<xref ref-type="bibr" rid="bib28">Langen et al., 2017</xref>). Notably, the region with VEGFR3<sup>low</sup> (type H) Emcn<sup>+</sup> vasculature and OSX<sup>+</sup> cells is significantly increased in the metaphysis of <italic>pLIVE-Dll4<sub>(E12)</sub></italic>-injected mice relative to control (<xref ref-type="fig" rid="fig4">Figure 4A–C</xref>). Notch signaling in bone ECs was previously shown to lead to an expansion of type H vasculature and increased osteogenesis, but it also promotes artery formation (<xref ref-type="bibr" rid="bib50">Ramasamy et al., 2014</xref>). However, the abundance of arteries and small arterioles is not significantly altered by Dll4<sub>(E12)</sub> (<xref ref-type="fig" rid="fig4">Figure 4D</xref>).</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Effect of Dll4<sub>(E12)</sub> on bone vasculature.</title><p>(<bold>A</bold>) Tile scan images of Emcn (red), VEGFR3 (green), and Osterix (OSX)- (cyan) stained sections of <italic>pLIVE-Dll4<sub>(E12)</sub></italic> and control femur at 11 weeks of age. Dashed line indicates the border of VEGFR3<sup>high</sup> and VEGFR3<sup>low</sup> area. (<bold>B</bold>) Higher magnifications of insets in (<bold>A</bold>) showing the metaphysis close to growth plate (1’ and 2’) and bone marrow close to transition zone (1’’ and 2’’). Stainings show VEGFR3 (green) and OSX (cyan). Note increase in OSX<sup>+</sup> cells and presence of OSX-stained nuclei close to VEGFR3<sup>high</sup> vessels after Dll4<sub>(E12)</sub> treatment. (<bold>C</bold>) Quantification of VEGFR3<sup>low</sup> area per region of interest (ROI) in the metaphysis. Data represent mean ± s.e.m. (n = 5 mice) (p-values determined by unpaired t-test with Welch’s correction). (<bold>D</bold>) Tile scan images of BCAM (green) stained sections of <italic>pLIVE-Dll4<sub>(E12)</sub></italic> and control femur. Graph shows quantification of the number of BCAM<sup>+</sup> arteries per ROI in the metaphysis. Data represent mean ± s.e.m. (n = 3 mice) (p-values determined by unpaired t-test with Welch’s correction).</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig4">Figure 4C and D</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-60183-fig4-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60183-fig4-v2.tif"/></fig></sec><sec id="s2-5"><title>Bone formation is not increased by Jag1-Asp<sub>8x</sub> and Jag1<sub>(JV1)</sub></title><p>Homotypic signaling interactions between Notch receptors and the ligand Jagged1 in osteochondral progenitors negatively regulate the pool of these progenitors but also promote bone formation (<xref ref-type="bibr" rid="bib67">Youngstrom et al., 2016</xref>; <xref ref-type="bibr" rid="bib32">Liu et al., 2016</xref>). Moreover, Delta and Jagged ligands have distinct, sometimes opposite biological functions in certain processes such as retinal angiogenesis or pancreas development (<xref ref-type="bibr" rid="bib2">Benedito et al., 2009</xref>; <xref ref-type="bibr" rid="bib17">Golson et al., 2009</xref>). To address whether exogenous Jagged1 has the capacity to enhance bone formation, we generated a soluble Jag1-Asp<sub>8x</sub> fusion protein in which, analogous to Dll4-Asp<sub>8x</sub>, the transmembrane and intracellular domain are replaced by His<sub>6x</sub> and Asp<sub>8x</sub> sequence motifs. In parallel, a high affinity variant of Jag1-Asp<sub>8x</sub>, termed Jag1<sub>(JV1)</sub>, was generated by replacing several amino acid residues in the ligand ECD, as previously reported (<xref ref-type="bibr" rid="bib34">Luca et al., 2017</xref>; <xref ref-type="fig" rid="fig5">Figure 5A</xref>). Jag1-Asp<sub>8x</sub> and Jag1<sub>(JV1)</sub> proteins were purified from HEK293 cell culture supernatants. SDS-PAGE and Western blotting confirmed the correct molecular weight of the purified proteins (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A-C</xref>). Soluble Jag1<sub>(JV1)</sub> inhibits <italic>DLL4, HEY1, HEY2,</italic> and <italic>EFNB2</italic>, known targets of Notch signaling, in cultured HUVECs, whereas immobilized Jag1<sub>(JV1)</sub> induces upregulation of Notch target genes at higher levels compared to Jag1-Asp<sub>8x</sub> stimulation (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1D and E</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Bone formation is not changed by recombinant Jag1-Asp<sub>8x</sub> and Jag1<sub>(JV1)</sub>.</title><p>(<bold>A</bold>) Schematic diagram showing the domain organization of murine Jag1 full-length protein and recombinant Jag1-Asp<sub>8x</sub> and Jag1<sub>(JV1)</sub> fusion proteins. Fusion proteins contain 6x His epitope tag (green boxes) and Asp<sub>8x</sub> negatively charged peptide motif (blue boxes) instead of the transmembrane (TM) domain and cytoplasmic region (CR) of Jag1. Missense mutations were introduced in the calcium-binding C2 and DSL (Delta-Serrate-Lin) domains to generate Jag1<sub>(JV1)</sub> with increased Notch binding affinity. The resulting amino acid replacements are highlighted in red. SP, signal peptide. (<bold>B</bold>) Tile scan images of Collagen I alpha one chain (Col1a1) (green) staining on the femur sections of control, <italic>pLIVE-Jag1-Asp<sub>8x</sub></italic> and <italic>pLIVE-Jag1<sub>(JV1)</sub></italic>-injected mice at the age of 11 weeks. Nuclei, DAPI (blue). (<bold>C</bold>) Representative 3D reconstruction from micro-computed tomography (µ-CT) measurements of tibial metaphysis of <italic>pLIVE-Jag1<sub>(JV1)</sub></italic> and control-injected mice. Diagrams show bone parameters measured in µ-CT analyses: bone volume/total volume (BV/TV) in percentage, trabecular thickness in millimeters, connectivity density in one per cubic millimeter, trabeculae number in one per millimeter, and trabecular separation in millimeters. Data represent mean ± s.e.m. (n = 5 mice), (p-values determined by unpaired t-test with Welch’s correction).</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig5">Figure 5C</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-60183-fig5-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60183-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Generation of Jag1-Asp<sub>8x</sub> and Jag1<sub>(JV1)</sub> recombinant proteins.</title><p>(<bold>A</bold>) Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) analysis of purified Jag1-Asp<sub>8x</sub> recombinant protein. From left to right, protein molecular mass marker (Marker), extract of untransfected HEK293 cells (Cells (-)) OR <italic>pcDNA3.1-Jag1-Asp<sub>8x</sub></italic>-transfected cells (Cells (+)), supernatant after culture of untransfected (Supernatant (-)) OR <italic>pcDNA3.1-Jag1-Asp<sub>8x</sub></italic>-transfected cells (Supernatant (+)), flow-through after loading of Supernatant (+) on His-tag protein purification column (Flow-through), wash buffer (Wash), elution of Jag1-Asp<sub>8x</sub> (Elute), and Opti-MEM culture medium (Medium) were loaded. (<bold>A, B</bold>) SDS-PAGE analysis of purified Jag1-Asp<sub>8x</sub> (<bold>A</bold>) and Jag1<sub>(JV1)</sub> (<bold>B</bold>) recombinant proteins. From left to right, protein molecular mass marker (Marker), extract of untransfected (Cells (-)) or transfected HEK293 cells (Cells (+)), supernatant after culture of untransfected (Supernatant (-)) or transfected cells (Supernatant (+)), flow-through after loading of Supernatant (+) on His-tag protein purification column (Flow-through), wash buffer (Wash), elution of recombinant Jag1 (Elute) and Opti-MEM culture medium (Medium) were loaded. (<bold>C</bold>) Western blot analysis of eluted Jag1-Asp<sub>8x</sub> and Jag1<sub>(JV1)</sub> recombinant proteins used for in vitro stimulation experiments (<bold>D, E</bold>). Proteins detected at the expected molecular weight with anti-Jag1 and anti-His1 antibodies. (<bold>D, E</bold>) RT-qPCR analysis of human (<italic>HS) DLL4</italic>, <italic>HEY1</italic>, <italic>HEY2</italic>, <italic>HES1</italic>, <italic>EFNB2</italic>, and <italic>NRARP</italic> transcripts in confluent human umbilical vascular endothelial cells (HUVECs) after stimulation with soluble (<bold>D</bold>) or immobilized (poly-L-lysine coating) Jag1-Asp<sub>8x</sub>, Jag1<sub>(JV1)</sub>, and BSA (<bold>E</bold>). Data represent mean ± s.e.m. (n = 3) (p-values determined by ordinary one-way ANOVA with Tukey’s multiple comparison test).</p><p><supplementary-material id="fig5s1sdata1"><label>Figure 5—figure supplement 1—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1D,E</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-60183-fig5-figsupp1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60183-fig5-figsupp1-v2.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>Detection of Jag1-Asp<sub>8x</sub> and Jag1<sub>(JV1)</sub> in the bone.</title><p>(<bold>A</bold>) Tile scan confocal images of Jag1 (cyan) immunostaining in sections from control, <italic>pLIVE-Jag1-Asp<sub>8x</sub></italic> and <italic>pLIVE-Jag1<sub>(JV1)</sub></italic> femur. Nuclei, DAPI (blue). (<bold>B</bold>) Representative higher magnification images of CD31 (green) and Jag1 (cyan) staining in the metaphysis of control, <italic>pLIVE-Jag1-Asp<sub>8x</sub></italic> and <italic>pLIVE-Jag1<sub>(JV1)</sub></italic>-injected mice. Nuclei, DAPI (blue).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60183-fig5-figsupp2-v2.tif"/></fig></fig-group><p>To overexpress these recombinant proteins in vivo, cDNAs of <italic>Jag1-Asp<sub>8x</sub></italic> and <italic>Jag1<sub>(JV1)</sub></italic>, respectively, were cloned into <italic>pLIVE</italic> vector. Following hydrodynamic tail vein injection of male mice, both Jag1-Asp<sub>8x</sub> and Jag1<sub>(JV1)</sub> are readily detectable at bone surfaces in sections, but Jag1-Asp<sub>8x</sub> is also more broadly detected throughout the marrow cavity (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2A,B</xref>). Neither Jag1-Asp<sub>8x</sub> nor Jag1<sub>(JV1)</sub>, however, induce appreciable alterations in Col1a1 deposition (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). μ-CT analysis reveals a slight but significant increase in trabecular bone thickness in <italic>pLIVE-Jag1<sub>(JV1)</sub></italic>-injected mice, whereas BV/TV, connectivity density, trabecular number, and trabecular separation are not altered significantly (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). These results argue that only Dll4<sub>(E12)</sub> is able to stimulate substantial osteogenesis in adult mice, while Dll4-Asp<sub>8x</sub>, Jag1-Asp<sub>8x</sub>, and Jag1<sub>(JV1)</sub> lack this capacity.</p></sec><sec id="s2-6"><title>Sex-specific effects of Dll4<sub>(E12)</sub> on bone formation</title><p>Next, we investigated whether Dll4<sub>(E12)</sub> treatment provides any beneficial effects in the ovariectomy model of postmenopausal osteoporosis. In comparison to sham controls, ovariectomized female mice show significant reduction of trabecular bone, which is not improved by Dll4<sub>(E12)</sub> expression (<xref ref-type="fig" rid="fig6">Figure 6A–D</xref>). Similarly, Col1a1 and PDGFRβ immunoreactivity is not significantly altered by Dll4<sub>(E12)</sub> (<xref ref-type="fig" rid="fig6">Figure 6E–F</xref>).</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Bone formation is not increased by Dll4<sub>(E12)</sub> in ovariectomized female mice.</title><p>(<bold>A, B</bold>) Representative 3D micro-computed tomography (μ-CT) images of trabecular bone in the distal tibial metaphysis (<bold>A</bold>) and cortical bone in the mid-tibial diaphysis (<bold>B</bold>) of sham or ovariectomized mice treated with vehicle or <italic>pLIVE-Dll4<sub>(E12</sub></italic><sub>)</sub>. (<bold>C</bold>) Bone parameters measured by μ-CT analysis of trabecular bone volume/total volume, trabecular connectivity density, trabecular thickness, trabecular separation, bone surface, and trabecular number in the distal tibial metaphysis. Data represent mean ± SD. (n = 5 mice) (p-values determined by two-way ANOVA with Tukey’s multiple comparisons test). (<bold>D</bold>) Quantitation of μ-CT analysis of cortical bone consistency and cortical thickness in the mid-tibial diaphysis. Data represent mean ± SD. (n = 5 mice) (p-values determined by two-way ANOVA with Tukey’s multiple comparisons test). (<bold>E, F</bold>) Tile scan confocal images showing Collagen I alpha one chain (Col1a1) staining (green; <bold>E</bold>) and PDGFRβ staining (green; <bold>F</bold>) in femoral sections from ovariectomized female mice treated with vehicle or <italic>pLIVE-Dll4<sub>(E12</sub></italic><sub>)</sub>. Nuclei, DAPI (blue). Graphs show relative ratio (percentage) of Col1a area/DAPI area and PDGFRβ area/DAPI area. Data represent mean ± SD. (n = 5 mice) (p-values determined by two-tailed unpaired t-test (<bold>E</bold>) with Welch’s correction (<bold>F</bold>)). (<bold>G</bold>) Representative μ-CT images of trabecular bone in the distal tibial metaphysis of male, female sham, and ovariectomized mice. Graphs show quantitation of the trabecular bone volume/total volume, trabecular number, and bone surface. Data represent mean ± SD. (n = 5 mice), (p-values determined by one-way ANOVA followed by Sidak’s multiple comparisons test).</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig6">Figure 6C–G</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-60183-fig6-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60183-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Reduced Dll4<sub>(E12)</sub> immunoreactivity and trabecular bone in female mice compared to male mice.</title><p>(<bold>A, B</bold>) Representative overview confocal images of Collagen I alpha one chain (Col1a1) staining (green) in the femurs of wild-type male and female mice treated with vehicle (<bold>A</bold>) or <italic>pLIVE-Dll4<sub>(E12</sub></italic><sub>)</sub> (<bold>B</bold>). Nuclei, DAPI (blue). Data represent mean ± SD. (n = 5–7 mice) (p-values determined by two-tailed unpaired t-test (control) or unpaired t-test). (<bold>C, D</bold>) Representative overview confocal images of Dll4 staining (green) in the femurs of wild-type male and female mice treated with vehicle (<bold>C</bold>) or <italic>pLIVE-Dll4<sub>(E12</sub></italic><sub>)</sub> (<bold>D</bold>). Nuclei, DAPI (blue). Diagrams represent percentage of Dll4 area/DAPI area. Data represent mean ± SD. (n = 5–7 mice) (p-values determined by two-tailed unpaired t-test (control) or unpaired t-test with Welch’s correction (<italic>Dll4<sub>(E12</sub></italic><sub>)</sub>)).</p><p><supplementary-material id="fig6s1sdata1"><label>Figure 6—figure supplement 1—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A-D</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-60183-fig6-figsupp1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60183-fig6-figsupp1-v2.tif"/></fig></fig-group><p>Given that bone surface is substantially lower in adult female mice relative to age-matched males (<xref ref-type="fig" rid="fig6">Figure 6G</xref> and <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A,B</xref>), we reasoned that Dll4<sub>(E12)</sub> binding might depend on the sex of animals. Indeed, endogenous Dll4 immunoreactivity is already significantly lower in control females relative to males and the strong increase in femur sections from Dll4<sub>(E12)</sub>-expressing males is not mirrored by female samples (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1C, D</xref>). Together, these findings indicate that the biological effect of Dll4<sub>(E12)</sub> depends on the available bone surface, suggesting that this approach might not be beneficial in settings with low bone mass.</p><p>Anabolic therapy is a clinical approach for the treatment of osteoporosis, aiming at increase in bone mass. We therefore explored whether Dll4<sub>(E12)</sub> can be beneficial in female mice if used in combination with PTH. Indeed, hydrodynamic tail vein injection of female mice with <italic>pLIVE-Dll4<sub>(E12)</sub></italic> followed by daily PTH1-34 administration over a period of 3 weeks leads to a profound increase in Dll4 immunoreactivity in femoral sections (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1A, B</xref>). This effect is mirrored by significant increases in Col1a1, PDGFRβ, and Emcn immunostaining in response to combined Dll4<sub>(E12)</sub> and PTH1-34 treatment (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1C-E</xref>). Furthermore, the combination of Dll4<sub>(E12)</sub> and PTH1-34 increases the abundance of OSX<sup>+</sup> osteoprogenitors and the length of the metaphysis in adult females, whereas the Opn<sup>+</sup> area is not significantly enhanced relative to PTH1-34 alone (<xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2A, B</xref>).</p><p>Analysis of Dll4<sub>(E12)</sub>- and PTH1-34-treated femurs by μ-CT shows that the changes above are accompanied by profound increases in trabecular bone and, in particular, connectivity density and bone surface relative to control females or separate administration of either Dll4<sub>(E12)</sub> or PTH1-34 (<xref ref-type="fig" rid="fig7">Figure 7A–G</xref>). In contrast, the beneficial effects of PTH treatment on cortical bone are not enhanced by Dll4<sub>(E12)</sub> (<xref ref-type="fig" rid="fig7">Figure 7H–K</xref>). These findings indicate that Dll4<sub>(E12)</sub> can enhance trabecular bone formation in response to anabolic therapy.</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Synergistic action of recombinant Dll4<sub>(E12)</sub> and parathyroid hormone (PTH).</title><p>(<bold>A</bold>) Representative micro-computed tomography (μ-CT) images of trabecular bone in the distal femoral metaphysis of female wild-type mice treated with vehicle, <italic>pLIVE-Dll4<sub>(E12</sub></italic><sub>)</sub>, PTH, or the combination of both for 3 weeks. (<bold>B–G</bold>) Quantitative analysis of μ-CT data on trabecular bone volume/total volume (<bold>B</bold>), trabecular connectivity density (<bold>C</bold>), trabecular number (<bold>D</bold>), bone surface (<bold>E</bold>), trabecular thickness (<bold>F</bold>), trabecular separation (<bold>G</bold>) in the distal femoral metaphysis. Data represent mean ± SD. (n = 5 mice) (p-values determined by one-way ANOVAs (<bold>F, G</bold>) followed by Sidak’s multiple comparisons test or Brown-Forsythe and Welch’s ANOVAs (<bold>B, C, D, E</bold>) followed by Dunnett’s T3 multiple comparisons test). (<bold>H</bold>) Representative μ-CT images of cortical bone in the female midfemoral diaphysis. (<bold>I–K</bold>) Graphs from μ-CT analysis of the cortical bone volume/total volume (<bold>I</bold>), cortical thickness (<bold>J</bold>), and cortical porosity (<bold>K</bold>) in the midfemoral diaphysis. Data represent mean ± SD. (n = 5 mice) (p-values determined using one-way ANOVAs followed by Sidak’s multiple comparisons test).</p><p><supplementary-material id="fig7sdata1"><label>Figure 7—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig7">Figure 7B–G,I-K</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-60183-fig7-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60183-fig7-v2.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>Effects of combined parathyroid hormone (PTH) and Dll4<sub>(E12)</sub> administration.</title><p>(<bold>A</bold>) Time course of <italic>pLIVE-Dll4<sub>(E12</sub></italic><sub>)</sub> and PTH administration to adult wild-type female mice. (<bold>B–E</bold>) Representative overview confocal images and corresponding quantification of immunostainings for Dll4 (<bold>B</bold>, green), Collagen I alpha one chain (Col1a1) (<bold>C</bold>, green), PDGFRβ (<bold>D</bold>, green), Endomucin (<bold>E</bold>, red) in the femurs treated with vehicle, <italic>pLIVE-Dll4<sub>(E12</sub></italic><sub>)</sub>, PTH, or the combination of both. Nuclei, DAPI (blue). Data represent mean ± SD. (n = 4–5 mice). Statistical significance was assessed using one-way ANOVAs (<bold>B, C, D</bold>) followed by Sidak’s multiple comparisons test or Brown-Forsythe and Welch’s ANOVA (<bold>E</bold>) followed by Dunnett’s T3 multiple comparisons test.</p><p><supplementary-material id="fig7s1sdata1"><label>Figure 7—figure supplement 1—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1B-E</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-60183-fig7-figsupp1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60183-fig7-figsupp1-v2.tif"/></fig><fig id="fig7s2" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 2.</label><caption><title>Synergistic effects of Dll4<sub>(E12)</sub> and parathyroid hormone (PTH) on osteogenesis.</title><p>Representative overview confocal images and corresponding quantifications for Osterix (OSX) (<bold>A</bold>, white) and Opn (<bold>B</bold>, green) immunostaining in wild-type female femur after treatment with vehicle, <italic>pLIVE-Dll4<sub>(E12</sub></italic><sub>)</sub>, PTH, or the combination of both. Nuclei, DAPI (blue). Data represent mean ± SD. (n = 5 mice) (p-values determined using one-way ANOVA followed by Sidak’s multiple comparisons test).</p><p><supplementary-material id="fig7s2sdata1"><label>Figure 7—figure supplement 2—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2A,B</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-60183-fig7-figsupp2-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60183-fig7-figsupp2-v2.tif"/></fig></fig-group></sec><sec id="s2-7"><title>Analysis of Dll4<sub>(E12)</sub>-induced processes at single cell resolution</title><p>Next, we analyzed long bones from <italic>pLIVE-Dll4<sub>(E12)</sub></italic> and control-injected males at 3 wpi by scRNA-seq in order to identify the stromal cell populations mediating the response to Dll4<sub>(E12)</sub>. Following tissue dissociation, hematopoietic cells were depleted from single cell suspensions with magnetic-activated cell sorting and the remaining stromal single cells were captured and barcoded with the BD Rhapsody Express Single-Cell Analysis System (<xref ref-type="fig" rid="fig8">Figure 8A</xref>). We sequenced approximately 20,000 cells from long bones of four <italic>pLIVE-Dll4<sub>(E12)</sub></italic> and control-treated mice. The resulting cell libraries were filtered to remove barcode artifacts and low-quality cells using stringent parameters for low library complexity, mitochondrial gene overrepresentation, cell doublet probability, and low gene expression to ensure that downstream analysis was not affected by technical artifacts (<xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1A-D</xref>). A total of 7750 Dll4<sub>(E12)</sub> cells and 9265 control cells passed filtering and were carried forward for further analysis. To investigate the cell diversity in the Dll4<sub>(E12)</sub> and control group, we performed clustering of cells based on scaled expression profiles (Louvain algorithm), combined with manual clustering annotation using known and de novo identified marker genes. We identified five distinct cell populations in both <italic>pLIVE-Dll4<sub>(E12)</sub></italic> and control-injected bone: MSCs, chondrocytes, ECs, osteoblasts, and smooth muscle cells (SMCs) (<xref ref-type="fig" rid="fig8">Figure 8B–E</xref>). For each population, we then identified all genes that were differentially expressed between the <italic>pLIVE-Dll4<sub>(E12)</sub></italic> and control samples (Wilcoxon rank sum test). Due to their small number, SMCs were omitted from this analysis. Data analysis reveals that EC and osteoblast populations show no or only minor alterations in response to Dll4<sub>(E12)</sub>. Consistent with this finding, expression of EC markers (<italic>Pecam1</italic>), regulators of vascular growth (<italic>Vegfr2/Kdr</italic>), and of venous (<italic>Nr2f2, Vegfr3/Flt4</italic>) or arterial specification (<italic>Sox17, Efnb2</italic>) are not altered in the Dll4<sub>(E12)</sub> group (<xref ref-type="fig" rid="fig8">Figure 8F,I</xref>). Expression of Notch pathway ligands, receptors, and downstream targets is also only marginally affected in endothelium of the <italic>pLIVE-Dll4<sub>(E12)</sub></italic>-injected mice (<xref ref-type="fig" rid="fig8s2">Figure 8—figure supplement 2A, B</xref>).</p><fig-group><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>Single cell RNA sequencing (scRNA-seq) analysis of control and Dll4<sub>(E12)</sub>-treated bone.</title><p>(<bold>A</bold>) Overview of the sample processing and scRNA-seq procedure. (<bold>B</bold>) UMAP projection of all cells in <italic>pLIVE-Dll4<sub>(E12)</sub></italic> and control, colored by Louvain clusters. Endothelial cells (ECs), mesenchymal stromal cells (MSCs), smooth muscle cells (SMCs), chondrocytes, and osteoblasts are indicated. (<bold>C</bold>) UMAP projection of all cells colored by experimental condition (green = control, purple = Dll4<sub>(E12)</sub>). (<bold>D, E</bold>) Barplot showing absolute numbers of cells (<bold>D</bold>) and scaled expression heatmap of the top 10 marker genes (<bold>E</bold>) for each of the clusters shown in (<bold>B</bold>). (<bold>F–H</bold>) Differential expression volcano plots showing -log10(adjusted p-value) against average log-fold change of <italic>pLIVE-Dll4<sub>(E12)</sub></italic> vs. control in ECs (<bold>F</bold>), chondrocytes (<bold>G</bold>), and MSCs (<bold>H</bold>). Genes with adjusted p-values smaller than 1e-10 are colored in red. (<bold>I–K</bold>) Selected cell population relevant gene expression shown as violin (density) plots for EC (<bold>I</bold>), chondrocyte, (<bold>J</bold>) and MSC (<bold>K</bold>) subpopulations.</p><p><supplementary-material id="fig8sdata1"><label>Figure 8—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig8">Figure 8F–H</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-60183-fig8-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60183-fig8-v2.tif"/></fig><fig id="fig8s1" position="float" specific-use="child-fig"><label>Figure 8—figure supplement 1.</label><caption><title>Single cell RNA sequencing (scRNA) quality control statistics.</title><p>(<bold>A–D</bold>) Quality control plots. In each panel, the top plot shows distribution of count depths, middle plot shows knee plot, and the bottom plot shows cumulative count depth plotted as a function of cell barcodes sorted by count depth. Plots show control sample before filtering (<bold>A</bold>), control sample after filtering (<bold>B</bold>), <italic>pLIVE-Dll4<sub>(E12)</sub></italic> sample before filtering (<bold>C</bold>), and <italic>pLIVE-Dll4<sub>(E12)</sub></italic> sample after filtering (<bold>D</bold>).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60183-fig8-figsupp1-v2.tif"/></fig><fig id="fig8s2" position="float" specific-use="child-fig"><label>Figure 8—figure supplement 2.</label><caption><title>Extended analysis of differentially expressed genes.</title><p>(<bold>A</bold>) Differential expression volcano plots showing -log10(adjusted p-value) against average log-fold change of <italic>pLIVE-Dll4<sub>(E12)</sub></italic> vs. control for Notch pathway related genes (parent Gene Ontology [GO] term ‘Notch signaling pathway’ GO:0007219) for endothelial cell (EC), chondrocyte, osteoblast, and mesenchymal stromal cell (MSC) populations. (<bold>B</bold>) Heatmap of the average expression log-fold change of selected Notch pathway genes with a p-value &lt; 1e-10 and log-fold change &gt; 0.2 across the four major cell populations. (<bold>C</bold>) Heatmap of the average expression log-fold change of genes with a p-value &lt; 1e-10 and log-fold change &gt;0.2 across the four major cell populations. (<bold>D</bold>) Dot plot of GO analysis results showing all enriched GO terms with a p-value below 1e-5 across all four major cell populations. Color encodes hypergeometric test p-value, size of each dot is proportional to the odds ratio (OR). (<bold>E</bold>) Differential expression volcano plot for the osteoblast population showing -log10(adjusted p-value) against average log-fold change of <italic>pLIVE-Dll4<sub>(E12)</sub></italic> vs. control. Genes with an adjusted p-value less than 1e-10 are colored in red.</p><p><supplementary-material id="fig8s2sdata1"><label>Figure 8—figure supplement 2—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig8s2">Figure 8—figure supplement 2A-E</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-60183-fig8-figsupp2-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60183-fig8-figsupp2-v2.tif"/></fig></fig-group><p>Notably, MSCs and chondrocytes show the strongest response to overexpressed Dll4<sub>(E12)</sub>, although chondrocytes display a comparably smaller number of differentially expressed genes (<xref ref-type="fig" rid="fig8">Figure 8G and H</xref>). Dll4<sub>(E12)</sub> chondrocytes show normal expression of critical transcripts including the transcription factor Sox9 and the proteoglycan core protein Aggrecan (<italic>Acan</italic>) (<xref ref-type="fig" rid="fig8">Figure 8J</xref>), consistent with the results from the immunostaining of bone sections (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2C</xref>). In contrast, the alpha1 subunit of type X collagen (<italic>Col10a1</italic>), which is mainly expressed by hypertrophic chondrocytes in the growth plate, is upregulated after Dll4<sub>(E12)</sub> treatment (p = 3.97e-32) (<xref ref-type="fig" rid="fig8">Figure 8J</xref>).</p><p>In the MSC population, representative markers such as transcripts for the receptor tyrosine kinase PDGFRβ (<italic>Pdgfrb</italic>), a critical regulator of MSC proliferation, and Leptin receptor (<italic>Lepr</italic>), a marker of BM stromal cells, are not altered (<xref ref-type="fig" rid="fig8">Figure 8K</xref>). However, known pro-osteogenic genes like <italic>Igf2</italic> encoding insulin-like growth factor 2 (<xref ref-type="bibr" rid="bib5">Chen et al., 2010</xref>) are upregulated (p = 9.52e-121), whereas transcripts associated with negative regulation of osteogenesis are downregulated. The latter includes the transcript for insulin-like growth factor-binding protein 3 (<italic>Igfbp3</italic>) (p = 2.80e-166), a secreted protein that binds insulin-like growth factors and limits their bioavailability (<xref ref-type="bibr" rid="bib5">Chen et al., 2010</xref>), and matrix Gla (γ-carboxyglutamate) protein (<italic>Mgp</italic>) (p = 1.11e-159), a negative regulator of calcification (<xref ref-type="bibr" rid="bib64">Yagami et al., 1999</xref>; <xref ref-type="fig" rid="fig8">Figure 8H</xref> and <xref ref-type="fig" rid="fig8s2">Figure 8—figure supplement 2C</xref>). MSCs from Dll4<sub>(E12)</sub>-treated mice showed also increased expression of <italic>Angptl4</italic> (p = 9.82e-132), which encodes angiopoietin-like 4, a positive regulator of osteogenesis that is highly expressed at bone fracture sites but is also a stimulator of osteoclast-mediated bone resorption (<xref ref-type="bibr" rid="bib62">Wilson et al., 2015</xref>; <xref ref-type="bibr" rid="bib25">Knowles et al., 2010</xref>; <xref ref-type="fig" rid="fig8">Figure 8H</xref>, <xref ref-type="fig" rid="fig8s2">Figure 8—figure supplement 2C</xref>). Transcripts for the proteoglycan PRG4, a positive regulator of skeletogenesis and parathyroid hormone-mediated bone formation (<xref ref-type="bibr" rid="bib42">Novince et al., 2012</xref>), are also elevated in Dll4<sub>(E12)</sub> MSCs (p = 8.39e-112) (<xref ref-type="fig" rid="fig8">Figure 8H</xref> and <xref ref-type="fig" rid="fig8s2">Figure 8—figure supplement 2C</xref>).</p><p>GO analyses (hypergeometric test) of each cell population reveals an enrichment of GO terms for morphogenesis, development, vascular growth, and ossification among differentially expressed genes in the MSC population and, to much smaller extent, in chondrocytes (<xref ref-type="fig" rid="fig8s2">Figure 8—figure supplement 2D</xref>). Analysis of endogenous Notch receptor (<italic>Notch1-4</italic>) and ligand (<italic>Dll1, Dll4 and Jag1, Jag2</italic>) expression in Dll4<sub>(E12)</sub>-treated stromal cells, however, indicates no alterations except the downregulation of <italic>Notch3</italic> in MSCs (p = 1.10e-64) (<xref ref-type="fig" rid="fig8s2">Figure 8—figure supplement 2A, B</xref>). While Dll4<sub>(E12)</sub> results in a strong increase of OSX<sup>+</sup> cells in vivo, scRNA-seq analysis reveals very limited gene expression changes in osteoblasts (<xref ref-type="fig" rid="fig8s2">Figure 8—figure supplement 2E</xref>). Together, these data indicate that the pro-osteogenic effects of Dll4<sub>(E12)</sub> are mediated by MSCs.</p></sec><sec id="s2-8"><title>Dll4<sub>(E12)</sub> effects within the bone MSC subpopulations</title><p>Bone MSCs are highly heterogeneous, found in different locations and can be subdivided based on marker gene expression (<xref ref-type="bibr" rid="bib1">Baryawno et al., 2019</xref>; <xref ref-type="bibr" rid="bib46">Pinho and Frenette, 2019</xref>; <xref ref-type="bibr" rid="bib71">Zhou et al., 2014</xref>; <xref ref-type="bibr" rid="bib37">Mizoguchi et al., 2014</xref>). Subclustering (Louvain algorithm) of the MSC population in our scRNA-seq data identifies three distinct subpopulations (<xref ref-type="fig" rid="fig9">Figure 9A–C</xref>). Diaphyseal MSCs (dpMSCs) show high expression of <italic>Lepr</italic> and <italic>Kitl</italic>, the gene encoding stem cell factor, the ligand of c-Kit receptor (<xref ref-type="fig" rid="fig9">Figure 9A–C and E</xref>). Metaphyseal MSCs (mpMSCs) characterized by expression of markers associated with osteogenesis, namely of the transcription factor OSX (encoded by the gene <italic>Sp7</italic>), the secreted extracellular matrix protein periostin (<italic>Postn</italic>), and the transcriptional repressor and Notch pathway gene <italic>Hey1</italic> (<xref ref-type="fig" rid="fig9">Figure 9A–C and E</xref>). In addition, we find a small population of fibroblast-like cells, which express the proteoglycan Decorin (<italic>Dcn</italic>) and the glycosyl phosphatidylinositol-anchored cell surface protein Sca-1 (<italic>Ly6a</italic>) (<xref ref-type="fig" rid="fig9">Figure 9A–C</xref>). Notably, dpMSCs represent 85–86% of total MSCs in both the Dll4<sub>(E12)</sub> and control group (<xref ref-type="fig" rid="fig9">Figure 9A and B</xref>). Most of genes that are differentially expressed in Dll4<sub>(E12)</sub>-treated samples are also found in the dpMSC subpopulation. This includes the upregulated genes <italic>Igf2</italic> (p = 5.39e-88) and <italic>Prg4</italic> (p = 3.05e-90), which are known to promote osteogenesis, and the downregulated genes <italic>Igfbp3</italic> (p = 1.69e-156) and <italic>Mgp</italic> (p = 9.76e-148), which are inhibitors of bone formation (<xref ref-type="fig" rid="fig9">Figure 9D and E</xref>). Furthermore, UMAP projections show a significant increase in the fraction of <italic>Sp7/OSX</italic>-expressing cells in the dpMSC population (<xref ref-type="fig" rid="fig9">Figure 9F</xref>). Consistent with the <italic>Hey1-EGFP</italic> reporter results (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>), <italic>Hey1</italic> expression labels mpMSCs and a small fraction of dpMSCs. The latter might, as the <italic>Tg(Hey1-EGFP)<sup>ID40Gsat</sup></italic> reporter expression suggests (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>), represent cells in the transition zone between the metaphysis and diaphysis.</p><fig id="fig9" position="float"><label>Figure 9.</label><caption><title>Single cell RNA sequencing (scRNA-seq) analysis of mesenchymal stromal cell (MSC) subclusters.</title><p>(<bold>A</bold>) UMAP projection of MSCs in both control and <italic>pLIVE-Dll4<sub>(E12)</sub></italic> samples colored by Louvain clusters. Metaphyseal MSCs (mpMSCs), diaphyseal MSCs (dpMSCs), and fibroblasts are indicated. (<bold>B</bold>) Barplot showing absolute numbers of cells per sample (left), and scaled expression heatmap of the top 10 marker genes (right) in each of the clusters shown in (<bold>A</bold>). (<bold>C</bold>) UMAP projection of all cells colored by experimental condition green = control, purple = Dll4<sub>(E12)</sub>. (<bold>D</bold>) Differential expression volcano plots showing -log10(adjusted p-value) against average log-fold change of treatment/control for dpMSCs (left) and mpMSCs (right). Genes with an adjusted p-value less than 1e-10 are colored in red. (<bold>E</bold>) Violin plots showing selected differentially expressed genes in the three MSC subpopulations. Each violin is split along the vertical axis into control and <italic>pLIVE-Dll4<sub>(E12)</sub></italic>. (<bold>F</bold>) UMAP projections of control and Dll4<sub>(E12)</sub>-treated cells colored for the expression of <italic>Sp7</italic> and <italic>Hey1</italic>. (<bold>G</bold>) Heatmap of the average expression log-fold change of selected Notch pathway genes with a p-value &lt; 1e-10 and log-fold change &gt;0.2 in dpMSCs and mpMSCs.</p><p><supplementary-material id="fig9sdata1"><label>Figure 9—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig9">Figure 9D–G</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-60183-fig9-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60183-fig9-v2.tif"/></fig><p>The scRNA-seq data show no significant increase in total <italic>Hey1</italic><sup>+</sup> MSCs, which is presumably due to the low expression and therefore limited detection of this transcript (<xref ref-type="fig" rid="fig9">Figure 9F</xref>). Taken together, our results support that Dll4<sub>(E12)</sub> treatment promotes osteogenesis through effects in MSCs and, in particular, the dpMSC population. In contrast, molecular changes are limited in the EC and osteoblast populations, suggesting that these cells are not exposed or unresponsive to Dll4<sub>(E12)</sub>.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Notch signaling has multiple important functional roles in the skeletal system, including the maintenance and expansion of the mesenchymal progenitor cell pool and the coupling of angiogenesis and osteogenesis (<xref ref-type="bibr" rid="bib50">Ramasamy et al., 2014</xref>; <xref ref-type="bibr" rid="bib20">Hilton et al., 2008</xref>; <xref ref-type="bibr" rid="bib13">Engin et al., 2008</xref>; <xref ref-type="bibr" rid="bib26">Kusumbe et al., 2014</xref>; <xref ref-type="bibr" rid="bib17">Golson et al., 2009</xref>; <xref ref-type="bibr" rid="bib30">Limbourg et al., 2005</xref>). Interactions between Dll4 and Notch receptors, predominantly Notch1 but also Notch4, negatively control EC proliferation and angiogenic growth of the vasculature in most organs. In bone, however, Notch signaling promotes angiogenesis and triggers the expansion of type H vessels, which, in turn, results in increased osteogenesis (<xref ref-type="bibr" rid="bib50">Ramasamy et al., 2014</xref>; <xref ref-type="bibr" rid="bib51">Ramasamy et al., 2016</xref>). To promote bone angiogenesis and osteogenesis, we have designed synthetic Notch ligands containing poly-Asp peptide motifs, which have been previously shown to bind different regions in long bone including the primary spongiosa in proximity of the growth plate (<xref ref-type="bibr" rid="bib22">Kasugai et al., 2000</xref>; <xref ref-type="bibr" rid="bib36">Miller et al., 2008</xref>), a region containing a high amount of angiogenic vessels. It has also been shown that an Asp<sub>6x</sub> peptide preferentially binds to areas of bone resorption, whereas a different motif, (AspSerSer)<sub>6x</sub>, targets bone-forming surfaces (<xref ref-type="bibr" rid="bib70">Zhang et al., 2012</xref>). Future work will have to address whether other bone surface-binding moieties will endow Notch ligands with distinct and perhaps even more potent biological properties due to the activation of different target cell populations. Our scRNA-seq analysis shows, for example, that the Asp<sub>8x</sub> motif in Dll4<sub>(E12)</sub> leads to very limited changes in bone ECs. This might reflect that the spatial distance between the bone surface and ECs precludes sufficient physical contact between hydroxyapatite-bound Dll4<sub>(E12)</sub> and endothelial Notch receptors.</p><p>Nevertheless, we found that Dll4<sub>(E12)</sub> can trigger an increase in trabecular bone, whereas similar effects were not seen for Dll4-Asp<sub>8x</sub>, Jag1-Asp<sub>8x</sub>, or Jag1<sub>(JV1)</sub>. The underlying reasons for this difference are not clear, but it is possible that only Dll4<sub>(E12)</sub> accomplishes a critical level of Notch activation required for bone formation in adult male mice. This should, however, not lead to conclusions about the functional roles of endogenous Notch ligand expression. In fact, numerous reports have shown that Jagged1 can regulate osteogenic differentiation of bone MSCs and the ligand is also highly upregulated during fracture repair (<xref ref-type="bibr" rid="bib29">Li et al., 2009</xref>; <xref ref-type="bibr" rid="bib19">Hill et al., 2014</xref>; <xref ref-type="bibr" rid="bib11">Dishowitz et al., 2014</xref>; <xref ref-type="bibr" rid="bib45">Osathanon et al., 2013</xref>).</p><p>Notch signaling was shown to inhibit chondrocyte differentiation by suppressing the expression of the transcription factor Sox9, a known regulator of chondrogenesis (<xref ref-type="bibr" rid="bib6">Chen et al., 2013</xref>). Genetic disruption of Notch signaling in embryonic limb bud mesenchyme using <italic>Prx1-Cre</italic> transgenic mice led to the accumulation of hypertrophic chondrocytes in the growth plate, whereas chondrocyte proliferation was strongly reduced (<xref ref-type="bibr" rid="bib20">Hilton et al., 2008</xref>). Our findings show that Dll4<sub>(E12)</sub> treatment of adult mice increases the expression of <italic>Col10a1</italic> in chondrocytes, which encodes the alpha chain of type X collagen, a short chain collagen expressed by hypertrophic chondrocytes that is essential for growth plate development and mineralization of trabecular bone (<xref ref-type="bibr" rid="bib27">Kwan et al., 1997</xref>). The absence of appreciable accumulation of Dll4<sub>(E12)</sub> inside the growth plate, however, suggests that these alterations might be indirect. It was also shown that conditional activation of Notch signaling in osteocytes increases bone formation and mineralization, which is sufficient for the rescue of both age-associated and ovariectomy-induced bone loss (<xref ref-type="bibr" rid="bib32">Liu et al., 2016</xref>).While our work does not exclude anabolic effects of Dll4<sub>(E12)</sub> through the activation of Notch signaling in osteocytes, these cells were not recovered in our scRNA-seq data presumably due to the conditions of tissue dissociation.</p><p>Instead, our results indicate that Dll4<sub>(E12)</sub> activates Notch signaling primarily in immature MSCs and leads to the expansion of this population and, as shown previously (<xref ref-type="bibr" rid="bib20">Hilton et al., 2008</xref>), reduced Runx2 expression. It is also fully consistent with previous findings showing that genetic approaches leading to Notch activation in mesenchymal progenitors suppress differentiation and promote the expansion of these cells (<xref ref-type="bibr" rid="bib20">Hilton et al., 2008</xref>; <xref ref-type="bibr" rid="bib13">Engin et al., 2008</xref>; <xref ref-type="bibr" rid="bib4">Canalis et al., 2013</xref>). In this context, it is presumably highly advantageous that Dll4<sub>(E12)</sub>-mediated Notch activation is, in contrast to irreversible genetic modifications, transient and does not suppress osteoblastic differentiation, presumably because cells are not permanently exposed to the bone surface-bound recombinant protein. This is indicated by the absence of <italic>Hey1-GFP</italic> signal in OSX<sup>+</sup> cells but also the absence of major transcriptional alterations in osteoblasts.</p><p>MSCs are a heterogenous population of stromal cells, which includes cells with progenitor properties, colony-forming capacity ex vivo, and the potential to generate bone, fat, fibroblasts, and other cell types (<xref ref-type="bibr" rid="bib71">Zhou et al., 2014</xref>; <xref ref-type="bibr" rid="bib3">Bianco and Gehron Robey, 2000</xref>; <xref ref-type="bibr" rid="bib41">Nombela-Arrieta et al., 2011</xref>; <xref ref-type="bibr" rid="bib44">Ortinau et al., 2019</xref>). MSCs are likely to include comparably rare mesenchymal stem and progenitor cells characterized by the ability to give rise to multiple differentiated cell types in a clonal fashion (<xref ref-type="bibr" rid="bib3">Bianco and Gehron Robey, 2000</xref>; <xref ref-type="bibr" rid="bib41">Nombela-Arrieta et al., 2011</xref>; <xref ref-type="bibr" rid="bib43">Ono et al., 2014</xref>; <xref ref-type="bibr" rid="bib59">Uccelli et al., 2008</xref>). It might appear surprising that our scRNA-seq data show the strongest gene expression changes in dpMSCs, but previous work has established that vessel-associated MSCs in the diaphysis can give rise to bone-forming cells (<xref ref-type="bibr" rid="bib71">Zhou et al., 2014</xref>; <xref ref-type="bibr" rid="bib37">Mizoguchi et al., 2014</xref>; <xref ref-type="bibr" rid="bib57">Sivaraj et al., 2021</xref>). In fact, expansion of the metaphyseal region in response to Dll4<sub>(E12)</sub> might well involve the incorporation of dpMSCs from the adjacent transition zone and marrow. Taken together, we propose that the pro-osteogenic capacity of Dll4<sub>(E12)</sub> is primarily mediated by Notch-controlled expansion of immature MSCs. It is also feasible that bone formation is enhanced through the release of secreted signaling molecules acting in a paracrine fashion, which might apply to the alterations seen in chondrocytes.</p><p>Our study not only proves that the administration of exogenous Notch ligand can induce bone formation in adult mice, the results also show that this treatment does not lead to adverse side effects. Circulating Dll4<sub>(E12)</sub> might act as an antagonist and therefore disrupt critical endogenous Notch-ligand interactions in multiple organs, which might lead to defects in small intestine, liver, or T cell development that are known to be caused by Notch inhibition (<xref ref-type="bibr" rid="bib65">Yan et al., 2010</xref>; <xref ref-type="bibr" rid="bib49">Radtke et al., 1999</xref>; <xref ref-type="bibr" rid="bib60">van Es et al., 2005</xref>). The absence of such defects might reflect efficient retention of Dll4<sub>(E12)</sub> fusion protein in bone and thereby low bioavailability in other organs. It is, nevertheless, remarkable that even liver, the site of Dll4<sub>(E12)</sub> expression, does not show overt morphological alterations.</p><p>Together, our findings establish that bone-targeting and binding-optimized Dll4 ligand can be used to stimulate osteogenesis in adult mice without adverse side effects. We propose that Dll4<sub>(E12)</sub> might serve as a promising example for the design of future anti-osteoporosis drugs.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>, C57BL/6JRj)</td><td align="left" valign="bottom">WT</td><td align="left" valign="bottom">Janvier Labs</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom"><italic>Tg(Hey1-EGFP)<sup>ID40Gsat</sup></italic></td><td align="left" valign="bottom">GENSAT</td><td align="left" valign="bottom">MGI:4847129</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pcDNA3.1- Dll4(ECD)- His(6x)-Asp(8x)(plasmid)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Dll4-Asp<sub>(8x)</sub></td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pcDNA3.1- Dll4(ECD)- Variant- His(6x)-Asp(8x) (plasmid)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Dll4<sub>(E12)</sub></td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pLIVE-Dll4(ECD)-His(6x)-Asp(8x) (plasmid)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><italic>pLIVE-Dll4-Asp(8x</italic>)</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pLIVE-Dll4(ECD) Variant- His(6x)-Asp(8x) (plasmid)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><italic>pLIVE-Dll4(E12</italic>)</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pcDNA3.1- Jag1 (ECD)- His(6x)-Asp(8x)(plasmid)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Jag1- Asp<sub>(8x)</sub></td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pcDNA3.1- Jag1 (ECD)- JV1- His(6x)-Asp(8x)(plasmid)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Jag1<sub>(JV1)</sub></td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pLIVE- Jag1 (ECD)- His(6x)-Asp(8x) (plasmid)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><italic>pLIVE-Jag1- Asp(8x</italic>)</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pLIVE- Jag1 (ECD)- JV1- His(6x)-Asp(8x) (plasmid)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><italic>pLIVE-Jag1(JV1</italic>)</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">Human Umbilical Vein Endothelial Cells (HUVEC)</td><td align="left" valign="bottom">ThermoFisher</td><td align="left" valign="bottom">Cat# C0035C</td><td align="left" valign="bottom">Cell identity and absence of mycoplasma contamination or human pathogens were certified by the supplier</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">Human Embryonal kidney –293(HEK293)</td><td align="left" valign="bottom">DSMZ</td><td align="left" valign="bottom">Cat# ACC 305</td><td align="left" valign="bottom">Cell identity and absence of mycoplasma contamination were certified by the supplier</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Endomucin (Rat, monoclonal)</td><td align="left" valign="bottom">Santa Cruz</td><td align="left" valign="bottom">Cat# SC-65495</td><td align="left" valign="bottom">IF (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-PECAM-1(Rat, monoclonal)</td><td align="left" valign="bottom">Pharmigen</td><td align="left" valign="bottom">Cat# 553,370</td><td align="left" valign="bottom">IF (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-CD31(Goat, polyclonal)</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="left" valign="bottom">Cat# FAB3628</td><td align="left" valign="bottom">IF (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Pdgfrβ (Goat, polyclonal)</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="left" valign="bottom">Cat# AF1042</td><td align="left" valign="bottom">IF (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-NG2 (Rabbit, polyclonal)</td><td align="left" valign="bottom">Millipore</td><td align="left" valign="bottom">Cat# AB5320</td><td align="left" valign="bottom">IF (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-BCAM (Goat, polyclonal)</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="left" valign="bottom">Cat# AF8299</td><td align="left" valign="bottom">IF (1:50)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-ATP6V1B1+ ATP6V1B2 (Rabbit, polyclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Cat# ab200839</td><td align="left" valign="bottom">IF (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Aggrecan (Rabbit, polyclonal)</td><td align="left" valign="bottom">Millipore</td><td align="left" valign="bottom">Cat# AB1031</td><td align="left" valign="bottom">IF (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Sox9 (Goat, polyclonal)</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="left" valign="bottom">Cat# AF3075</td><td align="left" valign="bottom">IF (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Perilipin (Rabbit, polyclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">Cat# 9349</td><td align="left" valign="bottom">IF (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Osterix (Rabbit, polyclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Cat# ab22552</td><td align="left" valign="bottom">IF (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Collagen Type I (Rabbit, polyclonal)</td><td align="left" valign="bottom">Millipore</td><td align="left" valign="bottom">Cat# AB765P</td><td align="left" valign="bottom">IF (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Osteopontin (Goat, polyclonal)</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="left" valign="bottom">Cat# AF808</td><td align="left" valign="bottom">IF (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Osteocalcin (Rabbit, polyclonal)</td><td align="left" valign="bottom">LifeSpan BioSciences</td><td align="left" valign="bottom">Cat# LS-C17044</td><td align="left" valign="bottom">IF (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Runx2 (Rabbit, monoclonal)</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="left" valign="bottom">Cat# MAB2006</td><td align="left" valign="bottom">IF (1:50)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Dll4 (Goat, polyclonal)</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="left" valign="bottom">Cat# AF1389</td><td align="left" valign="bottom">IF (1:100)WB (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Jag1 (Goat, polyclonal)</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">Cat# J4127</td><td align="left" valign="bottom">IF (1:100)WB (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-GAPDH (Rabbit, monoclonal)</td><td align="left" valign="bottom">Ambion</td><td align="left" valign="bottom">Cat# AM4300</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-CD45-FITC (Rat, monoclonal)</td><td align="left" valign="bottom">eBioscience</td><td align="left" valign="bottom">Cat# 11–0451</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-CD8-Biotin (Rat, monoclonal)</td><td align="left" valign="bottom">eBioscience</td><td align="left" valign="bottom">Cat# 13–0081</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-CD4-APC (Rat, monoclonal)</td><td align="left" valign="bottom">eBioscience</td><td align="left" valign="bottom">Cat# 17-0042-82</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Streptavidin PE/Cy7</td><td align="left" valign="bottom">Thermo Scientific</td><td align="left" valign="bottom">Cat# SA1012</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Lineage Cell Depletion Kit</td><td align="left" valign="bottom">Miltenyi Biotec</td><td align="left" valign="bottom">Cat# 130-090-858</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">CD45 Microbeads</td><td align="left" valign="bottom">Miltenyi Biotec</td><td align="left" valign="bottom">Cat# 130-052-301</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">CD117 Microbeads</td><td align="left" valign="bottom">Miltenyi Biotec</td><td align="left" valign="bottom">Cat# 130-091-224</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Ter-119 Microbeads</td><td align="left" valign="bottom">Miltenyi Biotec</td><td align="left" valign="bottom">Cat# 130-049-901</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-rabbit Alexa Fluor-488 (Donkey, polyclonal)</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat# A21206</td><td align="left" valign="bottom">IF (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-rabbit Alexa Fluor-594 (Donkey, polyclonal)</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat# A21207</td><td align="left" valign="bottom">IF (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-rabbit Alexa Fluor-647 (Donkey, polyclonal)</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat# A31573</td><td align="left" valign="bottom">IF (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-rat Alexa Fluor-488 (Donkey, polyclonal)</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat# A21208</td><td align="left" valign="bottom">IF (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-rat Alexa Fluor-594 (Donkey, polyclonal)</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat# A21209</td><td align="left" valign="bottom">IF (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-rat Alexa Fluor-647 (Donkey, polyclonal)</td><td align="left" valign="bottom">Jackson ImmunoResearch</td><td align="left" valign="bottom">Cat# 712-605-153</td><td align="left" valign="bottom">IF (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-rat Alexa Fluor-647 (Donkey, polyclonal)</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat# A21247</td><td align="left" valign="bottom">IF (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-goat Alexa Fluor-488 (Donkey, polyclonal)</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat# A11055</td><td align="left" valign="bottom">IF (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-goat Alexa Fluor-647 (Donkey, polyclonal)</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat# A21447</td><td align="left" valign="bottom">IF (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-goat Alexa Fluor-647 (Donkey, polyclonal)</td><td align="left" valign="bottom">Thermo Scientific</td><td align="left" valign="bottom">Cat# A32849</td><td align="left" valign="bottom">IF (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-rabbit IgG HRP-linked (Goat)</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">Cat# 7074</td><td align="left" valign="bottom">WB (1:15000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-goat IgG HRP-linked (Donkey)</td><td align="left" valign="bottom">Antibody online</td><td align="left" valign="bottom">Cat# ABIN1536502</td><td align="left" valign="bottom">WB (1:15000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse IgG 656G HRP-linked (Sheep)</td><td align="left" valign="bottom">GE Healthcare</td><td align="left" valign="bottom">Cat# NA931</td><td align="left" valign="bottom">WB (1:40000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-goat IgG (H + L) Peroxidase AffiniPure Bovine</td><td align="left" valign="bottom">Jackson ImmunoResearch</td><td align="left" valign="bottom">Cat# 805-035-180</td><td align="left" valign="bottom">WB (1:15000)</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Human <italic>GAPDH</italic> Endogenous Control (VIC/MGB probe, primer limited)</td><td align="left" valign="bottom">Applied Biosystems</td><td align="left" valign="bottom">Cat# 4326317E</td><td align="left" valign="bottom">TaqMan probe Hs99999905_m1</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Human <italic>ACTB</italic> Endogenous Control (VIC/MGB probe, primer limited)</td><td align="left" valign="bottom">Applied Biosystems</td><td align="left" valign="bottom">Cat# 4326315E</td><td align="left" valign="bottom">TaqMan probe Hs99999903_m1</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Human <italic>HEY1</italic> TaqMan Gene Expression Assay (FAM)</td><td align="left" valign="bottom">Applied Biosystems</td><td align="left" valign="bottom">Cat# 4331182</td><td align="left" valign="bottom">TaqMan probe Hs00232618_m1</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Human <italic>DLL4</italic> TaqMan Gene Expression Assay (FAM)</td><td align="left" valign="bottom">Applied Biosystems</td><td align="left" valign="bottom">Cat# 4331182</td><td align="left" valign="bottom">TaqMan probe Hs00184092_m1</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Human <italic>HEY2</italic> TaqMan Gene Expression Assay (FAM)</td><td align="left" valign="bottom">Applied Biosystems</td><td align="left" valign="bottom">Cat# 4331182</td><td align="left" valign="bottom">TaqMan probe Hs00232622_m1</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Human <italic>HES1</italic> TaqMan Gene Expression Assay (FAM)</td><td align="left" valign="bottom">Applied Biosystems</td><td align="left" valign="bottom">Cat# 4331182</td><td align="left" valign="bottom">TaqMan probe Hs00172878_m1</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Human <italic>EFNB2</italic> TaqMan Gene Expression Assay (FAM)</td><td align="left" valign="bottom">Applied Biosystems</td><td align="left" valign="bottom">Cat# 4331182</td><td align="left" valign="bottom">TaqMan probe Hs00187950_m1</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Human <italic>NRARP</italic> TaqMan Gene Expression Assay (FAM)</td><td align="left" valign="bottom">Applied Biosystems</td><td align="left" valign="bottom">Cat# 4331182</td><td align="left" valign="bottom">TaqMan probe Hs01104102_s1</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Recombinant Human PTH (1-34)</td><td align="left" valign="bottom">BACHEM</td><td align="left" valign="bottom">Cat# H-4835-GMP, 4033364</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">BCA Protein Assay Kit</td><td align="left" valign="bottom">Pierce</td><td align="left" valign="bottom">Cat# 23225</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">RNeasy Plus Micro Kit</td><td align="left" valign="bottom">QIAGEN</td><td align="left" valign="bottom">Cat# 74034</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">iScript cDNA Synthesis Kit</td><td align="left" valign="bottom">BIO-RAD</td><td align="left" valign="bottom">Cat# 170–8891</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">SsoAdvanced Universal Probes Supermix</td><td align="left" valign="bottom">BIO-RAD</td><td align="left" valign="bottom">Cat# 172–5284</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">LEGENDplex Mouse Inflammation Panel (13-plex) with V-bottom plates</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 740446</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Anticoagulant EDTA-treated Microvettes</td><td align="left" valign="bottom">Sarstedt</td><td align="left" valign="bottom">Cat# 20.1341</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">BD Rhapsody Whole Transcriptome Analysis (WTA) Amplification kit</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">Cat# 633,801</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Agencourt AMPure XP magnetic beads</td><td align="left" valign="bottom">Beckman Coulter Life Sciences</td><td align="left" valign="bottom">Cat# A638880</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Disposable polystyrene columns</td><td align="left" valign="bottom">Thermo Scientific</td><td align="left" valign="bottom">Cat# 29922</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Amicon Ultra-0.5 Centrifugal Filter</td><td align="left" valign="bottom">Millipore</td><td align="left" valign="bottom">Cat# UFC500396</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Pierce Slide-A-Lyzer 10K MWCO Dialysis Cassettes</td><td align="left" valign="bottom">Thermo Scientific</td><td align="left" valign="bottom">Cat# 66380</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Ni-NTA agarose resin</td><td align="left" valign="bottom">Qiagen</td><td align="left" valign="bottom">Cat# 302010</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Sucrose</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">Cat# S0389</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">cOmplete ULTRA Tablets Protease Inhibitor Cocktail</td><td align="left" valign="bottom">Roche</td><td align="left" valign="bottom">Cat# 05892970001</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Phosphatase inhibitor cocktail set V</td><td align="left" valign="bottom">EMD Millipore</td><td align="left" valign="bottom">Cat# 524629</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">SimplyBlue SafeStain</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat# LC6060</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Gelatine</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">Cat# G1890</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Polyvinylpyrrolidone</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">Cat# P5288</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Trypsin-EDTA solution</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">Cat# T3924</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Paraformaldehyde</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">Cat# P6148</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">70 kDa Dextran, Texas Red Lysine fixable</td><td align="left" valign="bottom">Molecular Probes</td><td align="left" valign="bottom">Cat# D1864</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Calcein</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">Cat# C0875</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Fluoromount-G</td><td align="left" valign="bottom">Southern Biotech</td><td align="left" valign="bottom">Cat# 0100–01</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">ECL Prime Western Blotting Detection Reagent</td><td align="left" valign="bottom">GE-Healthcare</td><td align="left" valign="bottom">Cat# RPN2236</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">4-Hydroxy tamoxifen</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">Cat# H7904</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Hematoxilin</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">Cat# MHS16</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Dimethyl sulfoxide</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">Cat# D8418</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">MEM200 endothelial cells medium</td><td align="left" valign="bottom">ThermoFisher</td><td align="left" valign="bottom">Cat# M200500</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">LSGS</td><td align="left" valign="bottom">ThermoFisher</td><td align="left" valign="bottom">Cat# S00310</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">EBM-2 endothelial cells medium</td><td align="left" valign="bottom">Lonza</td><td align="left" valign="bottom">Cat# CC-3156</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">EGM-2 Single Quots</td><td align="left" valign="bottom">Lonza</td><td align="left" valign="bottom">Cat# CC-4176</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Opti-MEM</td><td align="left" valign="bottom">Gibco</td><td align="left" valign="bottom">Cat# 31985–047</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Poly-L-lysine</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">Cat# P6282</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">HEPES</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">Cat# H3537</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Ketamine</td><td align="left" valign="bottom">Zoetis</td><td align="left" valign="bottom">Cat# 344771</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Rompum</td><td align="left" valign="bottom">Bayer HealthCare</td><td align="left" valign="bottom">Cat# D-51368</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Collagenase I</td><td align="left" valign="bottom">Gibco</td><td align="left" valign="bottom">Cat# 17100–017</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Collagenase IV</td><td align="left" valign="bottom">Gibco</td><td align="left" valign="bottom">Cat# 17104–019</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Dispase</td><td align="left" valign="bottom">Gibco</td><td align="left" valign="bottom">Cat# 17105–041</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">ImageJ (v2.0.0 Fiji)</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib55">Schindelin et al., 2012</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Volocity (v6.3)</td><td align="left" valign="bottom">Perkin Elmer</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Illustrator (vCC2018)</td><td align="left" valign="bottom">Adobe</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">GraphPad Prism7</td><td align="left" valign="bottom">GraphPad Software</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">FlowJo (v10.3)</td><td align="left" valign="bottom">BD Life Sciences</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">DAPI stain</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">Cat# D9542</td><td align="char" char="." valign="bottom">(1 mg/mL)</td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Plasmid construction</title><p>To generate the Dll4-Asp<sub>8x</sub> soluble protein containing the Dll4 ECD fused to 6x His and 8x Asp peptide sequences, a cDNA fragment encoding amino acids 1–530 of murine Dll4 (<ext-link ext-link-type="uri" xlink:href="https://www.uniprot.org/uniprot/Q9JI71">https://www.uniprot.org/uniprot/Q9JI71</ext-link>) was amplified via PCR using the following oligonucleotide primers: <italic>Dll4(ECD)-BamHI-Fwd</italic>: 5'-<named-content content-type="sequence">ACTACATATAGGATCCaccctaggatttgctccagg</named-content>-3' and <italic>Dll4(ECD)-PolyD<sub>-</sub>XhoI-Rev</italic>: 5'-<named-content content-type="sequence">CTTATGATCTCGAGttagtcgtcgtcgtcgtcgtcgtcgtcgtgatggtgatggtgatgatctgttctgtttttcagaggacgc</named-content>-3'.</p><p>To generate the plasmid encoding the affinity variant Dll4<sub>(E12)</sub>, which contains several point mutations in the ECD (<xref ref-type="bibr" rid="bib4">Canalis et al., 2013</xref>), the plasmid encoding Dll4-Asp<sub>8x</sub> was modified with the QuickChange Lightning Multi Site-Directed Mutagenesis Kit (Cat#201515, Agilent Technologies) and the following primers: <italic>Dll4-g1242a</italic>: 5'-<named-content content-type="sequence">gctgcgggctccagcatcttccagc</named-content>-3', <italic>Dll4-t1479c</italic>: 5'-<named-content content-type="sequence">cctctgcagttgcccctcaatttcacctggc</named-content>-3', <italic>Dll4-a1513t</italic>: 5'-<named-content content-type="sequence">ggaaccttctcactcatcatccaagcttggcac</named-content>-3', <italic>Dll4-a1587t</italic>: 5'-<named-content content-type="sequence">aaactctctcatcagccaatt</named-content> <named-content content-type="sequence">catcatccaaggctc</named-content>-3', <italic>Dll4-c1740t</italic>: 5'-<named-content content-type="sequence">gcaagaagcgcgatgactacttcggacattatgag</named-content>-3', <italic>Dll4-t1777c</italic>: 5'-<named-content content-type="sequence">cagatggcagcccgtcctgcctgcc</named-content>-3', <italic>Dll4-a1803g</italic>: 5'-<named-content content-type="sequence">ctggtcacagtactccccagtccagcccg</named-content>-3'.</p><p>The generation of the Jag1-Asp<sub>8x</sub> soluble protein containing the Jag1 ECD fused to 6x His and 8x Asp peptide sequences involved a strategy analogous to the construction of Dll4-Asp<sub>8x</sub>. A cDNA covering amino acid residues 1–1067 of the murine Jagged1 ECD (<ext-link ext-link-type="uri" xlink:href="https://www.uniprot.org/uniprot/Q9QXX0">https://www.uniprot.org/uniprot/Q9QXX0</ext-link>) was amplified with the following oligonucleotide primers: <italic>Jagged1(ECD)-BamHI-Fwd</italic>: 5'-<named-content content-type="sequence">ACTACATATAGGATCCgccgcagcgatgcggtccccacg</named-content>-3' and <italic>Jagged1(ECD)-XhoI-PolyD-Rev</italic>: 5'-<named-content content-type="sequence">CTTATGATCTCGAGttagtcgtcgtcgtcgtcgtcgtcgtcgtgatggtgatggtgatgatctgttctgtttttcagaggac</named-content> gc-3'. Site-directed mutagenesis was used to generate Jag1<sub>(JV1)</sub>, a high affinity version of the Jag1 ECD due to several point mutations (<xref ref-type="bibr" rid="bib34">Luca et al., 2017</xref>), linked to 6x His and 8x Asp peptides with the following primers <italic>Jagged1-c260g&amp;t261g</italic>: 5'-<named-content content-type="sequence">gtatcagtcccgcgtcagggccggggga</named-content>-3', <italic>Jagged1-c95t</italic>: 5'-<named-content content-type="sequence">ggtgtgcggggccttgggtcagtttg</named-content>-3', <italic>Jagged1-c202g</italic>: 5'-<named-content content-type="sequence">cgcaagtgcaccggcgacgagtgt</named-content> g-3', <italic>Jagged1-g214a</italic>: 5'-<named-content content-type="sequence">gcaccGgcgacgagtgtaatacgtacttcaaagtg</named-content>-3', <italic>Jagged1-a545g&amp;g546a</italic>: 5'-<named-content content-type="sequence">attgcccacttcgagtatcgaatccgagtgacctgtgatg</named-content>-3'.</p><p>All PCRs were carried out using PrimeSTAR Max DNA Polymerase (R045B, Takara). The resulting PCR fragments were digested by restriction enzymes BamHI and XhoI (New England Biolabs) and the resulting fragments were inserted into the in vivo overexpression vector <italic>pLIVE</italic> (MIR-5420, Mirus) for in vivo studies and into the expression vector <italic>pcDNA3.1</italic> (Invitrogen) for experiments in cultured cells.</p></sec><sec id="s4-2"><title>HEK293 cell transfection and His-tagged protein purification</title><p>For overexpressing Dll4 or Jag1 recombinant proteins, 4 × 10<sup>6</sup> HEK293 cells were plated per 10 cm dish. Twenty hours later medium was refreshed and after 3 hr cells in each dish were transfected with 18 µg plasmid DNA of <italic>pcDNA3.1-Dll4-Asp<sub>8x</sub></italic>, <italic>pcDNA3.1-Dll4<sub>(E12)</sub>, pcDNA3.1-FRT-Jag1(ECD)-His<sub>(6x)</sub>-Asp<sub>8x</sub></italic>, and <italic>pcDNA3.1-FRT-Jag1(ECD)<sub>(JV1)</sub>-His<sub>(6x)</sub>-Asp<sub>8x</sub></italic> using the CalPhos Mammalian Transfection kit (631312, TaKaRa Bio), following the manufacturer’s instructions. Sixteen hours later Opti-MEM culture medium (31985–047, Gibco) was added to the cells.</p><p>Culture supernatants were collected at 24 hr post-transfection and clarified by centrifugation at 300× <italic>g</italic> for 15 min at 4°C. For whole cell lysate samples, cells were washed twice with PBS and 1 mM PMSF and incubated with RIPA modified buffer (20 mmol/L Tris-HCl, pH 8.0, 150 mmol/L NaCl, 0.5% Triton X-100, 0.1% SDS, 0.1% Na-DOC, 2 mmol/L EDTA, cOmplete ULTRA (05892970001, Roche), and phosphatase inhibitor cocktail set V (524629, EMD Millipore)) for 20 min at 4°C. Lysates were further sonicated, spun down at 4°C for 10 min at full speed, and protein concentration was quantified using BCA Protein Assay Kit (23225, Pierce).</p><p>For the purification of His-tagged recombinant proteins from supernatants, Ni-NTA agarose resin (302010, QIAGEN) packed in disposable polystyrene columns (29922, Thermo Scientific) were used. Binding of recombinant proteins to Ni-NTA resin was done in a buffer containing 20 mmol/L Tris-HCl, 150 mmol/L NaCl, and 4 mmol/L imidazole at pH 7.4. After the passage of lysates, beads were washed with wash buffer containing 20 mmol/L Tris-HCl, 150 mmol/L NaCl, and 20 mmol/L imidazole at pH 7.4 before His-tagged proteins were eluted into elution buffer containing 20 mmol/L Tris-HCl, 150 mmol/L NaCl, and 500 mmol/L imidazole, pH 7.4.</p><p>To remove imidazole, eluted proteins were dialyzed using Pierce Slide-A-Lyzer 10 K MWCO Dialysis Cassettes (66380, Thermo Scientific) in dialysis buffer (20 mmol/L Tris-HCl, 150 mmol/L NaCl at pH 7.4). To adjust the loading volume, 500 µL of supernatant, flow-through, and wash solution were concentrated to 30 µL using Amicon Ultra-0.5 Centrifugal Filter Unit with 3 KDa cutoff (UFC500396, Millipore). After quantitation, whole cell lysates, concentrated protein solutions, and eluted recombinant proteins were mixed with SDS loading buffer and boiled for 10 min. Samples were run on 8% SDS-PAGE gel and visualized by SimplyBlue SafeStain (LC6060, Invitrogen). Target proteins were detected by comparison with protein standard markers.</p></sec><sec id="s4-3"><title>HUVEC cell culture and Dll4 or Jag1 treatment in vitro</title><p>For Dll4 experiments, HUVECs (ThermoFisher, C0035C) were cultured in MEM200 medium (M200500, ThermoFisher) supplemented with LSGS (S00310, ThermoFisher), 2% FCS (631106, Clontech), and 1% penicillin-streptomycin solution (P4333, SIGMA). For Jag1 experiments, HUVECs (ThermoFisher, C0035C) were cultured in EBM2 medium (33156, Lonza) supplemented with EGM2 bullet kit (CC-4176, Lonza). HUVECs were grown in a humidified atmosphere with 5% CO<sub>2</sub> at 37°C. Cells were tested for mycoplasma contamination by the supplier. For Notch activation assays with immobilized Dll4 or Jag1 recombinant proteins, poly-L-lysine (P6282, SIGMA) coating was used in combination with Dll4-Asp<sub>8x</sub>, Dll4<sub>(E12)</sub>, Jag1-Asp<sub>8x</sub>, or Jag1<sub>(JV1)</sub>. Corning 60 mm × 15 mm culture dishes (430196, Corning) were pre-incubated with 0.2 mg of poly-L-lysine in 0.1 M sodium borate buffer (pH = 8.5) overnight at 37°C in the cell culture incubator (Heracell 240i, ThermoFisher). Dishes were washed four times with H<sub>2</sub>O followed by four times additional washes with PBS. Following incubation with 4 µg of Dll4, Jag1 recombinant proteins or BSA in 2 mL PBS for 12 hr at 4°C and four washes with PBS, each culture dish was seeded with 2.2 × 10<sup>5</sup> cells 4 mL complete medium and cultured for 16 hr.</p><p>For Notch inhibition assays, 4.5 × 10<sup>5</sup> cells per well were cultured in Corning six-well plates pre-coated with 0.1% Gelatin. The final volume of M200+ LSGS or EGM2 medium was adjusted to 2 mL and 20 µg of Dll4 recombinant, 35 μg of Jag1 recombinant proteins or BSA protein was added to confluent HUVECs for 8 hr at 37°C.</p></sec><sec id="s4-4"><title>Quantitative RT-PCR</title><p>For the analysis of gene expression, total RNA from HUVECs was collected directly from the culture dish with 350 µL RLT plus lysis buffer (1053393, Qiagen) followed by immediate RNA extraction using RNeasy Plus Micro Kit (Qiagen, 74034). Complementary DNA was generated with 500 ng RNA per reaction using iScript cDNA Synthesis Kit (170–8890, BIO-RAD). Quantitative PCR (qPCR) was performed on a CFX96 Touch Real-Time PCR Detection System (BIO-RAD). The following FAM-conjugated TaqMan gene expression probes (ThermoFisher) were used in combination with SsoAdvanced Universal Probes Supermix (BIO-RAD): <italic>DLL4</italic> (Hs00184092_m1), <italic>HEY1</italic> (Hs00232618_m1), <italic>HEY2</italic> (Hs00232622_m1), <italic>HES1</italic> (Hs00172878_m1), <italic>EFNB2</italic> (Hs00187950_m1), <italic>NRARP</italic> (Hs01104102_s1). VIC-conjugated <italic>ACTB</italic> (4352935) or VIC-conjugated <italic>GAPDH</italic> (44326317E) were used to normalize gene expression. HUVECs with at least three independent stimulation experiments for each gene were analyzed to obtain the relative expression differences using the 2<sup>-ΔΔCt</sup> method.</p></sec><sec id="s4-5"><title>Mice and in vivo experiments</title><p>C57BL/6J and <italic>Tg(Hey1-EGFP)<sup>ID40Gsat</sup></italic> males or C57BL/6J at the age of 8 weeks were used for hydrodynamic tail vein injection. Animals were anesthetized with 3.75% isoflurane and injected with 5 µg/g (plasmid/body weight) plasmid suspended in TransIT-EE hydrodynamic delivery solution (MIR5340, Mirus) according to the manufacturer’s instruction. The appropriate amount of plasmid was suspended in an injection volume of 10% of the body weight and injected into each individual mouse via the tail vein in 5–7 s as previously reported (<xref ref-type="bibr" rid="bib31">Liu et al., 1999</xref>).</p><p>For the ovariectomy osteoporosis model, 8-week-old C57BL/6J female mice were anesthetized by intraperitoneally injection of ketamine hydrochloride (Ketavet; 100 mg/kg body weight) and xylazine (Rompun; 16 mg/kg body weight) in sterile PBS. Once animals had entered the tolerance phase without foot reflexes, a small incision was made along the dorsal midline, the abdominopelvic cavity was opened, and ovaries were removed bilaterally. The skin was closed by metal clips. After that, analgesic Carprofen (Rimadyl; 4 mg/kg body weight) was applied subcutaneously. Mice in the sham group underwent the same procedure without removal of ovaries. Four weeks after the surgery, mice received <italic>pLIVE-Dll4(E12</italic>) or vehicle by hydrodynamic tail vein injection. Three weeks later, mice were analyzed and the successful ovariectomy was confirmed by the reduction of uterus size.</p><p>For PTH and <italic>pLIVE-Dll4<sub>(E12)</sub></italic> administration, 8-week-old C57BL/6J females were divided randomly into four groups: vehicle control, <italic>pLIVE-Dll4(E12</italic>), PTH, and PTH plus <italic>pLIVE-Dll4(E12</italic>). Following <italic>pLIVE-Dll4(E12</italic>) injection at day 0, PTH (1-34) (human) acetate salt (Bachem) was injected subcutaneously every day from day 1 to day 20 at a dose 100 mg/kg body weight, diluted in sterilized PBS. Mice were analyzed at day 21.</p><p>All animals were housed at the Max Planck Institute for Molecular Biomedicine and protocols were approved by animal ethics committees with permissions (Az 81–02.04.2019 .A114 and Az 81–02.04.2020 .A416) granted by the Landesamt für Natur, Umwelt und Verbraucherschutz (LANUV) of North Rhine-Westphalia.</p></sec><sec id="s4-6"><title>Bone sample preparation and immunohistochemistry</title><p>Freshly isolated femurs were collected from plasmid and vehicle-injected mice and immediately fixed in 4% ice-cold paraformaldehyde (PFA) solution for 24 hr. Decalcification was carried out with 0.5 M EDTA (pH 8.0) at 4°C with constant shaking on a horizontal shaker for 48 hr. Next, decalcified bones were immersed into 20% sucrose and 2% polyvinylpyrrolidone (PVP) for 24 hr. Finally, tissues were embedded and frozen in embedding solution containing 8% porcine gelatin together with 20% sucrose and 2% PVP. Cryosections of 80–100 µm thickness were generated with low-profile disposable blades 819 (LEICA) on a Leica CM2050 cryostat.</p><p>For immunostaining, bone sections were air-dried, rehydrated in PBS, permeabilized for 30 min with 0.3% Triton X-100 PBS and blocked in PBS containing 5% donkey serum at room temperature for 30 min. Blocked sections were incubated with primary antibodies diluted in 5% donkey serum in PBS overnight at 4°C. After primary antibody incubation, sections were washed with PBS for three times and incubated with appropriate Alexa-Fluor-conjugated secondary antibodies (1:400) diluted in PBS for overnight at 4°C. Nuclei were counterstained with DAPI after secondary antibody incubation. Sections were washed four times with PBS before mounting with FluoroMount-G (0100–01, Southern Biotech). Finally, the slides were air-dried and sealed with nail polish.</p><p>The following primary antibodies were used: rat anti-Endomucin (SC-65495, Santa Cruz, 1:100), rat anti-PECAM-1 (553370, Pharmingen), rabbit anti-Osterix (Abcam, ab22552, 1:1000), rat anti-Runx2 (MAB2006, R&amp;D, 1:50), rabbit anti-Collagen type I (AB675P, Millipore, 1:200), goat anti-Osteopontin (AF808, R&amp;D Systems, 1:100), rabbit anti-Osteocalcin (LS-C17044, LifeSpan BioSciences, 1:100), goat anti-Dll4 (AF1389, R&amp;D Systems, 1:100), goat anti-Jag1 (J4127, Sigma, 1:100), goat anti-PDGFRβ (AF1042, R&amp;D, 1:100), rabbit anti-NG2 (AB5320, Millipore), goat anti-BCAM (AF8299, R&amp;D Systems, 1:50), rabbit anti-ATP6V1B1+ ATP6V1B2 (ab200839, Abcam), rabbit anti-Aggrecan (AB1031, Millipore), goat anti-Sox9 (AF3075, R&amp;D Systems), rabbit anti-Perilipin (9349, Cell Signaling).</p><p>Secondary antibodies were: donkey anti-rat IgG conjugated to AF594 (A21209, Invitrogen), donkey anti-goat IgG conjugated to AF647 (A21447, Invitrogen), donkey anti-rabbit IgG conjugated to AF488 (A21206, Invitrogen), donkey anti-rabbit IgG conjugated to 594 (A21207, Invitrogen), donkey anti-rat IgG conjugated to 647 (712-605-153, Jackson ImmunoResearch), donkey anti-goat IgG conjugated to AF488 (A11055, Invitrogen), donkey anti-rabbit IgG conjugated to AF647 (A31573, Invitrogen), donkey anti-rat IgG conjugated to AF488 (A21208, Invitrogen), and donkey anti-goat IgG conjugated to AF647 (A32849, Thermo Scientific).</p></sec><sec id="s4-7"><title>Histology of liver and intestine</title><p>The dissected intestinal tract was flushed gently with cold PBS followed by a flush with 4% PFA. The intestine was fixed at 4°C for 16 hr. The median lobe of liver was dissected and fixed at 4°C for 16 hr. Formalin-fixed and paraffin-embedded tissues were sectioned at 7 μm thickness. Histochemical identification of intestinal cell types was performed with Alcian blue and Nuclear Fast Red double staining. Liver sections were stained with hematoxylin and eosin. Images were taken with Zeiss Axio Imager M1 microscope.</p></sec><sec id="s4-8"><title>Immunohistochemistry of lung</title><p>Lung sample preparation and immunohistochemistry were performed as previously described (<xref ref-type="bibr" rid="bib23">Kato et al., 2018</xref>). To expose the heart and lungs, the chest cavity of anesthetized mice was opened. Through the right ventricle with manual pressure, a warm (37°C) solution of 6% gelatin/PBS (G1890, Sigma) was gently perfused. After 15 min exposure to ice-cold paper tissue, the ventral trachea was cannulated with an intravenous catheter tube that was secured by tying a suture around the trachea. The lungs were inflated to full capacity by gently injecting warm (37°C) 1% low gelling agarose/PBS (A4018, Sigma). After 20 min exposure to ice-cold paper tissue, the lungs were placed in 2% PFA solution (PFA/PBS, 4°C, P6148, Sigma) for 30 min. After washing with cold PBS for 30 min, the lung lobes were sliced (150 µm) using vibrating blade microtome (VT1200, Leica). Lung slices were fixed in 4%PFA/PBS at 4°C for 1 hr, washed thoroughly in PBS and incubated twice in PBS for 30 min at room temperature. Lung slices were blocked (5% donkey serum, 0.5% Triton X-100 in PBS) overnight at 4°C. Next, sections were treated with primary antibodies (goat anti-CD31 (FAB3628, R&amp;D Systems, 1:100), rat anti-CD31 (553370, Pharmingen, 1:100), goat anti-DLL4 (R&amp;D Systems; AF1389, 1:100)) in blocking solution over night at 4°C. Following four washes with PBST (10 min each), sections were incubated with secondary antibodies (donkey anti-goat IgG AF488 [A11055, Invitrogen, 1:500], donkey anti-goat IgG AF647 [A21447, ThermoFisher, 1:500], donkey anti-rat IgG AF647 [A21247, Invitrogen, 1:500]) in blocking solution over night at 4°C. Nuclei were counterstained with DAPI (D9542, Sigma, 2 µg/mL). After four wash steps with PBS, sections were mounted using FluoroMount-G (Southern Biotech) under cover slips.</p></sec><sec id="s4-9"><title>Analysis of inflammatory cytokines and thymic T cells</title><p>Peripheral blood was collected into anticoagulant EDTA-treated Microvettes (20.1341, Sarstedt) for blood collection. Cells were removed from plasma by centrifugation for 15 min at 2000× <italic>g</italic> using an ice-cold refrigerated centrifuge. Cytokines levels were measured from the resulting supernatant with LEGENDplex Mouse Inflammation Panel (13-plex) with V-bottom plates (740446, Biolegend). Analysis and quantification were performed according to the manufacturer’s protocol. Data analysis was performed using software provided by Biolegend. Manual gating was used to define beads A and B, while an automatic gating strategy was used to gate individual cytokine in APC-PE plot.</p><p>Mice were euthanized for analysis at the age of 11 weeks. To prepare single cell suspensions of thymocytes, individual thymi were placed in pre-wet 70 µm cell strainers immersed in ice-cold 2% FCS/PBS in petri dishes for gentle disruption with the end of a 5 mL syringe plunger. Thymocytes were stained with rat-anti-CD45-FITC (11–0451, eBioscience), rat-anti-CD8-Biotin (13–0081, eBioscience), and rat-anti-CD4-APC (17-0042-82, eBioscience) followed by staining with Streptavidin PE/Cy7 (SA1012, Thermo Scientific). Flow cytometry was performed using a FACSAria Fusion with FACSDiva (BD Biosciences).</p></sec><sec id="s4-10"><title>Analysis of vascular leakage</title><p>Adult mice were injected with 1 mg of 70 kDa Dextran, Texas Red (Lysine fixable, D1864, Molecular Probes) dissolved in 200 µL of PBS via tail vein injection. Femur, liver, kidney, and lung were harvested from Dextran and PBS-injected mice after 15 min and subjected to sample preparation and staining as describe above for bone samples.</p></sec><sec id="s4-11"><title>Micro-CT analysis and histomorphometry</title><p>Tibiae were collected and attached soft tissue was removed thoroughly prior to fixation in 4% PFA overnight at 4°C. Fixed samples were analyzed with μ-CT 50 by Scanco Medical AG, Switzerland. A voxel size of 6 µm was chosen in all three spatial dimensions. For each sample, 500 slices were evaluated covering a total of 3 mm, X-ray voltage was 70 kVp, intensity 86 μA, and integration time 1000 ms, frame averaging 1.</p><p>Calcein double labeling was performed as reported previously (<xref ref-type="bibr" rid="bib48">Porter et al., 2017</xref>) with minor modifications to calculate bone formation rate (BFR) and mineral apposition rate (MAR). Briefly, mice were intraperitoneally injected with 10 mg/kg calcein (Sigma, C0875) dissolved in 2% sodium bicarbonate solution at the tenth day and third day before euthanasia. Bones were fixed in 4% PFA for 2 days at room temperature followed by transfer to 70% ethanol. Fixed bones were incubated with 5% potassium hydroxide for 96 hr at room temperature. Processed bones were embedded in bone embedding solution (8% porcine gelatin in the presence of 20% sucrose and 2% PVP). Cryosections were taken at 20 µm using low-profile blades on a Leica CM2050 cryostat. Single plane images were acquired from the sections using an LSM 880 confocal microscope (Carl Zeiss). Representative images show trabecular bone. MAR and BFR were calculated from trabecular bone in the metaphysis.</p></sec><sec id="s4-12"><title>Single cell sequencing of BM stromal cells</title><p>Femurs and tibiae were harvested 3 wpi from adult mice at the age of 11 weeks. Bones were crushed by pestle and mortar with ice-cold 2% FCS/PBS and followed by 30 min digestion at 37°C with collagenase cocktail by mixing with 2 mg/mL of collagenase IV (17104–019, Gibco), 2 mg/mL collagenase I (17100–017, Gibco), and 10 U/mL of Dispase (17105–041) in a 1:1:1 ratio. The resulting single cell suspension was subjected to depletion of lineage-positive hematopoietic cells with following reagents from Miltenyi Biotec: Lineage Cell Depletion Kit (130-090-858), CD45 Microbeads (130-052-301), CD117 Microbeads (130-091-224), Ter-119 Microbeads (130-049-901), and CD71-biotin (Biolegend, 113803) in combination with Anti-Biotin UltraPure MicroBeads (Miltenyi Biotec, 130-105-637). Lineage-depleted stromal cells were loaded into a BD Rhapsody Cartridge for capturing single cells for whole transcriptome according to the manufacturer’s instructions. scRNA libraries were prepared with The BD Rhapsody Whole Transcriptome Analysis (WTA) Amplification kit. DNA sequencing was performed on a NextSeq500 (Illumina).</p></sec><sec id="s4-13"><title>scRNA-seq bioinformatics and data access</title><p>FASTQ files from BD Rhapsody WTA and sequencing were first trimmed for adapters and Phred score (&gt;20) using TrimGalore! (0.6.4), discarding reads shorter than 66 bp after trimming. The first mate was then split into barcode and UMI using the pattern described in the BD Rhapsody Bioinformatics Handbook (revision 6.0, <xref ref-type="fig" rid="fig3">Figure 3</xref>), allowing up to two mismatches in each of the fixed sequences L1 and L2. A barcode whitelist was created by counting the occurrences of each of the three CLS sequences, choosing those that occur at least 1000 times, and forming every possible combination of CLS1-CLS2-CLS3. Reads were mapped using Salmon alevin (1.1.0) with the vM22 Gencode transcripts and genomic decoy sequences, including the above whitelist for barcode correction. Automatic filtering by Salmon alevin was disabled, and Alevin count matrices were used for downstream analyses. Count matrices were loaded into R using tximport (1.1.14). Empty wells were identified using DropletUtils (1.6.1) with an FDR cutoff of 0.001. Cells classified as empty wells or with less than 500 expressed genes, and genes with signal in less than 10 cells were removed from the analysis. Doublets were identified using scDblFinder (1.0.0) with default parameters and subsequently removed. Filtered count matrices were imported into Seurat (3.1.3). Mitochondrial gene contribution was estimated using Seurat’s PercentageFeatureSet, and cells with more than 20% mitochondrial reads were removed. Expression counts were normalized using scran normalize (1.14.6). Control and treatment samples were analyzed together as an integrated Seurat dataset. The data was scaled using Seurat’s ScaleData function and variable features were selected by FindVariableFeatures (nFeatures = 2000, selection.method=‘vst’).</p><p>Main cell type clusters were identified using Louvain clustering with a resolution parameter of 0.05, using the top 50 principal components (PCs). Marker genes were identified using Seurat’s FindAllMarkers function with default settings, and cells identified as hematopoietic were removed as contaminants. Marker expression was plotted using DoHeatmap on the top 10 marker genes in each cluster. Dimensionality reduction plots are based on UMAP projections using Seurat’s RunUMAP function.</p><p>For the MSC population subclustering, we first applied stricter empty droplet filtering (FDR = 0) to remove low complexity subpopulations. The expression values were re-scaled and variable feature selection was repeated. We then used the top six PCs for Louvain clustering at a resolution of 0.05 and UMAP projection. Marker genes were identified using Seurat’s FindAllMarkers function with default settings, and marker expression was plotted using DoHeatmap on the top five marker genes in each cluster.</p><p>Differentially expressed genes were identified separately for each cluster, using Seurat’s FindMarkers function with default settings (Wilcoxon rank sum test) on the Dll4<sub>(E12)</sub>-treated and control samples. Scaled expression violin plots are based on Seurat’s RNA assay and the ‘data’ slot. Each violin is scaled to the width of the plotting window.</p><p>GO analysis was performed using GOstats (2.52.0) hypergeometric testing. p-Values were multiple testing corrected using the Bonferroni method.</p><p>scRNA-seq data have been deposited in the GEO functional genomics data repository under the accession number GSE152285.</p></sec><sec id="s4-14"><title>Western blots</title><p>Half of the median liver lobe was dissected from plasmid and vehicle injected mice and snap-frozen in liquid nitrogen. Liver samples were homogenized in lysis buffer (50 mM Tris-HCl pH 7.4, 1 mM EDTA, 1% Triton X-100, 0.2% Na-DOC, 0.2% SDS, cOmplete ULTRA Proteinase inhibitor 1× [Roche, 05892970001], Phosphatase Inhibitor Cocktail Set V [524632-1SET, Merck], 1 mM PMSF) with Tissuelyser LT (QIAGEN) and clarified by centrifugation by 20,000× <italic>g</italic> for 20 min at 4°C. Protein concentration in lysates was measured using Pierce BCA Protein-Assay kit (23225, Pierce). Soluble supernatants were prepared in SDS-PAGE sample buffer and analyzed by SDS-PAGE and immunoblotting after loading 40 µg of total liver lysate. Signal was detected using horseradish peroxidase-conjugated secondary antibodies followed by ECL Prime Western Blotting Detection Reagents (RPN2232, GE Healthcare). Primary antibodies: goat anti-Dll4 (AF1389, R&amp;D, 1:200), rabbit anti-GAPDH (AM4300, Ambion, 1:1000). Secondary antibodies: goat anti-rabbit IgG, HRP-linked whole Ab (7074, Cell Signaling, 1: 15000), donkey anti-goat IgG, HRP-linked whole Ab (ABIN1536502, antibody online, 1:15,000).</p><p>0.5 μg recombinant Jag1 recombinant proteins were prepared in SDS-PAGE sample buffer and analyzed by SDS-PAGE, followed by immunoblotting. Primary antibodies used are mouse anti-His tag (Zymed; 372900 1:200) and goat anti-Jag1 (Sigma; J4127 1:500). Secondary antibodies used are sheep anti-mouse IgG 656G, HRP-linked whole Ab (HG-Healthcare, NA931, 1:40000) and Peroxidase AffiniPure bovine anti-goat IgG (H + L) (Jackson ImmunoResearch, 805-035-180, 1:15,000).</p></sec><sec id="s4-15"><title>Image acquisition, processing, and statistical analysis</title><p>Confocal image acquisition was performed using confocal microscope LSM880 (Zeiss). Z-stacks of images were processed and 3D reconstructed with Imaris software (version 9.50, Bitplane). Image J (NIH) and Illustrator (Adobe) software were used for image processing. Quantifications of vascular and bone-related parameters were performed with Fiji software on high-resolution images.</p><p>For quantification of OSX<sup>+</sup> and Runx2<sup>+</sup> cells, a region of 400 µm from growth plate toward the caudal region was selected in images of the metaphysis. Osteoclast surface/bone surface (Oc. S/BS; %) and osteoclast number/bone perimeter (No. Oc./B. Pm) were calculated based on ATP6V1B1 + ATP6V1B2 staining of bone sections. VEGFR3<sup>low</sup> area was calculated based on VEGFR3 staining and normalized to the total selected area. Adipocyte cell number was calculated based on Perilipin staining of bone sections. Artery number was calculated based on BCAM staining.</p><p>Col1a1, PDGFRb, Dll4, Endomucin, Opn areas were calculated based on the corresponding stainings and were normalized to DAPI area. The length of metaphysis was calculated as the mean of three values: length of left, right, and middle regions of metaphysis.</p><p>All images shown are representative for the respective staining in several experiments. Within one experiment laser excitation and confocal scanner detection were the same. All images shown in the figures are maximum intensity projections and are representative of at least three mice analyzed for each condition unless stated otherwise.</p><p>Statistical analysis was performed with GraphPad Prism software. All data are presented as mean ± s.e.m. or mean ± SD. Unpaired two-tailed Student’s t-test, Mann-Whitney U test, one-way and two-way ANOVA were used to determine statistical significance, as indicated in the legends. All experiments were performed independently at least three times and respective data were used for statistical analysis. Sample sizes for each experiment are described in the respective figure legends. No randomization or blinding was used and no animals were excluded from analysis. Several independent experiments were performed to guarantee reproducibility of findings.</p></sec></sec></body><back><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Investigation, Methodology, Writing – original draft</p></fn><fn fn-type="con" id="con2"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con3"><p>Investigation, Project administration, Methodology</p></fn><fn fn-type="con" id="con4"><p>Investigation, Project administration, Methodology</p></fn><fn fn-type="con" id="con5"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con6"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con7"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con8"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con9"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con10"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con11"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con12"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con13"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con14"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con15"><p>Conceptualization, Investigation, Project administration, Supervision, Writing – review and editing</p></fn><fn fn-type="con" id="con16"><p>Conceptualization, Supervision, Investigation, Project administration, Supervision, Writing – original draft, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>All animals were housed at the Max Planck Institute for Molecular Biomedicine and protocols were approved by animal ethics committees with permissions (Az 81-02.04.2019.A114 and Az 81-02.04.2020.A416) granted by the Landesamt für Natur, Umwelt und Verbraucherschutz (LANUV) of North Rhine-Westphalia. Every effort was made to minimize suffering.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-60183-transrepform1-v2.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>scRNA-seq data have been deposited in the GEO functional genomics data repository under the accession number GSE152285.</p><p>The following dataset was generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>RH</given-names></name><name><surname>Xu</surname><given-names>C</given-names></name><name><surname>Kruse</surname><given-names>K</given-names></name><name><surname>Jeong</surname><given-names>H</given-names></name><name><surname>Watson</surname><given-names>E</given-names></name><name><surname>Adams</surname><given-names>S</given-names></name><name><surname>Stehling</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Kato</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>Induction of osteogenesis by bone-targeted Notch activation</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE152285">GSE152285</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>The authors thank the Max Planck Society, the European Research Council (AdG 339409 AngioBone; AdG 786672 PROVEC), and the Leducq Foundation for funding. ECW was supported by the Alexander von Humboldt Foundation.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baryawno</surname><given-names>N</given-names></name><name><surname>Przybylski</surname><given-names>D</given-names></name><name><surname>Kowalczyk</surname><given-names>MS</given-names></name><name><surname>Kfoury</surname><given-names>Y</given-names></name><name><surname>Severe</surname><given-names>N</given-names></name><name><surname>Gustafsson</surname><given-names>K</given-names></name><name><surname>Kokkaliaris</surname><given-names>KD</given-names></name><name><surname>Mercier</surname><given-names>F</given-names></name><name><surname>Tabaka</surname><given-names>M</given-names></name><name><surname>Hofree</surname><given-names>M</given-names></name><name><surname>Dionne</surname><given-names>D</given-names></name><name><surname>Papazian</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>D</given-names></name><name><surname>Ashenberg</surname><given-names>O</given-names></name><name><surname>Subramanian</surname><given-names>A</given-names></name><name><surname>Vaishnav</surname><given-names>ED</given-names></name><name><surname>Rozenblatt-Rosen</surname><given-names>O</given-names></name><name><surname>Regev</surname><given-names>A</given-names></name><name><surname>Scadden</surname><given-names>DT</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A Cellular Taxonomy of the Bone Marrow Stroma in Homeostasis and Leukemia</article-title><source>Cell</source><volume>177</volume><fpage>1915</fpage><lpage>1932</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2019.04.040</pub-id><pub-id pub-id-type="pmid">31130381</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benedito</surname><given-names>R</given-names></name><name><surname>Roca</surname><given-names>C</given-names></name><name><surname>Sörensen</surname><given-names>I</given-names></name><name><surname>Adams</surname><given-names>S</given-names></name><name><surname>Gossler</surname><given-names>A</given-names></name><name><surname>Fruttiger</surname><given-names>M</given-names></name><name><surname>Adams</surname><given-names>RH</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The notch ligands Dll4 and Jagged1 have opposing effects on angiogenesis</article-title><source>Cell</source><volume>137</volume><fpage>1124</fpage><lpage>1135</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2009.03.025</pub-id><pub-id pub-id-type="pmid">19524514</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bianco</surname><given-names>P</given-names></name><name><surname>Gehron Robey</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Marrow stromal stem cells</article-title><source>The Journal of Clinical Investigation</source><volume>105</volume><fpage>1663</fpage><lpage>1668</lpage><pub-id pub-id-type="doi">10.1172/JCI10413</pub-id><pub-id pub-id-type="pmid">10862779</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Canalis</surname><given-names>E</given-names></name><name><surname>Parker</surname><given-names>K</given-names></name><name><surname>Feng</surname><given-names>JQ</given-names></name><name><surname>Zanotti</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Osteoblast lineage-specific effects of notch activation in the skeleton</article-title><source>Endocrinology</source><volume>154</volume><fpage>623</fpage><lpage>634</lpage><pub-id pub-id-type="doi">10.1210/en.2012-1732</pub-id><pub-id pub-id-type="pmid">23275471</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Jiang</surname><given-names>W</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>B-C</given-names></name><name><surname>Zuo</surname><given-names>G-W</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Luo</surname><given-names>Q</given-names></name><name><surname>Shi</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>B-Q</given-names></name><name><surname>Wagner</surname><given-names>ER</given-names></name><name><surname>Luo</surname><given-names>J</given-names></name><name><surname>Tang</surname><given-names>M</given-names></name><name><surname>Wietholt</surname><given-names>C</given-names></name><name><surname>Luo</surname><given-names>X</given-names></name><name><surname>Bi</surname><given-names>Y</given-names></name><name><surname>Su</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>He</surname><given-names>CJ</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Shen</surname><given-names>J</given-names></name><name><surname>Rastegar</surname><given-names>F</given-names></name><name><surname>Huang</surname><given-names>E</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>J-L</given-names></name><name><surname>Zhou</surname><given-names>J-Z</given-names></name><name><surname>Reid</surname><given-names>RR</given-names></name><name><surname>Luu</surname><given-names>HH</given-names></name><name><surname>Haydon</surname><given-names>RC</given-names></name><name><surname>He</surname><given-names>T-C</given-names></name><name><surname>Deng</surname><given-names>Z-L</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Insulin-like growth factor 2 (IGF-2) potentiates BMP-9-induced osteogenic differentiation and bone formation</article-title><source>Journal of Bone and Mineral Research</source><volume>25</volume><fpage>2447</fpage><lpage>2459</lpage><pub-id pub-id-type="doi">10.1002/jbmr.133</pub-id><pub-id pub-id-type="pmid">20499340</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Tao</surname><given-names>J</given-names></name><name><surname>Bae</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>M-M</given-names></name><name><surname>Bertin</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>T</given-names></name><name><surname>Lee</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Notch gain of function inhibits chondrocyte differentiation via Rbpj-dependent suppression of Sox9</article-title><source>Journal of Bone and Mineral Research</source><volume>28</volume><fpage>649</fpage><lpage>659</lpage><pub-id pub-id-type="doi">10.1002/jbmr.1770</pub-id><pub-id pub-id-type="pmid">22991339</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chesnut</surname><given-names>CH</given-names></name><name><surname>Silverman</surname><given-names>S</given-names></name><name><surname>Andriano</surname><given-names>K</given-names></name><name><surname>Genant</surname><given-names>H</given-names></name><name><surname>Gimona</surname><given-names>A</given-names></name><name><surname>Harris</surname><given-names>S</given-names></name><name><surname>Kiel</surname><given-names>D</given-names></name><name><surname>LeBoff</surname><given-names>M</given-names></name><name><surname>Maricic</surname><given-names>M</given-names></name><name><surname>Miller</surname><given-names>P</given-names></name><name><surname>Moniz</surname><given-names>C</given-names></name><name><surname>Peacock</surname><given-names>M</given-names></name><name><surname>Richardson</surname><given-names>P</given-names></name><name><surname>Watts</surname><given-names>N</given-names></name><name><surname>Baylink</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group</article-title><source>The American Journal of Medicine</source><volume>109</volume><fpage>267</fpage><lpage>276</lpage><pub-id pub-id-type="doi">10.1016/s0002-9343(00)00490-3</pub-id><pub-id pub-id-type="pmid">10996576</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chesnut</surname><given-names>CH</given-names></name><name><surname>Skag</surname><given-names>A</given-names></name><name><surname>Christiansen</surname><given-names>C</given-names></name><name><surname>Recker</surname><given-names>R</given-names></name><name><surname>Stakkestad</surname><given-names>JA</given-names></name><name><surname>Hoiseth</surname><given-names>A</given-names></name><name><surname>Felsenberg</surname><given-names>D</given-names></name><name><surname>Huss</surname><given-names>H</given-names></name><name><surname>Gilbride</surname><given-names>J</given-names></name><name><surname>Schimmer</surname><given-names>RC</given-names></name><name><surname>Delmas</surname><given-names>PD</given-names></name><collab>Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe BONE</collab></person-group><year iso-8601-date="2004">2004</year><article-title>Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis</article-title><source>Journal of Bone and Mineral Research</source><volume>19</volume><fpage>1241</fpage><lpage>1249</lpage><pub-id pub-id-type="doi">10.1359/JBMR.040325</pub-id><pub-id pub-id-type="pmid">15231010</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clarke</surname><given-names>BL</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Anti-sclerostin antibodies: utility in treatment of osteoporosis</article-title><source>Maturitas</source><volume>78</volume><fpage>199</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1016/j.maturitas.2014.04.016</pub-id><pub-id pub-id-type="pmid">24842796</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cosman</surname><given-names>F</given-names></name><name><surname>de Beur</surname><given-names>SJ</given-names></name><name><surname>LeBoff</surname><given-names>MS</given-names></name><name><surname>Lewiecki</surname><given-names>EM</given-names></name><name><surname>Tanner</surname><given-names>B</given-names></name><name><surname>Randall</surname><given-names>S</given-names></name><name><surname>Lindsay</surname><given-names>R</given-names></name><collab>National Osteoporosis Foundation</collab></person-group><year iso-8601-date="2014">2014</year><article-title>Clinician’s Guide to Prevention and Treatment of Osteoporosis</article-title><source>Osteoporosis International</source><volume>25</volume><fpage>2359</fpage><lpage>2381</lpage><pub-id pub-id-type="doi">10.1007/s00198-014-2794-2</pub-id><pub-id pub-id-type="pmid">25182228</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dishowitz</surname><given-names>MI</given-names></name><name><surname>Zhu</surname><given-names>F</given-names></name><name><surname>Sundararaghavan</surname><given-names>HG</given-names></name><name><surname>Ifkovits</surname><given-names>JL</given-names></name><name><surname>Burdick</surname><given-names>JA</given-names></name><name><surname>Hankenson</surname><given-names>KD</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Jagged1 immobilization to an osteoconductive polymer activates the Notch signaling pathway and induces osteogenesis</article-title><source>Journal of Biomedical Materials Research. Part A</source><volume>102</volume><fpage>1558</fpage><lpage>1567</lpage><pub-id pub-id-type="doi">10.1002/jbm.a.34825</pub-id><pub-id pub-id-type="pmid">23775982</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eastell</surname><given-names>R</given-names></name><name><surname>Devogelaer</surname><given-names>JP</given-names></name><name><surname>Peel</surname><given-names>NF</given-names></name><name><surname>Chines</surname><given-names>AA</given-names></name><name><surname>Bax</surname><given-names>DE</given-names></name><name><surname>Sacco-Gibson</surname><given-names>N</given-names></name><name><surname>Nagant de Deuxchaisnes</surname><given-names>C</given-names></name><name><surname>Russell</surname><given-names>RG</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients</article-title><source>Osteoporosis International</source><volume>11</volume><fpage>331</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1007/s001980070122</pub-id><pub-id pub-id-type="pmid">10928223</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Engin</surname><given-names>F</given-names></name><name><surname>Yao</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>T</given-names></name><name><surname>Zhou</surname><given-names>G</given-names></name><name><surname>Bertin</surname><given-names>T</given-names></name><name><surname>Jiang</surname><given-names>MM</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Zheng</surname><given-names>H</given-names></name><name><surname>Sutton</surname><given-names>RE</given-names></name><name><surname>Boyce</surname><given-names>BF</given-names></name><name><surname>Lee</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Dimorphic effects of Notch signaling in bone homeostasis</article-title><source>Nature Medicine</source><volume>14</volume><fpage>299</fpage><lpage>305</lpage><pub-id pub-id-type="doi">10.1038/nm1712</pub-id><pub-id pub-id-type="pmid">18297084</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>X</given-names></name><name><surname>McDonald</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Disorders of bone remodeling</article-title><source>Annual Review of Pathology</source><volume>6</volume><fpage>121</fpage><lpage>145</lpage><pub-id pub-id-type="doi">10.1146/annurev-pathol-011110-130203</pub-id><pub-id pub-id-type="pmid">20936937</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fung</surname><given-names>E</given-names></name><name><surname>Tang</surname><given-names>S-MT</given-names></name><name><surname>Canner</surname><given-names>JP</given-names></name><name><surname>Morishige</surname><given-names>K</given-names></name><name><surname>Arboleda-Velasquez</surname><given-names>JF</given-names></name><name><surname>Cardoso</surname><given-names>AA</given-names></name><name><surname>Carlesso</surname><given-names>N</given-names></name><name><surname>Aster</surname><given-names>JC</given-names></name><name><surname>Aikawa</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Delta-like 4 induces notch signaling in macrophages: implications for inflammation</article-title><source>Circulation</source><volume>115</volume><fpage>2948</fpage><lpage>2956</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.106.675462</pub-id><pub-id pub-id-type="pmid">17533181</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gil</surname><given-names>L</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Opas</surname><given-names>EE</given-names></name><name><surname>Rodan</surname><given-names>GA</given-names></name><name><surname>Ruel</surname><given-names>R</given-names></name><name><surname>Seedor</surname><given-names>JG</given-names></name><name><surname>Tyler</surname><given-names>PC</given-names></name><name><surname>Young</surname><given-names>RN</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Prostaglandin E2-bisphosphonate conjugates: potential agents for treatment of osteoporosis</article-title><source>Bioorganic &amp; Medicinal Chemistry</source><volume>7</volume><fpage>901</fpage><lpage>919</lpage><pub-id pub-id-type="doi">10.1016/s0968-0896(99)00045-0</pub-id><pub-id pub-id-type="pmid">10400344</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Golson</surname><given-names>ML</given-names></name><name><surname>Le Lay</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>N</given-names></name><name><surname>Brämswig</surname><given-names>N</given-names></name><name><surname>Loomes</surname><given-names>KM</given-names></name><name><surname>Oakey</surname><given-names>R</given-names></name><name><surname>May</surname><given-names>CL</given-names></name><name><surname>White</surname><given-names>P</given-names></name><name><surname>Kaestner</surname><given-names>KH</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Jagged1 is a competitive inhibitor of Notch signaling in the embryonic pancreas</article-title><source>Mechanisms of Development</source><volume>126</volume><fpage>687</fpage><lpage>699</lpage><pub-id pub-id-type="doi">10.1016/j.mod.2009.05.005</pub-id><pub-id pub-id-type="pmid">19501159</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hicks</surname><given-names>C</given-names></name><name><surname>Ladi</surname><given-names>E</given-names></name><name><surname>Lindsell</surname><given-names>C</given-names></name><name><surname>Hsieh</surname><given-names>JJ-D</given-names></name><name><surname>Hayward</surname><given-names>SD</given-names></name><name><surname>Collazo</surname><given-names>A</given-names></name><name><surname>Weinmaster</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>A secreted Delta1-Fc fusion protein functions both as an activator and inhibitor of Notch1 signaling</article-title><source>Journal of Neuroscience Research</source><volume>68</volume><fpage>655</fpage><lpage>667</lpage><pub-id pub-id-type="doi">10.1002/jnr.10263</pub-id><pub-id pub-id-type="pmid">12111827</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname><given-names>CR</given-names></name><name><surname>Yuasa</surname><given-names>M</given-names></name><name><surname>Schoenecker</surname><given-names>J</given-names></name><name><surname>Goudy</surname><given-names>SL</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Jagged1 is essential for osteoblast development during maxillary ossification</article-title><source>Bone</source><volume>62</volume><fpage>10</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.bone.2014.01.019</pub-id><pub-id pub-id-type="pmid">24491691</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hilton</surname><given-names>MJ</given-names></name><name><surname>Tu</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Bai</surname><given-names>S</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Kobayashi</surname><given-names>T</given-names></name><name><surname>Kronenberg</surname><given-names>HM</given-names></name><name><surname>Teitelbaum</surname><given-names>SL</given-names></name><name><surname>Ross</surname><given-names>FP</given-names></name><name><surname>Kopan</surname><given-names>R</given-names></name><name><surname>Long</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Notch signaling maintains bone marrow mesenchymal progenitors by suppressing osteoblast differentiation</article-title><source>Nature Medicine</source><volume>14</volume><fpage>306</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.1038/nm1716</pub-id><pub-id pub-id-type="pmid">18297083</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiménez-Alcázar</surname><given-names>M</given-names></name><name><surname>Rangaswamy</surname><given-names>C</given-names></name><name><surname>Panda</surname><given-names>R</given-names></name><name><surname>Bitterling</surname><given-names>J</given-names></name><name><surname>Simsek</surname><given-names>YJ</given-names></name><name><surname>Long</surname><given-names>AT</given-names></name><name><surname>Bilyy</surname><given-names>R</given-names></name><name><surname>Krenn</surname><given-names>V</given-names></name><name><surname>Renné</surname><given-names>C</given-names></name><name><surname>Renné</surname><given-names>T</given-names></name><name><surname>Kluge</surname><given-names>S</given-names></name><name><surname>Panzer</surname><given-names>U</given-names></name><name><surname>Mizuta</surname><given-names>R</given-names></name><name><surname>Mannherz</surname><given-names>HG</given-names></name><name><surname>Kitamura</surname><given-names>D</given-names></name><name><surname>Herrmann</surname><given-names>M</given-names></name><name><surname>Napirei</surname><given-names>M</given-names></name><name><surname>Fuchs</surname><given-names>TA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Host DNases prevent vascular occlusion by neutrophil extracellular traps</article-title><source>Science (New York, N.Y.)</source><volume>358</volume><fpage>1202</fpage><lpage>1206</lpage><pub-id pub-id-type="doi">10.1126/science.aam8897</pub-id><pub-id pub-id-type="pmid">29191910</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kasugai</surname><given-names>S</given-names></name><name><surname>Fujisawa</surname><given-names>R</given-names></name><name><surname>Waki</surname><given-names>Y</given-names></name><name><surname>Miyamoto</surname><given-names>K</given-names></name><name><surname>Ohya</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Selective drug delivery system to bone: small peptide (Asp)6 conjugation</article-title><source>Journal of Bone and Mineral Research</source><volume>15</volume><fpage>936</fpage><lpage>943</lpage><pub-id pub-id-type="doi">10.1359/jbmr.2000.15.5.936</pub-id><pub-id pub-id-type="pmid">10804024</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kato</surname><given-names>K</given-names></name><name><surname>Diéguez-Hurtado</surname><given-names>R</given-names></name><name><surname>Park</surname><given-names>DY</given-names></name><name><surname>Hong</surname><given-names>SP</given-names></name><name><surname>Kato-Azuma</surname><given-names>S</given-names></name><name><surname>Adams</surname><given-names>S</given-names></name><name><surname>Stehling</surname><given-names>M</given-names></name><name><surname>Trappmann</surname><given-names>B</given-names></name><name><surname>Wrana</surname><given-names>JL</given-names></name><name><surname>Koh</surname><given-names>GY</given-names></name><name><surname>Adams</surname><given-names>RH</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Pulmonary pericytes regulate lung morphogenesis</article-title><source>Nature Communications</source><volume>9</volume><elocation-id>2448</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-04913-2</pub-id><pub-id pub-id-type="pmid">29934496</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katsumi</surname><given-names>H</given-names></name><name><surname>Sano</surname><given-names>J-I</given-names></name><name><surname>Nishikawa</surname><given-names>M</given-names></name><name><surname>Hanzawa</surname><given-names>K</given-names></name><name><surname>Sakane</surname><given-names>T</given-names></name><name><surname>Yamamoto</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Molecular Design of Bisphosphonate-Modified Proteins for Efficient Bone Targeting In Vivo</article-title><source>PLOS ONE</source><volume>10</volume><elocation-id>e0135966</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0135966</pub-id><pub-id pub-id-type="pmid">26287482</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knowles</surname><given-names>HJ</given-names></name><name><surname>Cleton-Jansen</surname><given-names>AM</given-names></name><name><surname>Korsching</surname><given-names>E</given-names></name><name><surname>Athanasou</surname><given-names>NA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Hypoxia-inducible factor regulates osteoclast-mediated bone resorption: role of angiopoietin-like 4</article-title><source>FASEB Journal</source><volume>24</volume><fpage>4648</fpage><lpage>4659</lpage><pub-id pub-id-type="doi">10.1096/fj.10-162230</pub-id><pub-id pub-id-type="pmid">20667978</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kusumbe</surname><given-names>AP</given-names></name><name><surname>Ramasamy</surname><given-names>SK</given-names></name><name><surname>Adams</surname><given-names>RH</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Coupling of angiogenesis and osteogenesis by a specific vessel subtype in bone</article-title><source>Nature</source><volume>507</volume><fpage>323</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1038/nature13145</pub-id><pub-id pub-id-type="pmid">24646994</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwan</surname><given-names>KM</given-names></name><name><surname>Pang</surname><given-names>MK</given-names></name><name><surname>Zhou</surname><given-names>S</given-names></name><name><surname>Cowan</surname><given-names>SK</given-names></name><name><surname>Kong</surname><given-names>RY</given-names></name><name><surname>Pfordte</surname><given-names>T</given-names></name><name><surname>Olsen</surname><given-names>BR</given-names></name><name><surname>Sillence</surname><given-names>DO</given-names></name><name><surname>Tam</surname><given-names>PP</given-names></name><name><surname>Cheah</surname><given-names>KS</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Abnormal compartmentalization of cartilage matrix components in mice lacking collagen X: implications for function</article-title><source>The Journal of Cell Biology</source><volume>136</volume><fpage>459</fpage><lpage>471</lpage><pub-id pub-id-type="doi">10.1083/jcb.136.2.459</pub-id><pub-id pub-id-type="pmid">9015315</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langen</surname><given-names>UH</given-names></name><name><surname>Pitulescu</surname><given-names>ME</given-names></name><name><surname>Kim</surname><given-names>JM</given-names></name><name><surname>Enriquez-Gasca</surname><given-names>R</given-names></name><name><surname>Sivaraj</surname><given-names>KK</given-names></name><name><surname>Kusumbe</surname><given-names>AP</given-names></name><name><surname>Singh</surname><given-names>A</given-names></name><name><surname>Di Russo</surname><given-names>J</given-names></name><name><surname>Bixel</surname><given-names>MG</given-names></name><name><surname>Zhou</surname><given-names>B</given-names></name><name><surname>Sorokin</surname><given-names>L</given-names></name><name><surname>Vaquerizas</surname><given-names>JM</given-names></name><name><surname>Adams</surname><given-names>RH</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Cell-matrix signals specify bone endothelial cells during developmental osteogenesis</article-title><source>Nature Cell Biology</source><volume>19</volume><fpage>189</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1038/ncb3476</pub-id><pub-id pub-id-type="pmid">28218908</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Ominsky</surname><given-names>MS</given-names></name><name><surname>Warmington</surname><given-names>KS</given-names></name><name><surname>Morony</surname><given-names>S</given-names></name><name><surname>Gong</surname><given-names>J</given-names></name><name><surname>Cao</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Shalhoub</surname><given-names>V</given-names></name><name><surname>Tipton</surname><given-names>B</given-names></name><name><surname>Haldankar</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Winters</surname><given-names>A</given-names></name><name><surname>Boone</surname><given-names>T</given-names></name><name><surname>Geng</surname><given-names>Z</given-names></name><name><surname>Niu</surname><given-names>Q-T</given-names></name><name><surname>Ke</surname><given-names>HZ</given-names></name><name><surname>Kostenuik</surname><given-names>PJ</given-names></name><name><surname>Simonet</surname><given-names>WS</given-names></name><name><surname>Lacey</surname><given-names>DL</given-names></name><name><surname>Paszty</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis</article-title><source>Journal of Bone and Mineral Research</source><volume>24</volume><fpage>578</fpage><lpage>588</lpage><pub-id pub-id-type="doi">10.1359/jbmr.081206</pub-id><pub-id pub-id-type="pmid">19049336</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Limbourg</surname><given-names>FP</given-names></name><name><surname>Takeshita</surname><given-names>K</given-names></name><name><surname>Radtke</surname><given-names>F</given-names></name><name><surname>Bronson</surname><given-names>RT</given-names></name><name><surname>Chin</surname><given-names>MT</given-names></name><name><surname>Liao</surname><given-names>JK</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Essential role of endothelial Notch1 in angiogenesis</article-title><source>Circulation</source><volume>111</volume><fpage>1826</fpage><lpage>1832</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.0000160870.93058.DD</pub-id><pub-id pub-id-type="pmid">15809373</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Song</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA</article-title><source>Gene Therapy</source><volume>6</volume><fpage>1258</fpage><lpage>1266</lpage><pub-id pub-id-type="doi">10.1038/sj.gt.3300947</pub-id><pub-id pub-id-type="pmid">10455434</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>P</given-names></name><name><surname>Ping</surname><given-names>Y</given-names></name><name><surname>Ma</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Zaidi</surname><given-names>S</given-names></name><name><surname>Gao</surname><given-names>S</given-names></name><name><surname>Ji</surname><given-names>Y</given-names></name><name><surname>Lou</surname><given-names>F</given-names></name><name><surname>Yu</surname><given-names>F</given-names></name><name><surname>Lu</surname><given-names>P</given-names></name><name><surname>Stachnik</surname><given-names>A</given-names></name><name><surname>Bai</surname><given-names>M</given-names></name><name><surname>Wei</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>New</surname><given-names>MI</given-names></name><name><surname>Rowe</surname><given-names>DW</given-names></name><name><surname>Yuen</surname><given-names>T</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Zaidi</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Anabolic actions of Notch on mature bone</article-title><source>PNAS</source><volume>113</volume><fpage>E2152</fpage><lpage>E2161</lpage><pub-id pub-id-type="doi">10.1073/pnas.1603399113</pub-id><pub-id pub-id-type="pmid">27036007</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luca</surname><given-names>VC</given-names></name><name><surname>Jude</surname><given-names>KM</given-names></name><name><surname>Pierce</surname><given-names>NW</given-names></name><name><surname>Nachury</surname><given-names>MV</given-names></name><name><surname>Fischer</surname><given-names>S</given-names></name><name><surname>Garcia</surname><given-names>KC</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Structural biology. Structural basis for Notch1 engagement of Delta-like 4</article-title><source>Science (New York, N.Y.)</source><volume>347</volume><fpage>847</fpage><lpage>853</lpage><pub-id pub-id-type="doi">10.1126/science.1261093</pub-id><pub-id pub-id-type="pmid">25700513</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luca</surname><given-names>VC</given-names></name><name><surname>Kim</surname><given-names>BC</given-names></name><name><surname>Ge</surname><given-names>C</given-names></name><name><surname>Kakuda</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name><name><surname>Roein-Peikar</surname><given-names>M</given-names></name><name><surname>Haltiwanger</surname><given-names>RS</given-names></name><name><surname>Zhu</surname><given-names>C</given-names></name><name><surname>Ha</surname><given-names>T</given-names></name><name><surname>Garcia</surname><given-names>KC</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Notch-Jagged complex structure implicates a catch bond in tuning ligand sensitivity</article-title><source>Science (New York, N.Y.)</source><volume>355</volume><fpage>1320</fpage><lpage>1324</lpage><pub-id pub-id-type="doi">10.1126/science.aaf9739</pub-id><pub-id pub-id-type="pmid">28254785</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lyles</surname><given-names>KW</given-names></name><name><surname>Colón-Emeric</surname><given-names>CS</given-names></name><name><surname>Magaziner</surname><given-names>JS</given-names></name><name><surname>Adachi</surname><given-names>JD</given-names></name><name><surname>Pieper</surname><given-names>CF</given-names></name><name><surname>Mautalen</surname><given-names>C</given-names></name><name><surname>Hyldstrup</surname><given-names>L</given-names></name><name><surname>Recknor</surname><given-names>C</given-names></name><name><surname>Nordsletten</surname><given-names>L</given-names></name><name><surname>Moore</surname><given-names>KA</given-names></name><name><surname>Lavecchia</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Mesenbrink</surname><given-names>P</given-names></name><name><surname>Hodgson</surname><given-names>PK</given-names></name><name><surname>Abrams</surname><given-names>K</given-names></name><name><surname>Orloff</surname><given-names>JJ</given-names></name><name><surname>Horowitz</surname><given-names>Z</given-names></name><name><surname>Eriksen</surname><given-names>EF</given-names></name><name><surname>Boonen</surname><given-names>S</given-names></name><collab>HORIZON Recurrent Fracture Trial</collab></person-group><year iso-8601-date="2007">2007</year><article-title>Zoledronic acid and clinical fractures and mortality after hip fracture</article-title><source>The New England Journal of Medicine</source><volume>357</volume><fpage>1799</fpage><lpage>1809</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa074941</pub-id><pub-id pub-id-type="pmid">17878149</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>SC</given-names></name><name><surname>Pan</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Bowman</surname><given-names>BM</given-names></name><name><surname>Kopecková</surname><given-names>P</given-names></name><name><surname>Kopecek</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Feasibility of using a bone-targeted, macromolecular delivery system coupled with prostaglandin E(1) to promote bone formation in aged, estrogen-deficient rats</article-title><source>Pharmaceutical Research</source><volume>25</volume><fpage>2889</fpage><lpage>2895</lpage><pub-id pub-id-type="doi">10.1007/s11095-008-9706-0</pub-id><pub-id pub-id-type="pmid">18758923</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mizoguchi</surname><given-names>T</given-names></name><name><surname>Pinho</surname><given-names>S</given-names></name><name><surname>Ahmed</surname><given-names>J</given-names></name><name><surname>Kunisaki</surname><given-names>Y</given-names></name><name><surname>Hanoun</surname><given-names>M</given-names></name><name><surname>Mendelson</surname><given-names>A</given-names></name><name><surname>Ono</surname><given-names>N</given-names></name><name><surname>Kronenberg</surname><given-names>HM</given-names></name><name><surname>Frenette</surname><given-names>PS</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Osterix marks distinct waves of primitive and definitive stromal progenitors during bone marrow development</article-title><source>Developmental Cell</source><volume>29</volume><fpage>340</fpage><lpage>349</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2014.03.013</pub-id><pub-id pub-id-type="pmid">24823377</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neer</surname><given-names>RM</given-names></name><name><surname>Arnaud</surname><given-names>CD</given-names></name><name><surname>Zanchetta</surname><given-names>JR</given-names></name><name><surname>Prince</surname><given-names>R</given-names></name><name><surname>Gaich</surname><given-names>GA</given-names></name><name><surname>Reginster</surname><given-names>JY</given-names></name><name><surname>Hodsman</surname><given-names>AB</given-names></name><name><surname>Eriksen</surname><given-names>EF</given-names></name><name><surname>Ish-Shalom</surname><given-names>S</given-names></name><name><surname>Genant</surname><given-names>HK</given-names></name><name><surname>Wang</surname><given-names>O</given-names></name><name><surname>Mitlak</surname><given-names>BH</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis</article-title><source>The New England Journal of Medicine</source><volume>344</volume><fpage>1434</fpage><lpage>1441</lpage><pub-id pub-id-type="doi">10.1056/NEJM200105103441904</pub-id><pub-id pub-id-type="pmid">11346808</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>NIH Consensus Development</collab></person-group><year iso-8601-date="2001">2001</year><article-title>NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy, March 7-29, 2000: highlights of the conference</article-title><source>Southern Medical Journal</source><volume>94</volume><fpage>569</fpage><lpage>573</lpage><pub-id pub-id-type="doi">10.1097/00007611-200194060-00004</pub-id><pub-id pub-id-type="pmid">11440324</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noguera-Troise</surname><given-names>I</given-names></name><name><surname>Daly</surname><given-names>C</given-names></name><name><surname>Papadopoulos</surname><given-names>NJ</given-names></name><name><surname>Coetzee</surname><given-names>S</given-names></name><name><surname>Boland</surname><given-names>P</given-names></name><name><surname>Gale</surname><given-names>NW</given-names></name><name><surname>Lin</surname><given-names>HC</given-names></name><name><surname>Yancopoulos</surname><given-names>GD</given-names></name><name><surname>Thurston</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis</article-title><source>Nature</source><volume>444</volume><fpage>1032</fpage><lpage>1037</lpage><pub-id pub-id-type="doi">10.1038/nature05355</pub-id><pub-id pub-id-type="pmid">17183313</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nombela-Arrieta</surname><given-names>C</given-names></name><name><surname>Ritz</surname><given-names>J</given-names></name><name><surname>Silberstein</surname><given-names>LE</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The elusive nature and function of mesenchymal stem cells</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>12</volume><fpage>126</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1038/nrm3049</pub-id><pub-id pub-id-type="pmid">21253000</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Novince</surname><given-names>CM</given-names></name><name><surname>Michalski</surname><given-names>MN</given-names></name><name><surname>Koh</surname><given-names>AJ</given-names></name><name><surname>Sinder</surname><given-names>BP</given-names></name><name><surname>Entezami</surname><given-names>P</given-names></name><name><surname>Eber</surname><given-names>MR</given-names></name><name><surname>Pettway</surname><given-names>GJ</given-names></name><name><surname>Rosol</surname><given-names>TJ</given-names></name><name><surname>Wronski</surname><given-names>TJ</given-names></name><name><surname>Kozloff</surname><given-names>KM</given-names></name><name><surname>McCauley</surname><given-names>LK</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Proteoglycan 4: a dynamic regulator of skeletogenesis and parathyroid hormone skeletal anabolism</article-title><source>Journal of Bone and Mineral Research</source><volume>27</volume><fpage>11</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1002/jbmr.508</pub-id><pub-id pub-id-type="pmid">21932346</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ono</surname><given-names>N</given-names></name><name><surname>Ono</surname><given-names>W</given-names></name><name><surname>Nagasawa</surname><given-names>T</given-names></name><name><surname>Kronenberg</surname><given-names>HM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>A subset of chondrogenic cells provides early mesenchymal progenitors in growing bones</article-title><source>Nature Cell Biology</source><volume>16</volume><fpage>1157</fpage><lpage>1167</lpage><pub-id pub-id-type="doi">10.1038/ncb3067</pub-id><pub-id pub-id-type="pmid">25419849</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ortinau</surname><given-names>LC</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Lei</surname><given-names>K</given-names></name><name><surname>Deveza</surname><given-names>L</given-names></name><name><surname>Jeong</surname><given-names>Y</given-names></name><name><surname>Hara</surname><given-names>Y</given-names></name><name><surname>Grafe</surname><given-names>I</given-names></name><name><surname>Rosenfeld</surname><given-names>SB</given-names></name><name><surname>Lee</surname><given-names>D</given-names></name><name><surname>Lee</surname><given-names>B</given-names></name><name><surname>Scadden</surname><given-names>DT</given-names></name><name><surname>Park</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Identification of Functionally Distinct Mx1+αSMA+ Periosteal Skeletal Stem Cells</article-title><source>Cell Stem Cell</source><volume>25</volume><fpage>784</fpage><lpage>796</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2019.11.003</pub-id><pub-id pub-id-type="pmid">31809737</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osathanon</surname><given-names>T</given-names></name><name><surname>Ritprajak</surname><given-names>P</given-names></name><name><surname>Nowwarote</surname><given-names>N</given-names></name><name><surname>Manokawinchoke</surname><given-names>J</given-names></name><name><surname>Giachelli</surname><given-names>C</given-names></name><name><surname>Pavasant</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Surface-bound orientated Jagged-1 enhances osteogenic differentiation of human periodontal ligament-derived mesenchymal stem cells</article-title><source>Journal of Biomedical Materials Research. Part A</source><volume>101</volume><fpage>358</fpage><lpage>367</lpage><pub-id pub-id-type="doi">10.1002/jbm.a.34332</pub-id><pub-id pub-id-type="pmid">22847978</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinho</surname><given-names>S</given-names></name><name><surname>Frenette</surname><given-names>PS</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Haematopoietic stem cell activity and interactions with the niche</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>20</volume><fpage>303</fpage><lpage>320</lpage><pub-id pub-id-type="doi">10.1038/s41580-019-0103-9</pub-id><pub-id pub-id-type="pmid">30745579</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polacheck</surname><given-names>WJ</given-names></name><name><surname>Kutys</surname><given-names>ML</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Eyckmans</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Vasavada</surname><given-names>H</given-names></name><name><surname>Hirschi</surname><given-names>KK</given-names></name><name><surname>Chen</surname><given-names>CS</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A non-canonical Notch complex regulates adherens junctions and vascular barrier function</article-title><source>Nature</source><volume>552</volume><fpage>258</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1038/nature24998</pub-id><pub-id pub-id-type="pmid">29160307</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Porter</surname><given-names>A</given-names></name><name><surname>Irwin</surname><given-names>R</given-names></name><name><surname>Miller</surname><given-names>J</given-names></name><name><surname>Horan</surname><given-names>DJ</given-names></name><name><surname>Robling</surname><given-names>AG</given-names></name><name><surname>McCabe</surname><given-names>LR</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Quick and inexpensive paraffin-embedding method for dynamic bone formation analyses</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>42505</elocation-id><pub-id pub-id-type="doi">10.1038/srep42505</pub-id><pub-id pub-id-type="pmid">28198415</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Radtke</surname><given-names>F</given-names></name><name><surname>Wilson</surname><given-names>A</given-names></name><name><surname>Stark</surname><given-names>G</given-names></name><name><surname>Bauer</surname><given-names>M</given-names></name><name><surname>van Meerwijk</surname><given-names>J</given-names></name><name><surname>MacDonald</surname><given-names>HR</given-names></name><name><surname>Aguet</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Deficient T cell fate specification in mice with an induced inactivation of Notch1</article-title><source>Immunity</source><volume>10</volume><fpage>547</fpage><lpage>558</lpage><pub-id pub-id-type="doi">10.1016/s1074-7613(00)80054-0</pub-id><pub-id pub-id-type="pmid">10367900</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramasamy</surname><given-names>SK</given-names></name><name><surname>Kusumbe</surname><given-names>AP</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Adams</surname><given-names>RH</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Endothelial Notch activity promotes angiogenesis and osteogenesis in bone</article-title><source>Nature</source><volume>507</volume><fpage>376</fpage><lpage>380</lpage><pub-id pub-id-type="doi">10.1038/nature13146</pub-id><pub-id pub-id-type="pmid">24647000</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramasamy</surname><given-names>SK</given-names></name><name><surname>Kusumbe</surname><given-names>AP</given-names></name><name><surname>Schiller</surname><given-names>M</given-names></name><name><surname>Zeuschner</surname><given-names>D</given-names></name><name><surname>Bixel</surname><given-names>MG</given-names></name><name><surname>Milia</surname><given-names>C</given-names></name><name><surname>Gamrekelashvili</surname><given-names>J</given-names></name><name><surname>Limbourg</surname><given-names>A</given-names></name><name><surname>Medvinsky</surname><given-names>A</given-names></name><name><surname>Santoro</surname><given-names>MM</given-names></name><name><surname>Limbourg</surname><given-names>FP</given-names></name><name><surname>Adams</surname><given-names>RH</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Blood flow controls bone vascular function and osteogenesis</article-title><source>Nature Communications</source><volume>7</volume><elocation-id>13601</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms13601</pub-id><pub-id pub-id-type="pmid">27922003</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ross</surname><given-names>RD</given-names></name><name><surname>Edwards</surname><given-names>LH</given-names></name><name><surname>Acerbo</surname><given-names>AS</given-names></name><name><surname>Ominsky</surname><given-names>MS</given-names></name><name><surname>Virdi</surname><given-names>AS</given-names></name><name><surname>Sena</surname><given-names>K</given-names></name><name><surname>Miller</surname><given-names>LM</given-names></name><name><surname>Sumner</surname><given-names>DR</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Bone matrix quality after sclerostin antibody treatment</article-title><source>Journal of Bone and Mineral Research</source><volume>29</volume><fpage>1597</fpage><lpage>1607</lpage><pub-id pub-id-type="doi">10.1002/jbmr.2188</pub-id><pub-id pub-id-type="pmid">24470143</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossouw</surname><given-names>JE</given-names></name><name><surname>Anderson</surname><given-names>GL</given-names></name><name><surname>Prentice</surname><given-names>RL</given-names></name><name><surname>LaCroix</surname><given-names>AZ</given-names></name><name><surname>Kooperberg</surname><given-names>C</given-names></name><name><surname>Stefanick</surname><given-names>ML</given-names></name><name><surname>Jackson</surname><given-names>RD</given-names></name><name><surname>Beresford</surname><given-names>SAA</given-names></name><name><surname>Howard</surname><given-names>BV</given-names></name><name><surname>Johnson</surname><given-names>KC</given-names></name><name><surname>Kotchen</surname><given-names>JM</given-names></name><name><surname>Ockene</surname><given-names>J</given-names></name><collab>Writing Group for the Women’s Health Initiative Investigators</collab></person-group><year iso-8601-date="2002">2002</year><article-title>Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial</article-title><source>JAMA</source><volume>288</volume><fpage>321</fpage><lpage>333</lpage><pub-id pub-id-type="doi">10.1001/jama.288.3.321</pub-id><pub-id pub-id-type="pmid">12117397</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saag</surname><given-names>KG</given-names></name><name><surname>Emkey</surname><given-names>R</given-names></name><name><surname>Schnitzer</surname><given-names>TJ</given-names></name><name><surname>Brown</surname><given-names>JP</given-names></name><name><surname>Hawkins</surname><given-names>F</given-names></name><name><surname>Goemaere</surname><given-names>S</given-names></name><name><surname>Thamsborg</surname><given-names>G</given-names></name><name><surname>Liberman</surname><given-names>UA</given-names></name><name><surname>Delmas</surname><given-names>PD</given-names></name><name><surname>Malice</surname><given-names>M-P</given-names></name><name><surname>Czachur</surname><given-names>M</given-names></name><name><surname>Daifotis</surname><given-names>AG</given-names></name><name><surname>Lane</surname><given-names>N</given-names></name><name><surname>Correa-Rotter</surname><given-names>R</given-names></name><name><surname>Yanover</surname><given-names>M</given-names></name><name><surname>Westhovens</surname><given-names>R</given-names></name><name><surname>Epstein</surname><given-names>S</given-names></name><name><surname>Adachi</surname><given-names>JD</given-names></name><name><surname>Poubelle</surname><given-names>P</given-names></name><name><surname>Melo-Gomes</surname><given-names>J</given-names></name><name><surname>Rodriguez-Portales</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis</article-title><source>New England Journal of Medicine</source><volume>339</volume><fpage>292</fpage><lpage>299</lpage><pub-id pub-id-type="doi">10.1056/NEJM199807303390502</pub-id><pub-id pub-id-type="pmid">9682041</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schindelin</surname><given-names>J</given-names></name><name><surname>Arganda-Carreras</surname><given-names>I</given-names></name><name><surname>Frise</surname><given-names>E</given-names></name><name><surname>Kaynig</surname><given-names>V</given-names></name><name><surname>Longair</surname><given-names>M</given-names></name><name><surname>Pietzsch</surname><given-names>T</given-names></name><name><surname>Preibisch</surname><given-names>S</given-names></name><name><surname>Rueden</surname><given-names>C</given-names></name><name><surname>Saalfeld</surname><given-names>S</given-names></name><name><surname>Schmid</surname><given-names>B</given-names></name><name><surname>Tinevez</surname><given-names>JY</given-names></name><name><surname>White</surname><given-names>DJ</given-names></name><name><surname>Hartenstein</surname><given-names>V</given-names></name><name><surname>Eliceiri</surname><given-names>K</given-names></name><name><surname>Tomancak</surname><given-names>P</given-names></name><name><surname>Cardona</surname><given-names>A</given-names></name><name><surname>Tinevez</surname><given-names>JY</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Fiji: an open-source platform for biological-image analysis</article-title><source>Nature Methods</source><volume>9</volume><fpage>676</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1038/nmeth.2019</pub-id><pub-id pub-id-type="pmid">22743772</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sekido</surname><given-names>T</given-names></name><name><surname>Sakura</surname><given-names>N</given-names></name><name><surname>Higashi</surname><given-names>Y</given-names></name><name><surname>Miya</surname><given-names>K</given-names></name><name><surname>Nitta</surname><given-names>Y</given-names></name><name><surname>Nomura</surname><given-names>M</given-names></name><name><surname>Sawanishi</surname><given-names>H</given-names></name><name><surname>Morito</surname><given-names>K</given-names></name><name><surname>Masamune</surname><given-names>Y</given-names></name><name><surname>Kasugai</surname><given-names>S</given-names></name><name><surname>Yokogawa</surname><given-names>K</given-names></name><name><surname>Miyamoto</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Novel drug delivery system to bone using acidic oligopeptide: pharmacokinetic characteristics and pharmacological potential</article-title><source>Journal of Drug Targeting</source><volume>9</volume><fpage>111</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.3109/10611860108997922</pub-id><pub-id pub-id-type="pmid">11697106</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sivaraj</surname><given-names>KK</given-names></name><name><surname>Jeong</surname><given-names>HW</given-names></name><name><surname>Dharmalingam</surname><given-names>B</given-names></name><name><surname>Zeuschner</surname><given-names>D</given-names></name><name><surname>Adams</surname><given-names>S</given-names></name><name><surname>Potente</surname><given-names>M</given-names></name><name><surname>Adams</surname><given-names>RH</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Regional specialization and fate specification of bone stromal cells in skeletal development</article-title><source>Cell Reports</source><volume>36</volume><elocation-id>109352</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2021.109352</pub-id><pub-id pub-id-type="pmid">34260921</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stapleton</surname><given-names>M</given-names></name><name><surname>Sawamoto</surname><given-names>K</given-names></name><name><surname>Alméciga-Díaz</surname><given-names>CJ</given-names></name><name><surname>Mackenzie</surname><given-names>WG</given-names></name><name><surname>Mason</surname><given-names>RW</given-names></name><name><surname>Orii</surname><given-names>T</given-names></name><name><surname>Tomatsu</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Development of Bone Targeting Drugs</article-title><source>International Journal of Molecular Sciences</source><volume>18</volume><elocation-id>E1345</elocation-id><pub-id pub-id-type="doi">10.3390/ijms18071345</pub-id><pub-id pub-id-type="pmid">28644392</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uccelli</surname><given-names>A</given-names></name><name><surname>Moretta</surname><given-names>L</given-names></name><name><surname>Pistoia</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Mesenchymal stem cells in health and disease</article-title><source>Nature Reviews. Immunology</source><volume>8</volume><fpage>726</fpage><lpage>736</lpage><pub-id pub-id-type="doi">10.1038/nri2395</pub-id><pub-id pub-id-type="pmid">19172693</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Es</surname><given-names>JH</given-names></name><name><surname>van Gijn</surname><given-names>ME</given-names></name><name><surname>Riccio</surname><given-names>O</given-names></name><name><surname>van den Born</surname><given-names>M</given-names></name><name><surname>Vooijs</surname><given-names>M</given-names></name><name><surname>Begthel</surname><given-names>H</given-names></name><name><surname>Cozijnsen</surname><given-names>M</given-names></name><name><surname>Robine</surname><given-names>S</given-names></name><name><surname>Winton</surname><given-names>DJ</given-names></name><name><surname>Radtke</surname><given-names>F</given-names></name><name><surname>Clevers</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells</article-title><source>Nature</source><volume>435</volume><fpage>959</fpage><lpage>963</lpage><pub-id pub-id-type="doi">10.1038/nature03659</pub-id><pub-id pub-id-type="pmid">15959515</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walsh</surname><given-names>MC</given-names></name><name><surname>Kim</surname><given-names>N</given-names></name><name><surname>Kadono</surname><given-names>Y</given-names></name><name><surname>Rho</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>SY</given-names></name><name><surname>Lorenzo</surname><given-names>J</given-names></name><name><surname>Choi</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Osteoimmunology: interplay between the immune system and bone metabolism</article-title><source>Annual Review of Immunology</source><volume>24</volume><fpage>33</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1146/annurev.immunol.24.021605.090646</pub-id><pub-id pub-id-type="pmid">16551243</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>SS</given-names></name><name><surname>Wong</surname><given-names>A</given-names></name><name><surname>Toupadakis</surname><given-names>CA</given-names></name><name><surname>Yellowley</surname><given-names>CE</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Expression of angiopoietin-like protein 4 at the fracture site: Regulation by hypoxia and osteoblastic differentiation</article-title><source>Journal of Orthopaedic Research</source><volume>33</volume><fpage>1364</fpage><lpage>1373</lpage><pub-id pub-id-type="doi">10.1002/jor.22898</pub-id><pub-id pub-id-type="pmid">25864912</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Cain-Hom</surname><given-names>C</given-names></name><name><surname>Choy</surname><given-names>L</given-names></name><name><surname>Hagenbeek</surname><given-names>TJ</given-names></name><name><surname>de Leon</surname><given-names>GP</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Finkle</surname><given-names>D</given-names></name><name><surname>Venook</surname><given-names>R</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Ridgway</surname><given-names>J</given-names></name><name><surname>Schahin-Reed</surname><given-names>D</given-names></name><name><surname>Dow</surname><given-names>GJ</given-names></name><name><surname>Shelton</surname><given-names>A</given-names></name><name><surname>Stawicki</surname><given-names>S</given-names></name><name><surname>Watts</surname><given-names>RJ</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Choy</surname><given-names>R</given-names></name><name><surname>Howard</surname><given-names>P</given-names></name><name><surname>Kadyk</surname><given-names>L</given-names></name><name><surname>Yan</surname><given-names>M</given-names></name><name><surname>Zha</surname><given-names>J</given-names></name><name><surname>Callahan</surname><given-names>CA</given-names></name><name><surname>Hymowitz</surname><given-names>SG</given-names></name><name><surname>Siebel</surname><given-names>CW</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Therapeutic antibody targeting of individual Notch receptors</article-title><source>Nature</source><volume>464</volume><fpage>1052</fpage><lpage>1057</lpage><pub-id pub-id-type="doi">10.1038/nature08878</pub-id><pub-id pub-id-type="pmid">20393564</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yagami</surname><given-names>K</given-names></name><name><surname>Suh</surname><given-names>JY</given-names></name><name><surname>Enomoto-Iwamoto</surname><given-names>M</given-names></name><name><surname>Koyama</surname><given-names>E</given-names></name><name><surname>Abrams</surname><given-names>WR</given-names></name><name><surname>Shapiro</surname><given-names>IM</given-names></name><name><surname>Pacifici</surname><given-names>M</given-names></name><name><surname>Iwamoto</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Matrix GLA protein is a developmental regulator of chondrocyte mineralization and, when constitutively expressed, blocks endochondral and intramembranous ossification in the limb</article-title><source>The Journal of Cell Biology</source><volume>147</volume><fpage>1097</fpage><lpage>1108</lpage><pub-id pub-id-type="doi">10.1083/jcb.147.5.1097</pub-id><pub-id pub-id-type="pmid">10579728</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>M</given-names></name><name><surname>Callahan</surname><given-names>CA</given-names></name><name><surname>Beyer</surname><given-names>JC</given-names></name><name><surname>Allamneni</surname><given-names>KP</given-names></name><name><surname>Zhang</surname><given-names>G</given-names></name><name><surname>Ridgway</surname><given-names>JB</given-names></name><name><surname>Niessen</surname><given-names>K</given-names></name><name><surname>Plowman</surname><given-names>GD</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Chronic DLL4 blockade induces vascular neoplasms</article-title><source>Nature</source><volume>463</volume><fpage>E6</fpage><lpage>E7</lpage><pub-id pub-id-type="doi">10.1038/nature08751</pub-id><pub-id pub-id-type="pmid">20147986</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yokogawa</surname><given-names>K</given-names></name><name><surname>Miya</surname><given-names>K</given-names></name><name><surname>Sekido</surname><given-names>T</given-names></name><name><surname>Higashi</surname><given-names>Y</given-names></name><name><surname>Nomura</surname><given-names>M</given-names></name><name><surname>Fujisawa</surname><given-names>R</given-names></name><name><surname>Morito</surname><given-names>K</given-names></name><name><surname>Masamune</surname><given-names>Y</given-names></name><name><surname>Waki</surname><given-names>Y</given-names></name><name><surname>Kasugai</surname><given-names>S</given-names></name><name><surname>Miyamoto</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Selective delivery of estradiol to bone by aspartic acid oligopeptide and its effects on ovariectomized mice</article-title><source>Endocrinology</source><volume>142</volume><fpage>1228</fpage><lpage>1233</lpage><pub-id pub-id-type="doi">10.1210/endo.142.3.8024</pub-id><pub-id pub-id-type="pmid">11181539</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Youngstrom</surname><given-names>DW</given-names></name><name><surname>Dishowitz</surname><given-names>MI</given-names></name><name><surname>Bales</surname><given-names>CB</given-names></name><name><surname>Carr</surname><given-names>E</given-names></name><name><surname>Mutyaba</surname><given-names>PL</given-names></name><name><surname>Kozloff</surname><given-names>KM</given-names></name><name><surname>Shitaye</surname><given-names>H</given-names></name><name><surname>Hankenson</surname><given-names>KD</given-names></name><name><surname>Loomes</surname><given-names>KM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Jagged1 expression by osteoblast-lineage cells regulates trabecular bone mass and periosteal expansion in mice</article-title><source>Bone</source><volume>91</volume><fpage>64</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1016/j.bone.2016.07.006</pub-id><pub-id pub-id-type="pmid">27416809</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Canalis</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Notch and the regulation of osteoclast differentiation and function</article-title><source>Bone</source><volume>138</volume><elocation-id>115474</elocation-id><pub-id pub-id-type="doi">10.1016/j.bone.2020.115474</pub-id><pub-id pub-id-type="pmid">32526405</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zanotti</surname><given-names>S</given-names></name><name><surname>Canalis</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Notch Signaling and the Skeleton</article-title><source>Endocrine Reviews</source><volume>37</volume><fpage>223</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.1210/er.2016-1002</pub-id><pub-id pub-id-type="pmid">27074349</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>G</given-names></name><name><surname>Guo</surname><given-names>B</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Tang</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>B-T</given-names></name><name><surname>Zheng</surname><given-names>L</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Pan</surname><given-names>X</given-names></name><name><surname>Chow</surname><given-names>H</given-names></name><name><surname>To</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Lee</surname><given-names>K</given-names></name><name><surname>Hou</surname><given-names>Z</given-names></name><name><surname>Dong</surname><given-names>N</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Leung</surname><given-names>K</given-names></name><name><surname>Hung</surname><given-names>L</given-names></name><name><surname>He</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Qin</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>A delivery system targeting bone formation surfaces to facilitate RNAi-based anabolic therapy</article-title><source>Nature Medicine</source><volume>18</volume><fpage>307</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.1038/nm.2617</pub-id><pub-id pub-id-type="pmid">22286306</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>BO</given-names></name><name><surname>Yue</surname><given-names>R</given-names></name><name><surname>Murphy</surname><given-names>MM</given-names></name><name><surname>Peyer</surname><given-names>JG</given-names></name><name><surname>Morrison</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Leptin-receptor-expressing mesenchymal stromal cells represent the main source of bone formed by adult bone marrow</article-title><source>Cell Stem Cell</source><volume>15</volume><fpage>154</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2014.06.008</pub-id><pub-id pub-id-type="pmid">24953181</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.60183.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ackert-Bicknell</surname><given-names>Cheryl</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03wmf1y16</institution-id><institution>University of Colorado</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><p>Osteoporosis most often treated by reducing bone resorption as there are limited choices of medication that are anabolic for bone. Previous studies have suggested that the Notch signaling pathway could be targeted to enhance osteogenesis. The authors have intriguingly generated a soluble bone targeted fusion protein comprised of a modified version of the extra-cellular domain of the Delta-like 4 Notch ligand and poly-aspartate peptide motif with binding affinity for hydroxyapatite in the bone matrix. This approach has high potential as a future therapeutic for osteoporosis.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.60183.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Ackert-Bicknell</surname><given-names>Cheryl</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03wmf1y16</institution-id><institution>University of Colorado</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="box1"><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Induction of osteogenesis by bone-targeted Notch activation&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Clifford Rosen as the Senior Editor. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>Summary:</p><p>Osteoporosis most often treated by reducing bone resorption as there are limited choices of medication that are anabolic for bone. Previous studies have suggested that the Notch signaling pathway could be targeted to enhance osteogenesis. In this study, the author have generated a soluble bone targeted fusion protein comprised of a modified version of the extra-cellular domain of the Delta-like 4 Notch ligand and poly-aspartate peptide motif with bind affinity for hydroxyapatite. Using a combination of single sequencing and histology, the authors show that this fusion protein can induce bone formation in mice and limited mechanistic information was learned. That said, this approach has high potential as a future therapeutic for osteoporosis. While the approach was considered novel, all reviewers agreed that this paper required additional data to demonstrate the true therapeutic potential of this fusion protein as a bone anabolic. In several instances requests for clarification were made. These comments are summarized below.</p><p>Essential Revisions:</p><p>1. All reviewers requested a relevant therapeutic model be employed to demonstrate that this fusion protein would work in the face of low bone mass. While several models (tail suspension, aging, etc) were proposed, it was agreed upon that an ovariectomy model might be the easiest and most relevant model in which to demonstrate effectiveness after bone loss. This was considered to be an essential experiment by all three reviewers. Even if this fusion protein fails to rescue bone after ovariectomy, this would be very import knowledge for the field and would increase our understanding about Notch signaling in bone.</p><p>2. Please show immunoreactivity of the liver expressed constructs in other organs than bone. This should include at minimum, the liver and spleen.</p><p>3. The dextran texas red showed that there is no barrier leakage in bone. This should also be shown in other highly vascularized organs.</p><p>4. The authors show immunoreactivity in the bone marrow of the Jag1-Asp8 in Figure 5A, but less for the Dll4-Asp8 construct. This point needs clarification and or additional explanation.</p><p>5. Since there is significant targeting of the cortical bone one would expect an effect in osteocytes. Surprisingly there was limited evidence of Notch activation in RNASeq studies. Could the lack of osteocyte signatures could be due to the method used for cell preparation? This requires clarification in methods, limitations and in the manuscript discussion.</p><p>6. In Figure 5, the authors claim that JAG1 activating ligand has no impact on bone mass; however, they do not show whether Notch is truly activated by this larger size ligand in vitro or in vivo. This was performed for DLL4 and could be similarly done for JAG1, as it may shed light on whether insufficient Notch signaling is observed within bone associated cells.</p><p>7. Due to the fact that the authors only assess phenotypes 3 weeks post-injection, it is difficult to separate direct vs. indirect effects or cell autonomous vs. non-autonomous effects of the cell specific Notch activation. One assessment that would help elucidate this would be to determine the overlap (Figure 7) of Hey1 and Sp7 double positive cells to determine whether active Notch signaling is promoting osteoblastic differentiation. Alternatively, the majority of Sp7+ cells may be Hey1 negative and therefore lead to the conclusion that Notch signaling must be down-regulated in order to achieve osteoblast differentiation, and may in fact be maintaining and expanding MSC populations that later go on to form osteoblasts. Alternatively or additionally, a more immediate time point could be assessed from Hey1-GFP mice injected with DLL4. GFP+ and GFP- MSCs could be FACS isolated and compared via qPCR for osteogenic and MSC markers. This may also give a better indication of how DLL4-mediated Notch activation is affecting MSCs in a cell autonomous manner.</p><p>8. The authors describe the effects of a modified Dll4-Asp8x fusion protein targeted to bone and demonstrate an increase in bone volume/total volume (BV/TV) due to an increase in trabecular thickness and bone formation. This is somewhat unexpected because 1. Asp8 usually targets bone resorbing surfaces whereas AspSerSerx6 targets bone forming surfaces (Zhang Nat Med 18;307,2012), 2. Activation of Notch signaling has been shown to inhibit osteogenesis and 3. Notch signaling affects osteoclastogenesis, albeit this is dependent on the Notch receptor activated and Dll4 would activate all Notch receptors. These points need clarification in this manuscript.</p><p>9. The authors do not report whether the animals studied were littermate and sex matched, This is a critical point as the bone microarchitecture of male and female mice is substantially different.</p><p>10. The data presented for the bone histomorphometry and uCT are incomplete. The authors show an effect on bone formation but do not provide data on osteoblast surface or number. Similarly, there is no effect on osteoclast number, but eroded surface is not shown. There is significant presence of Dll4 in cortical bone but uCT data on cortical bone are not provided. These data are essential for transparent interpretation of this study results.</p><p>11. Increased expression of markers of osteoblast differentiation and function is somewhat limited to Osx. Data on osteocalcin and proteoglycan were not quantified and immunohistochemistry does not reveal a pronounced effect. Please clarify.</p><p>12. For the RNA Seq data, it is surprising that bone marrow stromal (BMS) cells are affected whereas osteoblasts are not since BMS differentiate into osteoblasts and alterations in BMS cells would not explain an increase in mineral apposition rate unless they differentiate into osteoblasts. The markers of osteogenesis affected are not the classically defined osteogenic factors (IGF2, BP3, Prg4) and one needs to be cautious with the interpretation of these results and with the attribution of the effect to BMS cells.</p><p>13. The authors suggest possible therapeutic value of Dll4 fusion proteins but what was administered to the animals of this study was a construct expressing the protein in vivo. A more practical and convincing approach would be the injection of the protein itself. This should at minimum be discussed as a future-directions.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.60183.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1. All reviewers requested a relevant therapeutic model be employed to demonstrate that this fusion protein would work in the face of low bone mass. While several models (tail suspension, aging, etc) were proposed, it was agreed upon that an ovariectomy model might be the easiest and most relevant model in which to demonstrate effectiveness after bone loss. This was considered to be an essential experiment by all three reviewers. Even if this fusion protein fails to rescue bone after ovariectomy, this would be very import knowledge for the field and would increase our understanding about Notch signaling in bone.</p></disp-quote><p>As suggested by the reviewers, we have now included in revised Figure 6 a detailed characterization of sham operated versus ovariectomized (OVX) female mice, injected with PBS or <italic>pLIVE-Dll4<sub>(E12)</sub></italic> plasmid. We have performed micro-CT (revised Figure 6A and B) and provide quantitation of multiple parameters such as BV/TV, connectivity density, trabecular thickness, cortical consistency, trabecular separation, bone surface, trabecular number, and cortical thickness in revised Figure 6C and D.</p><p>Although the ovariectomy was successful and resulted in bone loss (revised Figure 6 A-D, G), <italic>pLIVE-Dll4<sub>(E12)</sub></italic> injection did not increase bone deposition in OVX females, as indicated by the micro-CT and histomorphometry analysis (revised Figure 6 A-D) as well as Col1a1 and PDGFRβ immunostaining (revised Figure 6E and F). Furthermore, we found that Dll4<sub>(E12)</sub> has no significant effect on bone formation in sham operated females (revised Figure 6A-D). Considering that our previous experiments with male mice resulted in significantly increased bone formation (revised Figure 1), the absence of beneficial effects in female animals is most likely caused by lower bone surface and therefore decreased Dll4<sub>(E12)</sub> binding relative to males (revised Figure 6G and Figure 6 suppl. 1). This could have been a somewhat disappointing result, but, fortunately, we found in further experiments that Dll4<sub>(E12)</sub> can have beneficial effects even in female mice. PTH administration to osteoporotic patients is used to increase bone formation (Augustine and Horwitz, Current Osteoporosis Report 2013, PMID: 24078470) and similar effects are seen in rodents (Li et al., Bone 1999, PMID: 9951776; Wein et al., CSH Perspective in Medicine 2018, PMID: 29358318). Therefore, we decided to combine Dll4<sub>(E12)</sub> and PTH administration to female mice and compare the results to single treatment groups and untreated controls, which revealed striking additive and, for some parameters, synergistic effects of Dll4<sub>(E12)</sub> and PTH on bone formation. These exciting new results are presented in revised Figure 7 (micro-CT data), revised Figure 7 suppl. 1 (Dll4 immunoreactivity, and Col1a, PDGFRβ and Emcn immunostaining), and in revised Figure 7 suppl. 2 (Osx and Opn immunostaining).</p><disp-quote content-type="editor-comment"><p>2. Please show immunoreactivity of the liver expressed constructs in other organs than bone. This should include at minimum, the liver and spleen.</p></disp-quote><p>Thank you for this suggestion. In revised Figure 1 suppl. 5, we now present Dll4 immunostaining for liver, spleen and lung, which indicates that there is no accumulation of Dll4<sub>(E12)</sub> in these organs. This confirms our overall experimental strategy and explains why effects of Dll4<sub>(E12)</sub> are confined to the skeletal system.</p><disp-quote content-type="editor-comment"><p>3. The dextran texas red showed that there is no barrier leakage in bone. This should also be shown in other highly vascularized organs.</p></disp-quote><p>We followed the reviewers’ suggestion and provide in revised Figure 2—figure supplement 2 A-C images and quantitation of Dextran Texas Red signal per tissue area in liver, spleen and lung of control versus Dll4<sub>(E12)</sub>-injected mice. These results show that there is no significant difference in Dextran leakage relative to control in all organs investigated.</p><disp-quote content-type="editor-comment"><p>4. The authors show immunoreactivity in the bone marrow of the Jag1-Asp8 in Figure 5A, but less for the Dll4-Asp8 construct. This point needs clarification and or additional explanation.</p></disp-quote><p>Thank you very much for this question. First of all, we need to emphasize that a direct comparison of these immunostainings is difficult because two different antibodies (anti-Dll4 and anti-Jag1, respectively) have been used. As they are binding different epitopes, these reagents are likely to have different properties with implications for staining intensity, specificity and background.</p><p>If one assumes that stainings predominantly reflect the distribution pattern of the Asp<sub>8x</sub>-coupled Notch ligands, Dll4-Asp<sub>8x</sub> (Figure 1—figure supplement 3A), Dll4<sub>(E12)</sub> (Figure 1B), and, to some extent, also Jag1<sub>(JV1)</sub> (Figure 5—figure supplement 2A) indeed appear to be more strongly confined to bone surface than Jag1-Asp<sub>8x</sub> (Figure 5—figure supplement 2A). These differences might reflect distinct modes of binding to different Notch receptors, which are known to be different for Jagged1 relative to Dll4 and also depend on receptor glycosylation (e.g. Luca et al., Science 2017, PMID: 28254785). However, it has to be noted that Jag1-Asp<sub>8x</sub> staining can be also seen at the surface of bone, indicating that the protein is present at the right place but does not show the same biological activity as Dll4<sub>(E12)</sub>. We can only speculate about the underlying reasons, but, presumably, only Dll4<sub>(E12)</sub> achieves the threshold of Notch activation leading to an increase in bone.</p><p>We now mention this aspect in the Discussion but have avoided overly speculative statements. We also clarify that our findings do not address the function of endogenous Jagged1, which has been previously linked to the regulation of osteogenic differentiation.</p><disp-quote content-type="editor-comment"><p>5. Since there is significant targeting of the cortical bone one would expect an effect in osteocytes. Surprisingly there was limited evidence of Notch activation in RNASeq studies. Could the lack of osteocyte signatures could be due to the method used for cell preparation? This requires clarification in methods, limitations and in the manuscript discussion.</p></disp-quote><p>As the reviewer points out correctly, there is indeed a lack of osteocytes in our scRNA-seq data, likely due to the fact that our collagenase-based digestion method could not release these cells from their lacunae in bone. This point is now mentioned in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>6. In Figure 5, the authors claim that JAG1 activating ligand has no impact on bone mass; however, they do not show whether Notch is truly activated by this larger size ligand in vitro or in vivo. This was performed for DLL4 and could be similarly done for JAG1, as it may shed light on whether insufficient Notch signaling is observed within bone associated cells.</p></disp-quote><p>As suggested by the reviewers, we present in revised Figure 5—figure supplement 2 new in vitro data showing the purification of Jag1-Asp<sub>8x</sub> and Jag1<sub>(JV1)</sub> proteins as well as the immunoblot detection of those protein by anti-Jag1 antibody. Both immobilized or in solution, Jag1-Asp<sub>8x</sub> and Jag1<sub>(JV1)</sub> proteins are able to affect Notch target gene expression in cultured cells (revised Figure 5—figure supplement 1D, E). The changes in transcript expression triggered by the two recombinant Jag1 proteins follow a similar trend but, as expected, the Jag1<sub>(JV1)</sub> variant is more potent in these assays.</p><disp-quote content-type="editor-comment"><p>7. Due to the fact that the authors only assess phenotypes 3 weeks post-injection, it is difficult to separate direct vs. indirect effects or cell autonomous vs. non-autonomous effects of the cell specific Notch activation. One assessment that would help elucidate this would be to determine the overlap (Figure 7) of Hey1 and Sp7 double positive cells to determine whether active Notch signaling is promoting osteoblastic differentiation. Alternatively, the majority of Sp7+ cells may be Hey1 negative and therefore lead to the conclusion that Notch signaling must be down-regulated in order to achieve osteoblast differentiation, and may in fact be maintaining and expanding MSC populations that later go on to form osteoblasts. Alternatively or additionally, a more immediate time point could be assessed from Hey1-GFP mice injected with DLL4. GFP+ and GFP- MSCs could be FACS isolated and compared via qPCR for osteogenic and MSC markers. This may also give a better indication of how DLL4-mediated Notch activation is affecting MSCs in a cell autonomous manner.</p></disp-quote><p>We are grateful for these comments and agree that it is important to understand how Dll4<sub>(E12)</sub> promotes osteogenesis. Various lines of evidence indicate that the treatment primarily affects immature (OSX-negative) mesenchymal stromal progenitor cells:</p><p>1) Dll4<sub>(E12)</sub> leads to increased expression of <italic>Hey1-GFP</italic> signal in vessel-associated in the metaphysis and adjacent transition zone to the diaphysis. These cells show only weak or no nuclear expression of Osterix (Figure 3—figure supplement 1).</p><p>2) Our scRNA-seq data shows profound Dll4<sub>(E12)</sub>-induced gene expression changes in diaphyseal mesenchymal stromal cells (dpMSCs) but not in osteoblasts. This argues that, while we see an increase in OSX+ cells, gene expression in this population is not substantially altered by Dll4<sub>(E12)</sub> (revised Figure 8F-G and Figure 8—figure supplement 3D, E).</p><p>3) Previous work by us and others has shown that vessel-associated mesenchymal stromal cells in the diaphysis can give rise to bone-forming cells (Zhou et al., Cell Stem Cell 2014, PMID: 24953181; Mizoguchi et al., Dev Cell 2014, PMID: 24823377; Sivaraj et al., Cell Rep 2021, PMID: 34260921).</p><p>Altogether, our results indicate that Dll4<sub>(E12)</sub> activates Notch signaling primarily in immature mesenchymal stromal cells (revised Figure 9G), leads to the expansion of this population (Figure 3—figure supplement 2A, B) and, consistent with earlier studies (Hilton et al., Nat Med 2008, PMID: 18297083), reduced Runx2 expression (revised Figure 3B). This is fully consistent with previous findings showing that genetic approaches leading to Notch activation in mesenchymal progenitors suppress differentiation and promote the expansion of these cells (Hilton et al., Nat Med 2008, PMID: 18297083; Engin et al., Nat Med 2008, PMID: 18297084; Canalis et al., Endocrinology 2013, PMID: 23275471). In this context, it is presumably highly advantageous that Dll4<sub>(E12)</sub>-mediated Notch activation is, in contrast to genetic approaches, transient and does not suppress osteoblastic differentiation, presumably because cells are not permanently exposed to the bone surface-bound recombinant protein. This is also supported by the absence of <italic>Hey1-GFP</italic> signal in OSX+ cells (Figure 3—figure supplement 1) and lack of major transcriptional alterations in osteoblasts (Figure 8—figure supplement 2E). These findings might be conceptually relevant for the development of future strategies aiming at improved bone formation. We have added a paragraph covering the points above to the Discussion and trust that this addresses the question about the underlying mechanism raised by the reviewer.</p><disp-quote content-type="editor-comment"><p>8. The authors describe the effects of a modified Dll4-Asp8x fusion protein targeted to bone and demonstrate an increase in bone volume/total volume (BV/TV) due to an increase in trabecular thickness and bone formation. This is somewhat unexpected because 1. Asp8 usually targets bone resorbing surfaces whereas AspSerSerx6 targets bone forming surfaces (Zhang Nat Med 18;307,2012), 2. Activation of Notch signaling has been shown to inhibit osteogenesis and 3. Notch signaling affects osteoclastogenesis, albeit this is dependent on the Notch receptor activated and Dll4 would activate all Notch receptors. These points need clarification in this manuscript.</p></disp-quote><p>Thank you very much for these questions. There is indeed a substantial amount of literature describing different bone-homing moieties including the one mentioned in your comment. Other publications, such as Kusagi et al., (JBMR 2010, PMID: 10804024) and Miller et al., (Pharm. Res. 2008, PMID: 18758923), show that poly-Asp peptides bind different regions in long bone including the primary spongiosa in proximity of the growth plate. This property of poly-Asp peptides was appealing to us because we were initially trying to activate Notch signaling in the metaphyseal endothelium and, in fact, our own data also supports the deposition of Asp<sub>8x</sub>-fused proteins in the distal metaphysis (Figure 1—figure supplement 2, Figure 1—figure supplement 3A and Figure 5—figure supplement 2). We appreciate that other bone-homing peptides and reagents might provide different and perhaps even potent biological properties. This question will be an interesting topic for future work but extends beyond the scope of the current study, which establishes that Notch ligand fusion proteins containing bone-homing peptide sequences can be used to promote osteogenesis without adverse effects in other organs. We now mention the properties of different bone-homing epitopes in the Discussion.</p><p>Potential effects on osteoclastogenesis were not investigated further because vATPase+ osteoclasts were not significantly different between Dll4<sub>(E12)</sub>-treated and control mice.</p><disp-quote content-type="editor-comment"><p>9. The authors do not report whether the animals studied were littermate and sex matched, This is a critical point as the bone microarchitecture of male and female mice is substantially different.</p></disp-quote><p>We agree that this is a very important aspect. As discussed above under point 1, we had initially performed all experiments with male mice. In our revision, additional experiments revealed that females show less binding of recombinant Dll4, which is consistent with the lower bone surface in these mice relative to males (revised Figure 6 and Figure 6—figure supplement 1). Remarkably, the combination of Dll4<sub>(E12)</sub> and PTH yields very strong effects in female animals, which indicates, for some of the parameters analyzed, synergy between the two treatments (revised Figure 7A, B). The sex of the animals in specific experiments is now indicated in the manuscript and figure legends.</p><disp-quote content-type="editor-comment"><p>10. The data presented for the bone histomorphometry and uCT are incomplete. The authors show an effect on bone formation but do not provide data on osteoblast surface or number. Similarly, there is no effect on osteoclast number, but eroded surface is not shown. There is significant presence of Dll4 in cortical bone but uCT data on cortical bone are not provided. These data are essential for transparent interpretation of this study results.</p></disp-quote><p>We are presenting in revised Figure 1E the data on osteoblast surface/ bone surface (Ob.S/BS (%)) as well as the graph on eroded surface/ bone surface (ES/BS (%)). Unfortunately, we don’t have micro-CT results for cortical bone in this data set. However, micro-CT analysis of female cortical bones show no benefit of Dll4<sub>(E12)</sub> or the combination of Dll4<sub>(E12)</sub> and PTH relative to vehicle control of PTH alone, respectively (revised Figure 7H-K).</p><disp-quote content-type="editor-comment"><p>11. Increased expression of markers of osteoblast differentiation and function is somewhat limited to Osx. Data on osteocalcin and proteoglycan were not quantified and immunohistochemistry does not reveal a pronounced effect. Please clarify.</p></disp-quote><p>We appreciate reviewers’ comment and have added quantitation graphs for Opn, Osteocalcin immunostained area in control and Dll4<sub>(E12)</sub> treated mice in revised Figure 3. Additional quantitation for PDGFRβ, NG2, Acan and <italic>Sox9</italic> covered area are now shown in revised Figure 3—figure supplement 2.</p><disp-quote content-type="editor-comment"><p>12. For the RNA Seq data, it is surprising that bone marrow stromal (BMS) cells are affected whereas osteoblasts are not since BMS differentiate into osteoblasts and alterations in BMS cells would not explain an increase in mineral apposition rate unless they differentiate into osteoblasts. The markers of osteogenesis affected are not the classically defined osteogenic factors (IGF2, BP3, Prg4) and one needs to be cautious with the interpretation of these results and with the attribution of the effect to BMS cells.</p></disp-quote><p>In our view, the sum of our data indicates that Dll4<sub>(E12)</sub> acts on immature progenitors, which increase in number, give rise to more osteoblasts and thereby enhance bone formation. Profound transcriptional changes are absent in osteoblasts, indicating that Dll4<sub>(E12)</sub> increases the number but does not alter the molecular properties of these cells.</p><p>We agree that it is not clear to which extent alterations in various other pathways might contribute to the effect of Dll4<sub>(E12)</sub> and we have put more emphasis on the role of Notch activation in mesenchymal stromal cells in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>13. The authors suggest possible therapeutic value of Dll4 fusion proteins but what was administered to the animals of this study was a construct expressing the protein in vivo. A more practical and convincing approach would be the injection of the protein itself. This should at minimum be discussed as a future-directions.</p></disp-quote><p>We agree that the injection of recombinant proteins could be a next logical step in the development of potential new treatments. At the same time, the ongoing pandemic has recently shown that viral vectors or mRNA-based therapeutic approaches can play very important roles and such treatments are under development for various diseases apart from COVID19.</p><p>The aim of the current study was to address whether recombinant, bone-homing Notch ligands can be, in principle, used to increase bone formation. We have tested various constructs and might generate new versions in the future, which was greatly facilitated by the fact that we did not have to produce and purify large amounts of recombinant protein for each candidate. In this regard, our study also shows how candidate therapeutics can be developed and tested without excessive costs.</p></body></sub-article></article>